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Abstract 
Background  
Kaposi͛s “aƌĐoŵa ;K“Ϳ is a lǇŵphaŶgiopƌolifeƌatiǀe disease whose causative agent is herpesvirus 
HHV-8. KS is characterized by hyperproliferation of HHV-8 infected spindle cells - cells of 
endothelial origin that represent the typical component of KS lesions. In previous studies we 
reported that circulating endothelial progenitor cells (EPCs), identified as CD45
dim
/CD34
+
/KDR
+
, are 
increased in patients with classic KS (cKS) and we also demonstrated that in cKS patients EPCs - 
isolated and cultured as Endothelial colony-forming cells (ECFCs) - are HHV-8 infected and can act 
as viral reservoir. Therefore, in this study we investigated whether ECFCs isolated from cKS 
patients are endowed with features typical of spindle cells in order to evaluate whether they may 
represent the precursors of spindle cells.  
Moreover, in preliminary studies we surprisingly observed that not only ECFCs isolated from cKS 
patients but also ECFCs isolated from healthy donors expressed LYVE-1 and podoplanin – 
lymphatic markers expressed by spindle cells in KS lesions. Since several studies supported the 
hypothesis that adult lymphangiogenesis could be promoted by the presence of bone marrow 
derived lymphatic endothelial progenitor cells (LEPCs) we also investigated the lymphangiogenic 
potential of ECFCs to evaluate whether they can act also as LEPCs. In particular, we evaluated the 
expression of lymphatic markers in basal condition and we investigated whether the lymphatic 
differentiation of ECFCs could be fostered by fibronectin a component of the tumor 
microenvironment whose presence correlates with tumor lymphangiogenesis and metastasis. In 
addition, we also evaluated whether migration stimulating factor (MSF), an oncofetal isoform of 
fibronectin released by cancer stromal cells and tumor associated macrophages, could promote 
lymphatic differentiation of ECFCs. 
Methods 
83 cKS patients and 86 healthy HHV-8 seronegative donors were enrolled in the study. ECFCs were 
isolated using a protocol previously optimized in our lab. PBMCs were seeded in EGM-2 medium in 
culture plates coated with fibronectin and ECFC colonies were identified by microscopic visual 
inspection as colonies of cells with cobblestone-like morphology. Once isolated, ECFC colonies 
were expanded in culture plates coated with collagen. During the isolation phase, the time of 
appearance and the frequency of ECFC colonies were analyzed. During the following expansion 
phase, ECFC phenotype and the presence of HHV8-infection - assessed as expression of the viral 
latent nuclear antigen (LANA) - were analyzed by immunofluorescence. ECFC were functionally 
characterized by evaluating their cell viability, proliferative potential, vasculogenesis ability by 
Matrigel assay and cytokine production by ELISA. The molecular signature of ECFCs was also 
analyzed by gene array analysis.  
To investigate the lymphatic differentiative potential of ECFCs the expression of typical lymphatic 
markers (PROX-1, podoplanin, LYVE-1 and VEGFR-3) was analyzed by Real Time PCR and confocal 
microscopy. To evaluate the possible role of fibronectin in promoting lymphatic differentiation, 
ECFCs were cultured on either fibronectin or collagen and the effects of stimulation with MSF 
were also analyzed. 
Results 
In our study ECFC colonies appeared earlier (p<0.001) and with higher frequency (p<0.001) when 
isolated from cKS patients than healthy donors. Moreover, the frequency of ECFC colonies was 
higher in cKS patients with rapidly evolving disease than in cKS patients with slowly evolving 
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disease (p<0.05). All screened ECFC colonies isolated from cKS patients contained HHV8-infected 
cells. During the expansion phase, ECFCs isolated from cKS patients were endowed with a higher 
proliferative potential (p<0.05), a higher vasculogenic ability in vitro (p<0.05) and a higher 
production of IL-6 (p<0.05) than ECFCs isolated from healthy donors. In addition, preliminary 
analysis of the gene expression profile revealed that patients and healthy controls segregated by 
clustering, thus confirming that gene expression profile differs between ECFCs isolated from cKS 
patients and healthy donors.  
A further relevant result of this study was the observation that ECFCs are endowed with the ability 
to express the typical lymphatic markers PROX-1, podoplanin, LYVE-1 and VEGFR-3. In particular, 
lymphatic markers were expressed by donor-derived ECFCs cultured on both fibronectin and 
collagen and they were upregulated by ECFC treatment with MSF (p<0.05). 
Conclusion 
In this study we demonstrated that ECFCs obtained from cKS patients are endowed with features 
that may be particularly relevant to KS pathogenesis, suggesting that ECFCs may act as putative 
precursors of the spindle cells and contribute to the development of KS lesions. 
Moreover, we demonstrated that ECFCs isolated from peripheral blood of adult healthy donors 
expressed markers typical of lymphatic endothelium, suggesting that ECFCs may act also as LEPCs 
thus participating in lymphangiogenic and lymphovasculogenic processes. 
 
1 
 
Index 
1.Introduction .................................................................................................................................................... 4 
1.1 Endothelial Progenitor Cells (EPCs) ......................................................................................................... 5 
1.1.1 EPCs in the development of blood vascular system and postnatal neovascularization .................. 5 
1.1.2 Role of EPCs in physiological and pathological conditions ............................................................... 8 
1.1.3 Strategies to study EPCs in adult peripheral blood ........................................................................ 10 
1.1.3.1 EPC identification by flow cytometry ...................................................................................... 10 
1.1.3.2 Isolation and in vitro culture of EPCs ....................................................................................... 11 
1.1.3.2.1 Endothelial colony-forming cells (ECFCs) ......................................................................... 12 
1.1.3.2.2 Other cultured EPCs ......................................................................................................... 13 
1.2 The lymphatic vascular system .............................................................................................................. 16 
1.2.1 Structure and functions of the lymphatic vascular system ............................................................ 16 
1.2.2 Development of the lymphatic vascular system in mammals ........................................................ 18 
1.2.3 Immunophenotype of lymphatic endothelial cells (LECs) .............................................................. 20 
1.2.3.1 PROX-1 ..................................................................................................................................... 21 
1.2.3.2 VEGFR-3 ................................................................................................................................... 22 
1.2.3.3 LYVE-1 ...................................................................................................................................... 23 
1.2.3.4 Podoplanin ............................................................................................................................... 24 
1.2.4 Lymphatic endothelial progenitor cells (LEPCs) ............................................................................. 24 
1.2.5 Tumor-associated lymphangiogenesis ........................................................................................... 26 
1.2.5.1 Role of soluble factors ............................................................................................................. 26 
1.2.5.2 Role of the extracellular matrix (ECM) .................................................................................... 28 
ϭ.ϯ Kaposi͛s “aƌĐoŵa ;K“Ϳ ............................................................................................................................ 29 
1.3.1 Epidemiology and clinical variants ................................................................................................. 29 
1.3.2 Histopathology of KS ...................................................................................................................... 32 
1.3.2.1 Spindle cells in KS lesions ........................................................................................................ 32 
1.3.2.1.1 Origin of the spindle cells ................................................................................................. 33 
1.3.2.1.2 In vitro culture of KS spindle cells..................................................................................... 35 
1.3.2.2 Histopathological and clinical staging of KS ............................................................................ 35 
1.3.3 Etiopathogenesis of KS ................................................................................................................... 37 
1.3.3.1 Human Herpes Virus 8 (HHV-8) ............................................................................................... 37 
1.3.3.2 Role of the immune system in KS pathogenesis ...................................................................... 40 
1.3.3.3 Involvement of the endothelial compartment in KS pathogenesis ......................................... 42 
1.3.4 EPCs in KS ........................................................................................................................................ 44 
2 
 
2. Aim of the study .......................................................................................................................................... 45 
3. Material and methods ................................................................................................................................. 48 
3.1 Reagents ................................................................................................................................................ 49 
3.2 Cell lines ................................................................................................................................................. 53 
3.3 Subjects enrolled ................................................................................................................................... 54 
3.4 Isolation and expansion of Endothelial Colony Forming Cells (ECFCs) .................................................. 55 
3.4.1 Isolation of Peripheral Blood Mononuclear cells (PBMCs) ............................................................. 55 
3.4.2 ECFC culture .................................................................................................................................... 56 
3.4.2.1 ECFC isolation .......................................................................................................................... 56 
3.4.2.2 ECFC expansion ........................................................................................................................ 57 
3.4.2.3 ECFC in vitro stimulation with MSF ......................................................................................... 57 
3.5 ECFC characterization ............................................................................................................................ 57 
3.5.1 ECFC immunophenotype ................................................................................................................ 57 
3.5.1.1 Evaluation of hematopoietic and endothelial markers expression by flow cytometry .......... 57 
3.5.1.2 Ulex Europaeus Agglutinin I (UEA I) and Dil-ac-LDL immunofluorescence staining ................ 58 
3.5.2 Evaluation of the expression of lymphatic markers ....................................................................... 58 
3.5.2.1 Evaluation of the expression of genes typically expressed by LECs ........................................ 58 
3.5.2.1.1 RNA extraction, quantification and retro-transcription ................................................... 58 
3.5.2.1.2 Q-PCR ................................................................................................................................ 59 
3.5.2.2 Evaluation of lymphatic markers expression by confocal microscopy .................................... 60 
3.5.2.2.1 Evaluation of PROX-1, Podoplanin and LYVE-1 expression by multicolor confocal 
microscopy....................................................................................................................................... 60 
3.5.2.2.2 Evaluation of VEGFR-3 expression by confocal microscopy ............................................. 61 
3.5.3 Evaluation of HHV-8 infection ........................................................................................................ 62 
3.5.4 Cell senescence ............................................................................................................................... 62 
3.5.5 Cell proliferation ............................................................................................................................. 63 
3.5.6 In vitro vasculogenesis .................................................................................................................... 63 
3.5.7 Cytokine production ....................................................................................................................... 63 
3.5.8 Gene array analysis ......................................................................................................................... 64 
3.6 Statistical analysis .................................................................................................................................. 64 
4. Results ......................................................................................................................................................... 65 
4.1 Comparison between ECFCs isolated from cKS patients and healthy controls ..................................... 66 
4.1.1 Efficiency of ECFC colonies isolation .............................................................................................. 66 
4.1.2 In vitro expansion of ECFCs ............................................................................................................ 69 
4.1.2.1 Immunophenotype .................................................................................................................. 69 
3 
 
4.1.2.2 Detection of HHV-8 infection .................................................................................................. 71 
4.1.2.3 Senescence .............................................................................................................................. 72 
4.1.2.4 Proliferative potential .............................................................................................................. 73 
4.1.2.5 In vitro vasculogenic potential ................................................................................................ 75 
4.1.2.6 Cytokine production ................................................................................................................ 76 
4.1.2.7 Gene array analysis .................................................................................................................. 77 
4.2 Evaluation of lymphatic differentiative potential of ECFCs ................................................................... 79 
4.2.1 Evaluation of lymphatic differentiative potential of ECFCs in basal conditions ............................. 80 
4.2.1.1 Detection of mRNA encoding for lymphatic markers by Q-PCR.............................................. 80 
4.2.1.2 Detection of lymphatic markers by confocal microscopy ....................................................... 82 
4.2.1.2.1 Optimization of protocols for lymphatic markers detection by confocal microscopy ..... 82 
4.2.1.2.2 Lymphatic markers detection in ECFCs by confocal microscopy...................................... 84 
4.2.1.2.3 Evaluation of lymphatic markers coexpression in ECFCs ................................................. 87 
4.2.2 Evaluation of lymphatic differentiation of ECFCs upon stimulation with MSF .............................. 88 
4.2.2.1 Optimization of ECFC stimulation with MSF ............................................................................ 88 
4.2.2.2 Detection of mRNA encoding for lymphatic markers in ECFC colonies stimulated with MSF 89 
4.2.2.3 Lymphatic markers detection by confocal microscopy in ECFCs stimulated with MSF .......... 90 
5. Discussion .................................................................................................................................................... 92 
6. References ................................................................................................................................................. 103 
 
 
 
 
 
 
4 
 
 
 
 
 
1.Introduction 
 
 
 
 
 
 
 
 
 
 
 
 
5 
 
1.1 Endothelial Progenitor Cells (EPCs) 
1.1.1 EPCs in the development of blood vascular system and postnatal 
neovascularization 
In vertebrates, the vascular system is composed by a complex network of vessels essential for the 
transport of gases, fluids, macromolecules and cells [Adams RH et al, 2007]. Its development 
represents one of the earliest events that take place during embryonic organogenesis [Coultas L et 
al, 2005]. In particular, in mouse embryo, vascular system development starts at day 6.5-7 of 
gestation when mesodermal precursors, known as hemangioblasts, aggregate forming structures 
called ͞Blood Islands͟ [Dzierzak E et al, 1998]. 
Hemangioblasts are multipotent precursors, able to differentiate in both hematopoietic and 
endothelial precursors [Carmeliet P et al, 2003]. In embryo, the development of the vascular 
system is based on two mechanisms: vasculogenesis and angiogenesis. In particular, 
vasculogenesis - which consists in de novo formation of blood vessels by aggregation of 
endothelial precursors - allows the formation of the primitive vascular plexus starting from blood 
island mesodermal precursors whereas angiogenesis – which consists in blood vessel formation 
starting from pre-existing vessels – mediates the remodelling process of the primitive vascular 
plexus that lead to the formation of a functional vascular system [Coultas L et al, 2005]. 
In postnatal life, new blood vessel formation occurs in several physiological and pathological 
conditions. In particular, it is required for the proper postnatal development and contributes to 
physiological processes which necessitate of endothelial cell proliferation such as tissue repair and 
regeneration or angiogenesis of female reproductive system during ovarian cycle and pregnancy 
[Marçola M et al, 2015]. Moreover, neovascularization in adult life is also a key process of some 
important pathological conditions such as tumor growth (so called tumor-angiogenesis) [Marçola 
M et al, 2015]. 
Until 15 years ago, it was thought that in postnatal life only angiogenesis contributes to new blood 
vessel formation whereas vasculogenesis took place only during embryonic development. In 1997 
and 1998 respectively, two groups described for the first time circulating endothelial progenitor 
cells (EPCs) in adults [Asahara T et al, 1997; Shi Q et al, 1998]. In particular, they reported that 
human CD34
+
 cells isolated from bone marrow, umbilical cord blood and peripheral blood could 
differentiate into endothelial cells in vitro and in vivo and could contribute to neo-
endothelialization and neovascularization in adult organisms in in vivo murine models [Asahara T 
et al, 1997; Shi Q et al, 1998]. Therefore, it was proposed that also in postnatal life both 
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angiogenesis and vasculogenesis could contribute to neovascularization and that both mature 
endothelial cells and EPCs could be involved in these processes. In particular, it was hypothesized 
that EPCs could play a crucial role in postnatal vascularization since mature endothelial cells are 
terminally differentiated and endowed with a low proliferative potential [Peichev M et al, 2000; 
Ishikawa M et al, 2004]. 
In the following years, further studies were performed to better define EPC phenotype and 
functions. On the basis of ͞precursor cell͟ definition, the authors proposed that cells identified as 
EPCs must possess specific features. In particular, EPCs must express stemness markers (i.e. CD34, 
CD133 or CD117) [Peichev M et al, 2000] and endothelial markers such as Kinase insert Domain 
Receptor - KDR (also called vascular endothelial growth factor receptor 2 – VEGFR-2 – or flk-1). In 
support of this hypothesis, Pelosi et al reported that CD34
+
/KDR
+
 bone marrow-derived cells were 
endowed with high proliferative potential and could generate both hematopoietic and endothelial 
precursors in vitro [Pelosi E et al, 2002]. Moreover, EPCs must be characterized by the ability to 
differentiate into mature endothelial cells, acquiring - during in vitro culture - the expression of 
typical endothelial markers (i.e. basal expression of CD31, CD144, Von Willebrand factor (vWF) and 
eNOS and e-selectin expression after stimulation with proinflammatory cytokines) [Asahara T et al, 
1997; Kaushal S et al, 2001]. Finally, Urbich et al proposed that EPCs must be endowed with a high 
proliferative potential and the ability to incorporate in pre-exsisting vessels in order to support 
endothelial repair and vascularization [Urbich C et al, 2004]. Since in literature several protocols 
for EPCs in vitro culture and characterization are reported, EPC phenotype and functions were 
deeply debated; therefore this topic will be discussed in a dedicated chapter. 
EPCs are usually located in the bone marrow inside the ͞stem cell niche͟ and only a low number of 
EPCs circulate in peripheral blood. EPCs can be mobilized from the bone marrow by physiological 
and pathological stimuli coming from the peripheral tissues. In particular, EPC mobilization from 
the bone marrow is promoted by angiogenic factors (VEGF-A), cytokines (GM-CSF, SDF-1), 
hormones (erythropoietin, estrogens) and drugs (statins) [Dimmeler S et al, 2001; Vasa M et al, 
2001 a; Heeschen C et al, 2003; Strehlow K et al, 2003; Walter DH et al, 2002]. In fact, high levels 
of angiogenic factors and cytokines – in particular VEGF and SDF-1 - can be detected in hypoxic 
peripheral tissues where they induce EPC mobilization [Marçola M et al, 2015; Xiao Q et al, 2008; 
Yamaguchi J et al, 2003; Shintani S et al, 2001; Kalka C et al, 2000]. The immune cells located in 
hypoxic tissues also promote EPC mobilization participating in the production of soluble factors. In 
particular, macrophages and T-lymphocytes produce VEGF that induces the production of 
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monocyte chemoattractant protein (MCP)-1 by endothelial cells [Jaipersad AS et al, 2014]. MCP-1 
increases the permeability of endothelial layer and attracts EPCs [Fujiyama S et al, 2003; Hong KH 
et al, 2005]. 
EPC mobilization relies on the activation of complex mechanisms [Heissig B et al, 2002]. Several 
studies demonstrated that EPC mobilization, beyond the action of soluble factors (mainly VEGF 
and SDF-1), required proteinases and metalloproteases [Takahashi T et al, 1999]. In particular, 
soluble factors such as SDF-1 create a chemotactic gradient that promote EPCs mobilization 
whereas proteases and metalloproteases degrade extracellular matrix, cleaving the interaction 
between EPCs and the bone marrow stroma allowing EPC mobilization. Moreover, the 
metalloprotease MMP-9 cleaves the ligand c-Kit which is present on the membrane of bone 
marrow cells (m-Kit) thus promoting the release of c-Kit in its soluble form (s-Kit, also called stem 
cell factor- SCF) that promotes EPC mobilization [Heissig B et al, 2002]. Also nitric oxid (NO) 
produced by stromal cells and growth factors produced by hematopoietic stem cells foster EPC 
mobilization [Aicher A et al, 2003]. 
Once EPCs are released from bone marrow into the bloodstream, they migrate toward the 
angiogenic sites where they home and differentiate acquiring all the phenotypic features typical of 
mature endothelial cells. During the homing process, EPCs adhere and then transmigrate through 
the cytokine-activated endothelial cells to reach the ischemic tissues. EPC adhesion to endothelial 
cells is mediated by integrins. In particular, βϮ-iŶtegƌiŶ aŶd αϰβϭ-integrin mediate adhesion and 
are also involved in EPC transmigration [Chavakis E et al, 2005]. Moreover, EPC adhesion to 
denuded vessels is mediated by vitronectin receptors –αVβϯ aŶd αVβϱ iŶtegƌiŶs – aŶd βϭ-integrins 
that bind extracellular matrix [Urbich C et al, 2004]. 
In the site of angiogenesis, EPCs promote revascularization directly by proliferating, integrating in 
the pre-existing vessels and differentiating into mature endothelial cells; moreover, they support 
neovascularization also in a paracrine manner, by releasing soluble factors that in turn sustain 
angiogenesis. 
In the last years, several studies described the presence of EPCs inside niches within the vascular 
walls [Psaltis PJ et al, 2015]. These cells, called vascular wall EPCs (VW-EPCs) were described by 
Ingram et al in 2005 [Ingram DA et al, 2005]. In this study, the authors analyzed by clonogenic 
assays mature endothelial cells derived from vessel walls. In particular, they analyzed two 
different population of mature endothelial cells - HUVEC (Human Umbilical Cord Endothelial Cells) 
and HCAEC (Human Coronary Artery Endothelial Cells) - and they observed that both populations 
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contained a hierarchy of low and high proliferative EPCs endowed with self-renewal capacity 
[Ingram DA et al, 2005]. Fang at al also identified a population of endothelial colony-forming cells 
within endothelial cells isolated from pulmonary vessels of adult mice [Fang S et al, 2012]. These 
observations support the hypothesis that adult neovascularization could be supported also by 
EPCs resident within the vessel walls [Psaltis PJ et al, 2015]. 
1.1.2 Role of EPCs in physiological and pathological conditions 
In healthy subjects, the endothelial cell turnover is low in basal condition and can be reactivated in 
some physiological conditions. In fact, neo-endothelialization and neovascularization processes 
are required for the manteinance of endothelial homeostasis and also occur in female 
reproductive system during ovarian cycle and pregnancy [Marçola M et al, 2015]. 
Since mature endothelial cells are endowed with a low proliferative potential, circulating EPCs 
seem to play a crucial role in neovascularization process in adult. In particular, in vivo studies in 
animal models demonstrated that labeled donor-derived progenitor cells could be detected in 
ischemic tissues of recipient animals after bone marrow transplantation [Crosby JR et al, 2000; 
Jackson KA et al, 2001]. These evidences were then confirmed also in clinical studies by 
observation that EPCs can be mobilized after tissue injury (i.e. burns, coronary artery bypass or 
acute myocardial infarction) thus contributing to neovascularization processes [Urbich C et al, 
2004]. 
Moreover, clinical studies showed that EPCs alteration in number and/or functions can be 
associated to phatological conditions and among them cardiovascular diseases are the most 
studied and best characterized. In fact, EPC alterations represent an independent risk factor for 
cardiovascular diseases [Schmidt-Lucke C et al, 2005]. Several studies reported EPC dysfunction or 
reduction in patients affected by cardiovascular diseases such as CAD (coronary artery disease) 
[Lee PS et al, 2014], PAD (peripheral artery disease) [Fadini GP et al, 2006 a; Fadini GP et al, 2006 
b] or congestive heart failure [Nonaka-Sarukawa M et al, 2007; Michowitz Y et al, 2007]. In 
addition, EPC alterations are also associated to cardiovascular risk factors such as smoking, 
hypertension, diabetes and hypercholesterolemia. In particular, one of the mechanisms through 
which smoking promotes the development of cardiovascular diseases consists in the reduction of 
EPC number due to the increased oxidative stress and the reduced nitric oxide bioavailability 
[Werner N et al, 2005]. Therefore, EPCs were proposed as a biological and prognostic marker to 
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assess the severity of cardiovascular diseases and to predict events in patients with CAD [Lee PS et 
al, 2014]. 
Besides cardiovascular diseases, EPC alterations have also been reported in other pathological 
conditions. In particular, dysfunctional and reduced EPCs have been described in diseases 
associated with impaired endothelial repair capacity and reduced vasculogenic ability [Calcaterra F 
et al, 2014] whereas increased EPC number has been reported in pathological conditions - such as 
tumor -which are characterized by increased vasculogenesis [Marçola M et al, 2015]. In fact, the 
number of circulating EPCs has been reported to be increased in patients with many different 
types of cancer and, in some cases, it correlates with the volume of the tumoral mass thus 
supporting the hypothesis that EPCs play a role in neovascularization that fosters tumor 
development by promoting tumor growth and metastasis formation [Bertolini F et al, 2006; 
Marçola M et al, 2015]. Therefore it has been proposed that EPC number could be used as a 
prognostic and/or diagnostic biomarker and that EPCs could represent a possible target for new 
strategies for tumor treatment [Bertolini F et al, 2006; Fang D et al, 2010]. Moreover, the role of 
EPCs in tumor neovascularization was investigated by several research groups using mouse models 
and reporting that EPCs are able to incorporate into the vasculature of solid tumor xenografts; 
nevertheless, the extent of the reported contribution is highly variable ranging from 0% to about 
100% [Lyden D et al, 2001; De Palma M et al, 2003; Purhonen S et al, 2008]. The different results 
reported may rely on the different strategies used for EPC identification into neovascularization 
sites and on the different tumor model used (type of tumor and tumor stage) [Gao D et al, 2009]. 
In 2005, Peters et al analyzed tumor samples derived from individuals who developed cancer after 
bone-marrow transplantation with donor of the opposite sex. In particular, they used multicolor 
FISH technique with X or Y chromosome specific probes and observed that about 5% of 
endothelial cells in tumor were bone-marrow derived supporting the hypothesis that EPCs 
participate in tumor neovascularization [Peters BA et al, 2005]. 
In conclusion, EPCs could be a possible new target for therapies that aim to promote angiogenesis 
in pathological conditions characterized by defective angiogenesis and could represent a novel 
source of autologous cells to promote vascularization of ischemic tissues [Sukmawati D et al, 
2015]. 
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1.1.3 Strategies to study EPCs in adult peripheral blood 
IŶ ϭ99ϳ, Asahaƌa͛s gƌoup desĐƌiďed foƌ the fiƌst tiŵe EPCs showing that isolated CD34+ 
hematopoietic progenitor cells obtained from adult peripheral blood resembled the embryonic 
angioblasts, were able to differentiate in endothelial cells and were involved in revascularization 
processes [Asahara T et al, 1997]. After this first description, several approaches have been used 
to study and characterize EPCs. In particular, the approaches reported in literature can be divided 
in two main strategies: identification of circulating EPCs based on cell surface markers expression 
or in vitro culture of EPCs isolated from peripheral blood [Fadini GP et al, 2012; Hirschi KK et al, 
2008]. 
1.1.3.1 EPC identification by flow cytometry 
The first strategy that can be used for EPC characterization is based on the use of antigen-specific 
antibodies conjugated to a fluorochrome that allow the identification, by flow cytometry, of 
specific cell populations in blood samples. The advantages of this technique, which is deemed as 
the gold standard for EPC quantification in peripheral blood, are: the rapidity of execution, 
requirement of small volume of blood and no need for ex vivo manipulation of the sample. The 
inconvenience of this approach is that, even after years of research, there is not yet a consensus 
on the marker combination to be used for EPC identification [Timmermans F et al, 2009; Basile DP 
et al, 2014]. According to the definition of ͞endothelial progenitor͟, at least one marker of 
immaturity/stemness plus at least one marker of the endothelial lineage are required to define the 
antigenic phenotype of EPCs (Figure 1). 
 
Figure 1: Antigen expression in circulating endothelial progenitor cells (EPCs), circulating endothelial mature 
cells, microparticles, platelets and hematopoietic cells (Bertolini F et al, Nat Rev Cancer, 2006). 
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In particular, CD34 and/or CD133 are used as stemness markers; CD34 is the prototypical stem cell 
antigen and CD133 is expressed on the surface of more immature hematopoietic cells than CD34. 
On the other hand, KDR is the most common endothelial marker used for EPC identification. 
Unfortunately, the specificity of this combination is impaired by the fact that these markers are 
expressed also by circulating hematopoietic progenitors. In addition, circulating endothelial cells 
(CECs) are KDR
+
 and may also express CD34. Therefore, the analysis of CD45 expression was 
introduced in the protocol for EPC identification in order to exclude hematopoietic cells which 
express CD45. Notably, Case et al demonstrated that the vast majority of CD34
+
/CD133
+
/KDR
+ 
cells 
in the blood
 
are actually hematopoietic progenitor cells (HPC) expressing CD45; moreover, they 
showed by endothelial cell and hematopoietic cell clonogenic assays that only the rare CD45
- 
subpopulation is not endowed with hematopoietic activity and should therefore represent the 
true EPCs [Case J et al, 2007]. 
Nevertheless, despite only CD45
-
 subpopulation seems to contain the true EPCs and CD133 marker 
allows the distinction between EPCs and mature endothelial cells, the cell population identified 
with marker combination that includes also CD45 and CD133 is really rare and difficult to be 
detected with sufficient accuracy to be used in clinical studies as biomarker [Fadini GP et al, 2012]. 
Therefore, the most used combination for defining EPCs in clinical studies is CD45
dim
/CD34
+
/KDR
+ 
as it allows the identification of a population that has widely been demonstrated to correlate with 
the severity of cardiovascular disesases. In this respect, several studies have demonstrated that 
CD45
dim
/CD34
+
/KDR
+
 cells can be used as valuable prognostic marker as well as a marker for 
treatment monitoring [Schmidt-Lucke C et al, 2010]. 
1.1.3.2 Isolation and in vitro culture of EPCs 
The second strategy to study EPCs consists in EPCs in vitro culture. This approach allows to obtain 
a number of cells sufficient for their detailed phenotypic and functional characterization. EPCs 
obtained in vitro can also be use for in vivo experiments in animals and for cell-based therapies 
[Fadini GP et al, 2012]. 
However, after the first description by Asahara, several protocols were proposed for isolation and 
in vitro culture of EPCs from peripheral blood mononuclear cells (PBMCs). Despite the use of 
different protocols allows the isolation of different types of cells, all these cell populations were 
initially called EPCs on the basis of their endothelial phenotype [Prater DN et al, 2007]. This 
confused situation was clarified for the first time in 2007 by Ingram, Yoder and colleagues who 
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described and compared the three cell types commonly called EPCs and their respective cell 
culture protocols [Yoder MC et al, 2007]. The three cell types are named: colony forming unit 
(CFU)-Hill cells, circulating angiogenic cells (CAC) and Endothelial colony-forming cells (ECFCs) and 
they are characterized by different phenotype, angiogenic potential and functions [Madonna R, 
2015]. Among these cell populations, only ECFCs are considered the true EPCs [Fadini GP et al, 
2012] (Figure 2). 
 
Figure 2: Cell types commonly called EPCs in the past and their respective cell culture protocols (Fadini GP et 
al, Circ Res 2012). 
1.1.3.2.1 Endothelial colony-forming cells (ECFCs) 
In 2004, Ingram et al described a culture method that allowed to obtain a population of EPCs 
called ECFCs [Ingram DA et al, 2004]. Briefly, PBMCs are seeded in culture plates coated with 
collagen-I and are cultured in presence of conditions that promote endothelial differentiation; 
ECFC colonies appeared 2-3 weeks after PBMCs seeding and are composed by cells with 
endothelial characteristics. Due to their phenotypic and functional features, ECFCs are considered 
to be the true EPCs [Ingram DA et al, 2004; Ligi I et al, 2011; Rosti V et al, 2010; Leicht SF et al, 
2011; Medina RJ et al, 2010; Jodon de Villeroche V et al, 2010]. In fact, ECFCs are characterized by 
cobblestone-like morphology, express endothelial markers (i.e. CD31, CD34, CD105, CD144, 
CD146, KDR and vWF), up-take Dil-acLDL (acetylated LDL labeled with 1,1’ - dioctadecyl – 3,3,3’,3͛ - 
tetramethyl - indocarbocyanineperchlorate), bind Ulex europaeus lectin 1 (UEA-1) and do not 
express CD45, CD14 and CD115. ECFCs also display a relatively high level of telomerase and a high 
proliferative potential [Ingram DA et al, 2004]. In particular, basing on a clonogenic single cell 
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assay, Ingram et al described in ECFC population the existence of a hierarchy of EPCs. In fact, using 
this strategy, ECFCs can be divided according to their proliferative and clonogenic potential thus 
identifying a population endowed with a high proliferative potential (HPP-ECFCs) [Ingram DA et al, 
2004]. In addition, ECFCs promote in vivo angiogenesis by contributing to vessel formation in 
models of ischemia and when implanted subcutaneously in matrices, such as collagen, or in 
human skin substitutes [Reviewed in Critser PJ et al, 2010]. 
In literature, a second protocol that allows to obtain cells endowed with characteristics similar to 
those of ECFCs was described [Gulati R et al, 2003; Fuchs S et al, 2006; Smadja DM et al, 2011; 
Imanishi T et al, 2005; Meneveau N et al,2011]. The cells obtained with this protocol are called 
late-EPCs or outgrowth EPCs. Briefly, mononuclear cells are seeded in culture plates coated with 
fibronectin and are cultured in presence of conditions that promote endothelial differentiation. 
Similar to ECFCs, late-EPC colonies appear after 2-3 weeks of culture. Late-EPCs also share with 
ECFCs other characteristics. In fact, late-EPCs have a cobblestone-like morphology, express 
endothelial markers (KDR, CD144, eNOS, vWF) and show the ability to form capillary structures 
both in vitro and in vivo matrigel models [Gulati R et al, 2003]. Moreover, also late-EPCs do not 
express CD45 and CD14. In particular, Gulati et al demonstrated that late-EPCs developed only 
from CD14
-
 fraction of PBMCs [Gulati R et al, 2003]. 
Therefore, since different research groups isolate and culture cells endowed with the typical 
characteristics of ECFCs both on collagen and fibronectin, in a previous study published in 2013 we 
investigated whether the substrate used for cell isolation and culture could affect ECFC culture 
[Colombo E et al, 2013]. In particular, we confirmed that ECFCs can be efficiently isolated and 
expanded from adult peripheral blood on both culture plates coated with collagen or fibronectin. 
Moreover, we optimized a protocol for ECFCs isolation and expansion; in fact, we observed that 
ECFC isolation on fibronectin followed by ECFC expansion on collagen represented, in our hand, 
the most efficient strategy to culture ECFCs [Colombo E et al, 2013]. 
1.1.3.2.2 Other cultured EPCs 
Different cell populations have been called EPCs in the past. The use of the same name for cell 
population endowed with different features created a confuse situation. In particular, also the cell 
populations described in this chapter - CFU-Hill and CACs - have been called EPCs in the past 
despite only ECFCs are now considered the true EPCs.  
CFU-Hill colony counting method was the first method developed for EPC culture. It was originally 
proposed by Asahara et al [Asahara T et al, 1999] and it was later optimized to avoid the presence 
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of contaminant such as mature endothelial cells [Hill JM et al, 2003; Vasa M et al, 2001 a]. CFU-Hill 
colony counting method can be performed also with a commercially available kit (Endocult, 
StemCell Technologies). In particular, PBMCs are seeded at low density in culture plates coated 
with fibronectin and cultured for two days; nonadherent cells are then collected and replated. 
After 5 to 9 days of culture colonies of adherent cells arise. These colonies, called colony –forming 
CFU-Hill, are composed by a cluster of round cells surrounded by spindle-shaped cells. CFU-Hill 
cells possess characteristics typical of endothelial cells since the express CD31, CD34 CD105, 
CD144, CD146, vWF, KDR and uptake Dil-acLDL. Despite that, CFU-Hill cells are endowed with 
some features typical of monocytes/macrophages. In particular, they are characterized by a low 
proliferative potential, express pan-leukocyte marker CD45 and monocyte/macrophage markers 
CD14 and CD115, are able to phagocyte bacteria and possess a nonspecific esterase activity [Yoder 
MC et al, 2007]. Moreover, Rehman et al. demonstrated that CFU-Hill cells do not proliferate, but 
release proangiogenic factors such as VEGF, granulocyte colony-stimulating factor (G-CSF) 
granulocyte-macrophage colony-stimulating factor (GM-CSF) and hepatocyte growth factor (HGF) 
[Rehman J et al, 2003; Kalka C et al, 2000]. 
Another cell population erroneously defined EPC is represented by CACs whose culture protocol 
was described by Vasa in 2001 [Vasa M et al, 2001 b]. Briefly, PBMCs are seeded in culture plates 
coated with fibronectin and are cultured under ͞endothelial͟ differentiation conditions using a 
specific culture medium supplemented with serum and endothelial growth factors. The fourth day 
non adherent cells are removed and CACs with a spindle-shaped morphology remain adherent to 
the plate. CACs are also called early-EPCs since they appear few days after PBMCs seeding. Like 
CFU-Hill cells, CACs produce high levels of proangiogenic factors, are endowed with a low 
proliferative potential and express both endothelial cells markers and the markers of 
monocytic/macrophagic lineage CD45 and CD14 [Yoder MC et al, 2007]. In addition, recent studies 
highlighted the fact that the angiogenic properties of CACs isolated in vitro with this method could 
due to the platelet-derived proteins [Critser PJ et al, 2010]. In fact, Prokopi et al observed that 
contaminated PBMCs fraction used for CACs isolation was also enriched in platelets; during 
culture, platelets and platelet microparticles were taken up by monocytes. Through this 
mechanism many platelet proteins, which are also used as endothelial markers, were transferred 
on the membranes of monocytes that apparently acquired an endothelial phenotype. In particular, 
Prokopi et al described this mechanism using a proteomic analysis demonstrating that CACs 
expressed surface endothelial-platelet antigens such CD31, several integrins and Ulex Europaeus 
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lectin binding but they did not express mRNA for the same surface proteins [Prokopi M et al, 
2009]. 
In conclusion, both CFU-Hill cells and CACs can not be considered the true EPCs since they are 
monocytes/macrophages which express also endothelial markers. In fact, they originate from 
CD14
+
 fraction of PBMCs, as confirm by several studies that used several different 
mieloproliferative disorders to proved that early outgrowth EPCs derived from hematopoietic cells 
[Piaggio G et al, 2009; Gunsilius E et al, 2000]. Other typical features of CFU-Hill and CACs are: 
secretion of high amount of pro-angiogenic factors and low proliferative potential [Rehman J et al, 
2003]. Therefore it has been proposed these cell populations should be better defined as 
angiogenic macrophages that, by secreting angiogenic factors and chemokines, promote 
angiogenesis in a paracrine way [Pearson JD, 2010]. In fact, in vivo studies highlighted the role of 
monocytes in promoting angiogenesis by secretion of pro-angiogenic factors and releasing of 
enzymes that degrade matrix [Anghelina M et al, 2006] and, in 2009, Krenning et al summarized in 
a review the evidences that demonstrate that EPCs can act similarly [Krenning G et al, 2009]. 
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1.2 The lymphatic vascular system 
1.2.1 Structure and functions of the lymphatic vascular system 
Lymphatic vessels are located in most of the internal organs and in the skin but not in the bone 
marrow, central nervous system and avascular tissues such as cornea, epidermis, cartilage, hair 
and nails [Alitalo K et al, 2005]. The lymphatic vasculature begins with blind-ended lymphatic 
capillaries that drain lymph - the protein-rich interstitial fluid- from the interstital spaces within 
organs. The lymphatic capillaries are thin-walled vessels with a diameter of approximately 30–80 
µm; they lack fenestrations and are not surrounded by pericytes – that usually surround blood 
capillaries - or smooth muscle cells. Lymphatic capillaries are characterized by the presence of a 
discontinuous basement membrane and are composed of a single layer of overlapping oak-leaf-
shaped lymphatic endothelial cells (LECs) that form loose intercellular junctions. In fact, unlike 
blood vascular endothelial cells (BECs) that are characterized by zipper-like junctions, LECs posses 
button-like junctions thus making lymphatic capillaries highly permeable to fluids and allowing 
also the entrance of large macromolecules, migrating cells and pathogens. LECs that compose 
lymphatic capillaries are anchored through filaments to collagen fibers of extracellular matrix. 
When interstitial pressure is high the lymphatic capillaries are kept open by forces applied through 
the filaments that regulate the valve-like opening into the lumen of lymphatic vessels [Alitalo K et 
al, 2011; Alitalo K et al, 2012] (Figure 3). 
 
Figure 3: Lymphatic vasculature structure and features (Stacker et al, Blood, 2014). 
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The capillaries drain lymph into larger collecting ducts, sparsely covered by smooth muscle cells, 
called pre-collecting vessels and thereafter to collecting lymphatic vessels that are characterized 
by the presence of a layer of smooth muscle cells, basement membrane and valves. Collecting 
lymphatic vessels share some features with small veins; in fact, lymph propulsion is supported by 
contraction of smooth muscle cells and surrounding skeletal muscles, as well as arterial pulsations 
and the presence of valves prevents backflow [Alitalo K et al, 2011]. The collecting lymphatic 
vessels drain lymph into sentinel lymph nodes acting as afferent lymphatic vessels. Sentinel lymph 
nodes are the first organs that receive cells and fuids drained from peripheral tissues. Cells and 
fluids are then transferred by the efferent vessels of the sentinel lymph nodes to distal lymph 
nodes [Alitalo K et al, 2012]. Finally, lymph returns to the blood circulation through the thoracic 
duct and the lymphatic duct draining into the left and right subclavian veins, respectively [Alitalo K 
et al, 2005; Oliver G et al, 2004; Alitalo K et al, 2011]. 
Lymphatic vessels were described for the first time by Aselli in 1622 but despite its important role 
in physiological and pathological conditions, the lymphatic system drew scientific community 
attention only in the last twenty years. The lymphatic system is typical of higher vertebrates that 
are characterized by large body size and a complex cardiovascular system. For these reasons they 
need a secondary vascular system in order to maintain the fluid balance in the body [Alitalo K. et 
al, 2005]. Therefore, the main function of lymphatic system is to drain lymph from the interstitial 
spaces back to blood circulation. However, the maintenance of colloid osmotic volume is not the 
only function of lymphatic system. Besides lymphatic vessels, the lymphatic system is composed 
also by lymphoid organs and is involved in the immune response [Oliver G et al, 2004]. Lymphoid 
organ are classified as primary and secondary. In particular, in primary lymphoid organs – thymus 
and bone marrow – lymphocytes are formed and mature to become immunocompetent whereas 
in secondary lymphoid organs - lymph nodes, tonsils, spleen, Peyer's patches and mucosa 
associated lymphoid tissue (MALT) – mature lymphocytes are responsible for mounting the 
specific defense of the. In fact, drained lymph contains macromolecules and cells - mainly antigen 
presenting cells (APCs) - that, once reached the lymph nodes, initiate specific immune responses. 
Moreover, in pathological conditions, lymphatic system plays a crucial role also in systemic 
dissemination of infectious agents and tumor cells thus contribuiting to tumor metastatization 
[Alitalo K et al, 2011]. In addition, lymphatic system plays also a role in lipid absorbtion from 
intestinal tract. In particular, lacteal lymphatic vessels, located inside the intestinal villi, are 
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deputated to the absorbtion of lipid particles – called chylomicrons – released by enterocytes 
[Oliver G et al, 2004; Alitalo K et al, 2011]. 
1.2.2 Development of the lymphatic vascular system in mammals 
In the past years, two different models have been proposed to explain the lymphatic vascular 
system development. On the one hand, in 1902, Sabin proposed that LECs derive from endothelial 
cells localized in the ĐaƌdiŶal ǀeiŶ. AĐĐoƌtiŶg to “aďiŶ͛s ŵodel, a suďset of eŶdothelial Đells loĐated 
in the cardinal vein differentiates toward lymphatic phenotype and forms the primary lymphatic 
sacs from which the lymphatic vascular system develops through remodelling and sprouting 
mechanisms (͞the centrifugal system͟) [Sabin F, 1902]. On the other hand, in 1910, Huntington 
and McClure proposed a model of ͞centripetal sprouting͟ in which primary lymph sacs could arise 
in the mesenchime by concrescence of discontinuous and independent lymph vesicles [Huntington 
GS et al, 1910]. Despite the presence of lymphatic vessels deriving from mesenchymal 
lymphangioblasts has been reported in Xenopus [Ny A et al, 2005] and chick embryos [Wilting J et 
al, 2003], the model proposed by Sabin is the most accepted for the development of the lymphatic 
system in mammals, since it was confirmed by both imaging in zebrafish [Yaniv K et al, 2006] and 
by in vivo models of lineage tracing in mice [Srinivasan RS et al. 2007]. AĐĐoƌdiŶg to “aďiŶ͛s 
hypothesis, mice models confirmed that the lymphatic vascular system develops in parallel, but 
secondary to the development of the blood vascular system. In particular, at embryonic day (E) 9 
endothelial cells into the cardinal vein start to express the lymphatic vessel endothelial 
Hyaluronan (HA) receptor (LYVE-1) which is the first lymphatic marker to be expressed and 
therefore LYVE-1 expression can be considered the first evidence that venous endothelial cells are 
able to respond to a lymphatic-inducing signal. At day E9.5, the expression of the transcription 
factor SOX18 fosters the expression of the homeobox transcription factor (PROX-1) in a subset of 
LYVE-1
+
 endothelial cells located in the anterior cardinal vein. PROX-1, acting as a master gene 
regulator in lymphatic differentiation, induces endothelial cells to acquire a lymphatic phenotype 
(i.e. expression of lymphatic molecules including vascular endothelial growth factor receptor 3 - 
VEGFR-3) through the interaction with the venous orphan nuclear receptor COUP-TFII [Alitalo K et 
al, 2011]. Therefore, LYVE-1
+
/PROX-1
+
/VEGFR-3
+ 
LECs originated from the cardinal vein migrate 
and sprout in response to the stimulus of VEGF-C produced by surrounding mesenchyme thus 
giving rise to primary lymphoid sacs [Kukk E et al,1996]. In later stages LECs acquire a mature 
phenotype consisting in the expression of other typical lymphatic markers such as podoplanin and 
neuropilin-2 (NRP-2). In particular, NRP-2 is involved VEGF-VEGFR signaling. In fact, by acting as co-
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receptor for VEGF-C, NRP-2 renders LECs more responsive to VEGF-C arising from the lateral 
mesenchyme [Xu Y et al, 2010; Tammela T et al, 2010]. 
From primary lymphoid sacs, LECs migrate and sprout forming the primary lymphatic plexus that 
further develops into the mature lymphatic vascular system [Alitalo K et al, 2005]. In line with the 
process of lymphatic vascular development described in mice models and according to the 
observation that blood and lymphatic systems are similar in structure and share the expression of 
some molecular markers, Oliver et al suggested that BECs can be considered as the default 
endothelial cells and that PROX-1 is necessary and sufficient to induce their trans-differentiation 
toward lymphatic phenotype. In particular, Oliver et al proposed a model for lymphatic vascular 
development in mammals that is composed by 4 sequential stages characterized by the acquisition 
of LEC competence, LEC bias, LEC specification and LEC differentiation and maturation of 
lymphatic vessels (Figure 4). 
 
Figure 4: Model for differentiation of lymphatic vascular system proposed by Oliver G et al (Oliver G et al, 
Nat Rev Immunol, 2004). 
In fact, they stated that, as a first step in lymphatic vascular development, the subset of vascular 
endothelial cells from which the lymphatic vessels originated must became competent to respond 
to initial signals that induce lymphatic differentiation. In particular, competent endothelial cells, 
according to this model, seem to be represented by the subset of endothelial cells that start to 
express PROX-1 in response to still unidentified signals. Once competent, PROX-1
+
 cells became 
committed (biased) and can differentiate only into LECs. Therefore PROX-1
+ 
endothelial cells 
differentiate by upregulating the expression of typical lymphatic molecules and dowregulating the 
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expression of BEC markers thus acquiring the typical phenotype of LECs. Finally, LECs that originate 
in cardinal vein sprout forming lymphatic sacs from which mature lymphatic vessels develop 
[Oliver G et al, 2004]. 
The two models proposed - respectively by Sabin and by Huntington and McClure - to describe the 
lymphatic vascular system development were in contrast. Sabin proposed a centrifugal model in 
which LECs develop from cardinal vein and sprout forming lymphatic vessels whereas Huntington 
and McClure proposed a centripetal model in which LECs originate from mesodermal precursors. 
In addition, the evidences reported in literature in the last years supported exclusively on model 
or the other. Recently, Nicenboim J. et al tried to reconcile the two models originally proposed by 
Sabin and Huntington and McClure. In particular, they proposed that LECs originate from veins but 
they do so starting from specialized mesoderm derived angioblasts located in a venous niche 
[Nicenboim J et al, 2015]. In fact, using a zebrafish model, the authors described for the first time a 
niche of specialized angioblasts within the cardinal vein from which cells destined to differentiate 
in LECs can arise. Such angioblasts can also generate arterial and venous fates. Moreover, they 
identify Wnt5b as a novel lymphatic inductive signal. In particular, they showed that it can also 
induĐe ͚aŶgioďlast-to-lǇŵphatiĐ͛ tƌaŶsitioŶ iŶ huŵaŶ eŵďƌǇoŶiĐ steŵ Đells [Nicenboim J et al, 
2015]. 
1.2.3 Immunophenotype of lymphatic endothelial cells (LECs) 
Until few years ago, lymphatic and blood vessels within tissues could be distinguished only at the 
histological level using morphological criteria based on the fact that lymphatic vessels are thinner 
and do not have the external layer of pericytes. In fact, several markers that are expressed by both 
blood and lymphatic vessels were known (i.e. CD31) but a specific marker for lymphatic vessels 
identification lacked [Oliver G et al, 2004]. Recently, researchers identified markers specifically 
expressed by lymphatic cells that can be used for identification of lymphatic vessels in tissues and 
for studying the lymphatic system and the mechanisms that regulate lymphatic vessel growth in 
order to identify possible therapeutic targets. In particular, among the lymphatic markers the most 
extensively used for LEC in vitro characterization and lymphatic vessel identification in tissue 
sections are: PROX-1, VEGFR-3, LYVE-1 and podoplanin [Tammela T et al, 2010] (Figure 5). 
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Figure 5: Key Molecular markers of lymphatic endothelial cells (Tammela T et al, Cell, 2010). 
1.2.3.1 PROX-1 
PROX-1 is a transcription factor and is considered the master control gene that regulates the 
expression of other lymphatic markers on LECs [Tammela T et al, 2010]. PROX-1 is located in the 
nucleus and can be use as constitutive marker of LECs both in normal and pathologic human 
tissues. In fact, it is expressed by LECs and it is not expressed by BECs as confirmed by the 
observation that its expression is mutually exclusive with that of PAL-E, a molecule used as marker 
for blood vessel identification in tissue sections [Wilting J et al, 2002]. PROX-1 expression starts in 
the early stage of lymphatic system development. In particular, in mice embryogenesis, starting 
from day E9.5 a subpopulation of endothelial cells PROX-1
+ 
can be detected on one side of the 
anterior cardinal vein and several studies described how lymphatic system develops starting from 
this population [Oliver G et al, 2004]. The importance of PROX-1 as the regulator of lymphatic 
system development was confirmed by animal models knockout for PROX-1. PROX-1
-/-
 mice 
embryos died perinatally in most genetic backgrounds - with the exception of NMRI mice that 
developed chylous ascites and adult-onset obesity - since they didŶ͛t deǀelop lǇŵph saĐk aŶd 
lymphatic vessels [Alitalo K et al, 2005]. In fact, in PROX-1
-/-
 mice the endothelial cells in the 
cardinal vein were not able to migrate, maintained the phenotype typical of BECs and did not 
express lymphatic endothelial markers [Oliver G et al, 2004]. Further studies also demonstrated 
that the overexpression of PROX-1 in mature BECs on the one hand promotes the expression of 
LEC specific genes and on the other one downregulates the expression of genes that are highly 
expressed by BECs [Wigle JT et al, 2002; Petrova TV et al, 2002]. The signals that induce the 
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expression of PROX-1 in cells destinated to lymphatic system development are still object of study 
[Tammela T et al, 2010]. In 2009, Francois et al proposed that homeobox transcription factor 
SOX18 could be required to induce the expression of PROX-1 and therefore may be involved in 
initiating the differentiation of endothelial cells of the cardinal vein towards lymphatic phenotype. 
The authors reported that, in endothelial cells located in the cardinal vein, SOX18 expression 
preceded the expression of PROX-1 and that PROX-1 promoter contained SOX18-binding sites 
[François M et al, 2008]. Moreover, they demonstrated that SOX18 silencing - by gene targeting of 
SOX18 locus or by homozygous expression of a dominant-negative mutant – abolished the 
expression of PROX-1 causing edema and embryonic death [François M et al, 2008]. 
1.2.3.2 VEGFR-3 
The first lymphatic marker to be described was VEGFR-3, a tyrosine kinase receptor that belongs 
to the family of vascular endothelial growth factor receptors. It is activated by its ligands VEGF-C 
and VEGF-D. VEGFR-3 expression starts in early stages of lymphatic system development, at day 
E12.5 in mice embryos and – by mediating signaling of VEGF-C - it plays a crucial role in 
lymphangiogenesis by fostering the sprouting of PROX-1
+
 cells in the cardinal vein and by 
promoting survival and proliferation of LECs [Adams RH et al, 2007]. 
In embryonic development, VEGFR-3 is expressed also by BECs and it is also involved in early blood 
vascular functions. This was shown in experiments in which VEGFR-3 deletion caused embryonic 
death and alteration in blood-vessel remodeling. However, after the early stages of development, 
VEGFR-3 expression is downregulated in BECs and becomes restricted to LECs in the late stage of 
development and in adulthood [Dumont DJ et al, 1998]. The importance of VEGFR-3 mediated 
signaling in lymphangiogensis was demonstrated in murine models where the homozygous 
deletion of VEGF-C caused severe lymphatic hypoplasia and embryos did not develop any 
lymphatic vasculature [Karkkainen MJ et al, 2004]. In fact, in mice knockout for VEGF-C, PROX-1
+
 
cells located in the cardinal veins initially differentiated in LEC but then were unable to migrate 
and form primary lymph sacs. Notably, despite VEGF-D is known to also supports 
lymphangiogenesis processes, VEGF-D deletion did not impair the development of lymphatic 
vasculature [Karkkainen MJ et al, 2004]. Moreover, Karkkainen et al described the presence of a 
missense mutation in VEGFR-3 gene - that causes the inactivation of tyrosin-kinase domain – in 
subjects affected by Milroy disease, a rare autosomal dominant disease characterized by 
lymphoedema [Karkkainen MJ et al, 2000]. The same research group described Chy mice as a 
possible model for studying hereditary lymphoedema and its possible therapy since they have a 
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similar mutation and develop lymphoedema [Karkkainen MJ et al, 2001]. Therefore, VEGF-C-
VEGFR-3 pathway seems to play a crucial role in regulating lymphangiogenesis. 
1.2.3.3 LYVE-1 
LYVE-1 is considered one of the most specific markers for the identification of lymphatic 
endothelium since it allow to distinguish lymphatic from blood vessels in many different peripheral 
tissues [Jackson DG et al, 2004]. Despite LYVE-1 is expressed by sinusoids in liver and spleen and 
by a subset of macrophages that infiltrate tumors and inflamed tissues, LYVE-1 expression is 
absent in primary and cultured fibroblasts, epithelial cells and hematopoietic cells. In histological 
analysis of tissue sections of intestine, skin and secondary lymphoid tissues, LYVE-1 stains 
specifically only lymphatic vessels which are also negative for the markers typically used for blood 
vessel identification (i.e. CD34, vWF, CD44). Moreover, LYVE-1
+
 vessels are also positive for the 
expression of other lymphatic markers such as PROX-1, podoplanin and VEGFR-3 [Jackson DG et al, 
2004]. 
LYVE-1 is an integral membrane glycoprotein that mediates binding and internalization of HA. HA 
binding is allowed by the presence of the HA-binding domain called ͞LINK͟ module located at the 
N-terminous of LYVE-1 extracellular domain. Moreover, LYVE-1 is characterized by high structural 
similarities with CD44 – its closest homologue expressed on lymphocytes - that is a HA receptor 
involved in the homing of inflammatory leukocytes [Banerji S et al, 1999]. 
During embryonic lymphangiogenesis, LYVE-1 is the first expressed marker of lymphatic 
endothelial commitment. In adults, LYVE-1 remains highly expressed in lymphatic capillaries but its 
expression decreases in the collecting lymphatic vessels [Alitalo K et al, 2005; Tammela T et al, 
2010]. The role of LYVE-1 in regulation of lymphatic vascular function has not yet been clarified 
since in vivo studies demonstrated that mice that lack the expression of LYVE-1 develop functional 
lymphatic vessels [Gale NW et al, 2007]. Two possible functions have been proposed for LYVE-1 
expressed on LECs. The first hypothesis is that LYVE-1 can act as an HA transporter thus 
participating to the process of HA catabolism. In particular, up-take HA can either be degraded 
inside LECs or released in the lumen of lymphatic vessels, via transcytosis. By this pathway, HA can 
be transported to other sites deputed to its catabolism: lymph nodes and liver. This hypothesis is 
supported by the fact that LECs express LYVE-1 on both luminal and baso-lateral side, thus 
allowing HA transcytosis [Prevo R et al, 2001]. The second possibility is that LYVE-1 by binding HA 
may play a role in the regulation of adhesion, entry and migration of cells in lymphatic vessels 
[Jackson DG et al, 2004]. 
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1.2.3.4 Podoplanin 
Podoplanin - also called T1α, E11 antigen, gp38, and PA2.26 – is a small O- and N-glycosylated 
transmembrane protein. In mouse embryos, podoplanin expression starts in PROX-1
+
 LECs 
sprouted from the cardinal vein at day E11.5. In adults, it is co-expressed with VEGFR-3 in the 
lymphatic endothelium [Breiteneder-Geleff S et al, 1999] whereas it is not expressed in larger 
lymphatic vessels and in all the blood vessels. Moreover podoplanin is also expressed in some non-
endothelial cells, such as kidney podocytes, osteoblastic cells and lung alveolar type I cells 
[Breiteneder-Geleff S et al, 1997]. Podoplanin seems to regulate several LEC functions as described 
in in vitro studies in which podoplanin promotes LEC adhesion, migration, and tubulogenesis 
formation. In vivo, it was reported that podoplanin deficient mice are characterized by 
dysfunctional lymphatic vessels [Schacht V et al, 2003]. Despite the role of podolanin in adults is 
still under investigation, several studies showed that podoplanin plays a crucial role in the process 
of separation of lymphatic vessels from the blood vessels in embryonic development [Tammela T 
et al, 2010]. In fact, podoplanin binds CLEC-2 (C-type lectin receptor 2) on platelets inducing their 
activation and aggregation [Suzuki-Inoue K et al, 2007]. Platelet aggregation in turn prevents blood 
from flowing into newly formed lymphatic vessels that bud from the cardinal vein. Uhrin et al 
demonstrated the role of podoplanin in inducing platelet aggregation showing that podoplanin 
knockout or pharmacological inhibition of platelet aggregation inhibited the formation of platelet 
aggregates in correspondence of the separation zone of cardinal veins and podoplanin
+
 lymph sacs 
[Uhrin P et al, 2010]. 
1.2.4 Lymphatic endothelial progenitor cells (LEPCs) 
Similar to the development of blood vascular system, also the process of lymphatic vessel 
formation (lymphatic neovascularization) depends on two mechanisms: de novo formation of 
lymphatic vessels starting from stem or progenitor cells (lymphovasculogenesis) and formation of 
new lymphatic vessels starting from pre-existing vessels (lymphangiogenesis). 
Until about 10 years ago, lymphatic vessel formation in adulthood was thought to occur only by 
lymphangiogenesis [Karpanen T et al, 2001; He Y et al, 2004]. Nevertheless, starting from 2003 
several studies suggest that lymphvasculogenesis may also occur in adulthood thus contributing to 
lymphatic neovasculaziation processes [Kerjaschki D et al, 2006; Maruyama K et al, 2005]. Since 
hematopoietic stem cells and EPCs play a well established role in adult neovascularization 
processes [Asahara T et al, 2011] it was hypothesized that a similar mechanism could occur also in 
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lymphatic neovasculaziation process. In particular, it was suggested that lymphatic endothelial 
progenitor cells (LEPCs) derived from bone marrow could participate in lymphatic vessel 
formation. In these years, many efforts have been made to validate this hypothesis. In 2003, 
Salven et al reported first evidence about LEPCs. In particular, they described in human fetal liver 
the presence of a CD34
+
/VEGFR-3
+
/CD133
+
 sub-population that in vitro was characterized by a 
high proliferative potential and the expression of both lymphatic and blood vascular markers. 
These observations suggested that these cells could act both as EPCs and LEPCs [Salven P et al, 
2003]. Moreover, two different studies reported that -in inflammatory conditions- after bone 
marrow transplantation, donor-derived cells labeled with GFP were localized and/or incorporated 
in newly formed lymphatic vessels [Maruyama K et al, 2005; Religa P et al, 2005]. In 2006, 
Kerjaschki et al confirmed these observations also in human. In fact, they reported that male-
recipient derived LECs were clearly detectable in lymphatic vessels of kidney-transplanted from 
female donor [Kerjaschki D et al, 2006]. 
In the last years, different cell populations have been described as potential LEPCs. In 2010, Lee at 
all identified a population of podoplanin
+
/CD11b
+
 macrophages derived from the bone marrow 
that contribute to lymphatic neovascularization both by transdifferentiating in lymphatic 
endothelial cells and by producing VEGF-C and other lymphangiogenic factors that promote 
proliferation of local pre-existent LECs [Lee JY et al, 2010; Kerjaschki D et al, 2006]. In other 
studies, LEPCs have been identified in the peripheral blood as cells that express CD34 in 
combination with the lymphatic markers VEGFR-3. Tan et al reported that CD34
+
/VEGFR-3
+
 cells, 
isolated by fluorescence-activated cell sorting from human cord blood mononuclear cells, acquired 
- after two weeks of culture in presence of VEGF-C - a lymphatic phenotype since they expressed 
typical lymphatic markers such as PROX-1, LYVE-1 and are characterized by high activity of ϱ͛-
nucleotidase, an enzyme preferentially expressed in LECs than in BECs [Tan YZ et al, 2014]. 
All these observations supported the hypothesis the lymphatic precursors cells derived from bone 
marrow or organs can actually participate to post-natal lymphatic vessels formation [Park C et al, 
2011]. Nevertheless, the identity and the characteristics of LEPCs have not yet been clearly 
defined and therefore, more extensive studies will be required to characterize the putative 
precursors of LECs involved in neo-lymphangiogenesis also in adulthood. 
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1.2.5 Tumor-associated lymphangiogenesis 
In adulthood, lymphangiogenesis is mainly inactive in physiological conditions and occurs only 
during luteal phase of menstrual cycle in corpus luteum formation and during pregnancy in 
endometrium [Alitalo K et al, 2005]. On the contrary lymphangiogenesis is observed in 
pathological conditions such as wound healing, allograft rejection, tissue and organ regeneration, 
autioimmunity, acute and chronic inflammation, and tumor [Alitalo K et al, 2005; Karpanen T et al, 
2008]. In particular, cancer represents a major cause of lymphangiogenesis in adult [Alitalo A et al, 
2012]. 
In fact, in the past, it was thought that lymphatic vascular system passively contribute to tumor 
cell dissemination in lymph nodes and distant organs providing channel through which tumor cells 
can transit. In support to this hypothesis several clinical studies showed that lymphangiogenesis in 
the proximity of solid tumors correlates with mestastasis in lymph node and distant organs in 
patients with melanoma or breast cancer [Achen MG et al, 2005]. This observation confirms that 
lymphatic vessels could represent a route that cancer cells can use to disseminate in lymph nodes 
and, in a second time, in other organs [Alitalo A et al, 2011]. Nevertheless, recent evidence 
suggests that lymphatic vasculature plays an active role in tumor spread and the tumor-associated 
lymphangiogenesis directly facilitate tumor dissemination [Li T et al, 2012]. In particular, recent 
studies documented that tumor associated lymphangiogenesis occurs also within draining lymph 
nodes, even before tumor cells colonize them [Qian CN et al, 2006]. Qian et al suggested the ͞seed 
and soil͟ theory according to which cancer (the ͞seed͟) is able to remotely modify and prepare the 
lymph node (the ͞soil͟) for its arrival. In particular, lymphangiogenesis in lymph nodes is mainly 
mediated by soluble factors produced within the primary tumor site (mainly VEGF-C and VEGF-A). 
Since high levels of prolymphangiogenic growth factors have been detected in blood of patients 
with cancer, it is possible that such soluble factors may act not only in sentinel lymph nodes but 
also in distant organs [Witte MH et al, 2011]. 
Several studies are therefore investigating the role of the tumor microenvironment, in particular 
soluble factors and components of extracellular matrix (ECM), in promoting tumor 
lymphangiogenesis in order to identify possible targets and develop new therapeutic strategies.  
1.2.5.1 Role of soluble factors 
The tumor microenvironment is rich in signaling molecules that regulate lymphangiogenesis in 
addition to blood vessels angiogenesis. In particular, tumor-induced lymphangiogenesis is 
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promoted by VEGF-C and VEGF-D. Such molecules are lymphatic growth factors and several 
studies reported that they are overexpressed in different type of cancers [Alitalo K et al, 2012]. In 
particular, VEGF-C and VEGF-D can be released in the tumor microenvironment by several cellular 
types: tumor cells themselves, stromal cells (i.e. cancer associated fibroblast – CAF), tumor-
infiltrating macrophages (TAMs) and platelets [Neuchrist C et al, 2003; Schoppmann SF et al, 2002; 
Alitalo K et al, 2011; Kerjaschki D, 2005]. 
Between these growth factors, VEGF-C is considered the most important in supporting tumor 
associate lymphangiogenesis [Achen M et al, 2005]. In fact, several clinical studies reported that 
high levels of VEGF-C correlate with lymph node metastatization [Alitalo A et al, 2011]. Moreover, 
in vivo studies - performed in murine models of different types of tumor - confirmed that VEGF-C 
overexpression promotes tumor lymphangiogenesis increasing lymphatic vessel diameter and 
density and increasing metastatization in lymph nodes and organ [Skobe M et al, 2001; Karpanen T 
et al, 2001]. In addition, VEGF-C overexpression promotes lymphangiogenesis even in mouse 
models of tumors characterized by low frequencies of lymph node metastatization such as the 
murine fibrosarcoma T241 cell line and the human prostate cancer cell line LAPC9 [Burton JB et al, 
2008; Hoshida T. et al, 2006]. 
Moreover, despite VEGF-D promotes lymphangiogenesis and metastatization in mouse models, 
VEGF-D levels in patients correlate with lymph node metastasis only in a small proportion of the 
reported clinical studies. Therefore VEGF-D seems to play a minor role in tumor 
lymphangiogenesis compared to VEGF-C [Alitalo A et al, 2012]. 
The pro lymphangiogenic function of both VEGF-C and –D is mediated by their ligation to their 
receptor VEGFR-3. Therefore, the inhibition of VEGFR-3 function using blocking antibodies or 
soluble receptors that sequester the ligands could represent possible therapeutic strategies to 
reduce tumor lymphangiogenesis. Despite further studies are needed to clarify the role of 
lymphangiogenesis and VEGF-C/VEGFR-3 pathway in tumor growth, it has been demonstrated that 
VEGFR-3 blockade reduces tumor growth rate in solid tumor such as breast cancer, melanoma and 
squamous cell carcinoma [Alam A et al, 2012; Lund A et al, 2012; Alitalo AK et al, 2013]. 
Moreover, also overexpression of VEGF-A was reported to promote lymphangiogenesis [Björndahl 
MA et al, 2005]. In particular, Björndahl et al reported that, in mice models of T241 fibrosarcoma, 
VEGF-A overexpression promoted peritumoral lymphatic vessel growth thus promoting formation 
of lymph node metastasis. In addition, in a corneal tumor model, the authors showed that 
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lymphangiogensis was fostered by VEGF-A through a VEGF-C/VEGF-D/VEGFR-3-independent 
pathway [Björndahl MA et al, 2005]. 
1.2.5.2 Role of the extracellular matrix (ECM) 
The extracellular matrix (ECM) is a highly organized meshwork of collagens, proteoglycans, 
glycoproteins, and growth factors. The major function of ECM is to provide support and anchorage 
to cells [Chen J et al, 2012]. In the last years, several studies revealed that the ECM not only has 
structural functions but, through integrin-mediated interaction, it can also regulate cell survival, 
differentiation, growth and migration. However, very little is known about the role of ECM in the 
regulation of tumor lymphangiogenesis. Evidences suggest that fibronectin may be involved in 
ECM-dependent lymphangiogenesis [Bae YK et al, 2013; Ou J et al, 2013; Kramer RH et al, 1985]. 
In particular, in vitro, fibronectin interacts with integrins α5β1 and α4β1 expressed on LECs, 
fostering the survival and growth of these cells. In vivo, the levels of fibronectin expression in 
tumor stroma correlates with lymphovascular invasion, lymph node metastasis and poor clinical 
outcome in breast cancer and other human tumors [Bae YK et al, 2013; Ou J et al, 2013]. 
Fibronectin is also highly expressed in Kaposi͛s “aƌĐoŵa, [Kramer RH et al, 1985] a tumor 
characterized by the proliferation of the typical spindle cells, cells of endothelial origin that 
express typical lymphatic markers such as VEGFR-3, LYVE-1 and podoplanin [Dupin N et al, 2006]. 
Futher evidences for a role of fibronectin in promoting lymphangiogenesis in human cancer derive 
from observation that EDA-fibronectin - an alternatively spliced oncofetal isoform of fibronectin 
whose most specific receptor is integrin α9 - promotes lymphangiogenesis. Moreover, its 
expression correlates with distant metastasis in colorectal carcinoma where integrin α9 is 
expressed on both LECs and tumor cells [Xiang L et al, 2012]. Another oncofetal truncated isoform 
of fibronectin – namely migration stimulating factor (MSF) - was described in tumor 
microenvironment [Schor SL et al, 2003] but its role in lymphangiogenic process has never been 
investigated. 
Altough fibronectin and its oncofetal isoforms are the ECM proteins that have been mainly 
involved in human cancer associated lymphangiogenesis, other ECM proteins may participate to 
this process. In particular, in literature was reported that also other ECM components, such as 
tenascin-C and osteopontin, seem to be involved in promoting tumor-lymphangiogenesis; in fact, 
also their stromal expression is associated with increased lymph node metastasis in various tumor 
types [Ishihara A et al, 2002; Rudland PS et al, 2002]. 
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1.3 Kaposi’s Sarcoma (KS) 
1.3.1 Epidemiology and clinical variants 
In 1872, the Hungarian dermatologist Moritz Kaposi first described idiopatisches multiples 
Pigmentsarkom der Haut ǁhiĐh ďeĐaŵe kŶoǁŶ as Kaposi͛s “aƌĐoŵa ;K“Ϳ [Braun M, 1982]. 
KS is a multifocal lymphangioproliferative disease, characterized by proliferation of endothelial 
cells and immune system deregulation. KS presents typically with cutaneous lesions with macular, 
papular, nodular, or plaque-like appearance but rarely it also involve visceral organs [Braun M, 
1982]. 
In 1994, Chang et al. discovered a new herpesvirus - called Human Herpes Virus 8 (HHV-8) or 
Kaposi͛s “aƌĐoŵa-associated herpesvirus (KSHV) - that was present in KS lesions of an AIDS patient 
[Chang Y et al, 1994]. This was the first evidence that a virus - HHV-8 - was the causative agent of 
KS as confirmed in further studies [Whitby D et al, 1995; Kedes DH et al, 1996; Martin JN et al, 
1998; O͛Brien TR et al, 1999].  
However, HHV-8 is necessary but not sufficient for KS development. Most of primary HHV-8 
infections are asymptomatic and in healthy people, the immune system is able to control the 
infection that persists in a latent form. HHV-8 reactivates and supports the development of KS 
lesions both in case of immunedeficiency – due to pathological (i.e. AIDS) and iatrogenic (i.e. 
transplants) conditions – and in the elderly - that are characterized by a low-grade of chronic state 
of inflammation (defined as inflammaging) [Antman K et al, 2000; Ascoli V et al, 2009]. 
Due to the close association between KS and HHV-8 infection, KS epidemiology reflects, at least in 
part, HHV-8 seroprevalence. The modes of HHV-8 transmission are still unclear, and both vertical 
and horizontal (sexual and non-sexual) transmission modes have been described. In particular, 
saliva-mediated HHV-8 transmission is also likely to occur since saliva of HHV-8 infected individuals 
was reported to contain high titer of virus [Rohner E et al, 2016]. Among the general population, 
the prevalence of HHV-8 is higher in sub-Saharan Africa (percentage of HHV-8 seropositive 
subjects within the total population: ≥ϱϬ%) than in Europe, United States, Asia and Australia 
(<4%). In Western World, a higher HHV-8 prevalence is observed in men who have sex with men 
(MSM) and in the Mediterranean region (4-35%) [Rohner E et al, 2016]. 
Based on epidemiological and clinical features, four clinical variants of KS are known: classic KS 
(cKS), endemic, AIDS-associated and iatrogenic KS. Despite they are all characterized by HHV-8 
infection and similar hystological features, these clinical variants develop in specific populations 
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and differ one from each other in rates of progression and anatomical sites os KS lesions [Antman 
K et al, 2000]. 
ClassiĐ Kaposis͛s “aƌĐoŵa ;ĐK“Ϳ 
cKS is a rare disease mainly found in the Mediterranean region, where HHV-8 seroprevalence is 
higher. In fact, cKS incidence is 10-fold higher in Italy, Greece, Israel and Turkey than in other 
European and North American Regions. In particular, the Italian islands Sardinia and Sicily are 
characterized by the highest incidence rates of cKS in Europe [Schwartz RA et al, 2008; Iscovich J et 
al, 2000]. cKS occurs mainly in middle-aged and elderly people of Mediterranean or Jewish descent 
[Iscovich J et al, 2000]. Despite HHV-8 can be transmitted both sexually and through saliva, only 
few familial KS cases were described thus suggesting that infectious (viral), genetic, and 
environmental factors, either independently or in combination may contribute to KS pathogenesis 
[Armyra K et al, 2014; Mancuso R et al, 2011]. 
cKS usually presents as cutaneous lesions that initially appear on the lower extremities. The onset 
of KS lesions on lower extremities is supported by low oxygenation of the tissues and therefore 
venous stasis and lymphedema are considered co-factors in KS development. In fact, several 
studies demonstrated that chronic exposure to hypoxia promotes viral reactivation in HHV8-
infected cells [Davis DA et al, 2001; Haque M et al 2003]. During disease progression KS can also 
involve the upper body and rarely the visceral organs.  
Among the four clinical variants, cKS is characterized by slow progression and good prognosis. 
Accordingly, treatment is individualized on the basis of the stage of disease and range from 
nonintervention to local therapy (i.e. intralesional chemotherapy, surgical excision) or systemic 
therapy (i.e. chemotherapy, radiotherapy) [Schwartz RA et al, 2008; Vano-Calvan S et al, 2011]. 
However, after treatment HHV-8 DNA is still detectable in PBMCs and in post-lesional skin, 
contributing to the relapses that frequently occur in cKS events [Dourmishev LA et al, 2003]. 
Moreover, cKS can represent a useful model of virus-associated tumor taking advantage from the 
absence of confounding factors such as iatrogenic immunosuppression or co-infection with other 
viruses (i.e. HIV) that are present in the other variant of KS. 
Endemic KS 
Endemic KS, also called African KS, is frequent in sub-Saharan Africa (Zaire, Uganda and Tanzania), 
where HHV-8 infection is endemic and the virus is mostly transmitted during childhood, vertically 
– from mother to child – and horizontally – for example between siblings [Plancoulaine S et al, 
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2000; Andreoni M et al, 2002]. Endemic KS affects both children (median age of 3 years and a 
male-to-female ratio of 1,7:1) and adults (median age of 35 years and a male-to-female ratio of 
15:1) [Schwartz RA et al, 2008]. It presents in four distinct clinical patterns: one is similar to cKS 
but affects predominantly young adults; the other three forms are aggressive and similar to AIDS-
associated KS. In particular, among the aggressive forms, one variant is a cutaneous disease which 
invades locally bones and soft tissues; another variant is characterized by florid muco-cutaneous 
and visceral manifestations; a third variant occurs in young children and is represented by a 
fulminant disease rapidly disseminating to visceral organs and lymph nodes [Hengge UR et al, 
2002]. 
AIDS-associated KS 
Co-infection by HIV-1 represents the major risk factor unique to this KS variant. In fact, AIDS-
associated KS affects HIV-positive patients affected by AIDS and is the most common malignancy 
in bisexual and homosexual men with AIDS [Dourmishev LA et al, 2003]. AIDS-associated KS is a 
very aggressive form and is characterized by frequent mucosal and visceral progression [Schwartz 
RA et al, 1996]. In previous studies it was hypothesized that the frequency and the aggressiveness 
of the AIDS-associated KS variant could be caused not only by the immunodeficiency related to 
HIV but also by HIV infection itself [Vogel J et al, 1988]. 
The introduction of HAART therapy (Highly Active Anti-Retroviral Therapy) for treatment of HIV 
infection produced a reduction of the incidence of KS in AIDS affected patients. In particular, in 
USA and Europe, a reduction between 33% and 95% has been observed in the KS incidence in 
HAART-treated patients. On the other hand, in Africa - where HIV infection is epidemic and the 
access to HAART treatment is limited – the incidence of AIDS-Associated KS is increasing [Semeere 
AS et al, 2012]. 
Iatrogenic KS 
Iatrogenic KS develops in subjects undergoing immunosuppressive therapy, in particular in organ-
transplant recipients. Several studies reported an increase in KS incidence in transplant recipients 
(100 fold or more) compared to general population in particular in renal and lung transplant 
recipient [Zavos G et al, 2014; Piselli P et al, 2009]. In fact, immunosuppressive therapy can favour 
HHV-8 reactivation in HHV-8 seropositive recipients. Nevertheless, cases of seroconversion after 
transplant were described, supporting the hypothesis that HHV-8 infection can also derive from 
transplanted organ [Hosseini-Moghaddam SM et al, 2012; Barozzi P et al, 2003; Luppi M et al, 
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2003]. The manifestations of Iatrogenic KS range from chronic to aggressive visceral organ 
involving form.  
Withdrawal or reduction of the immunosuppressive treatment usually is accompanied by KS 
remission. In particular, it was observed that the treatment with calcineurin inhibitor (i.e. 
Cyclosporine) promoted KS insurgence. In fact, it was documented that when the treatment was 
switched from Cyclosporine to mTOR (mammalian Targets Of Rapamycin) inhibitor, such as 
Sirolimus, KS lesions regressed [Stallone G et al, 2005]. 
1.3.2 Histopathology of KS 
1.3.2.1 Spindle cells in KS lesions 
The German pathologists Kobner (in 1883) and Philippson (in 1902) were the first to use the term 
spindle cells, talking about KS. Spindle cells, whose name derives from their spindle-shaped 
morphology, are the typical cells of KS lesions. In particular, they are the main component of KS 
lesions in the late stages of disease. Spindle cells are all HHV-8 infected and only a small 
percentage expresses markers of HHV-8 lytic replication while the majority of the cells are latently 
infected [Gessain A et al, 2005]. 
Even though spindle cells are considered the tumoral component of KS, their features differs from 
those of common tumor cells. In fact, spindle cells in KS lesions often are oligo- or polyclonal [Gill 
PS et al, 1998; Duprez R et al, 2007] and lack the genetic instability typical of the majority of tumor 
cells. Even in late stage lesions, spindle cells are typically diploid and do not have characteristic 
chromosomal rearrangement. Spindle cells differ from typical tumor cells also in their vitro 
behaviour; despite they can grow in culture [Ensoli B et al, 1998; Corbeil J et al, 1991; Lebbe C et 
al, 1997], spindle cells do not form foci, do not grow in soft agar and need exogenous growth 
factors for their survival and proliferation [Ensoli B et al, 1998]. Moreover, in in vivo models, 
spindle cells do not form persistent tumor when injected in nude mice [Herndier BG et al, 1994]. In 
fact, upon inoculation in nude mice, spindle cells, obtained from primary KS lesion, give rise to 
transient tumor, promote the formation of new vessels of murine origin in surrounding tissues but 
they survive for a short period of time and, after plug reabsorption, vessels of murine origin also 
disappear [Mutlu AD et al, 2007]. All these observations suggest that growth factors in the tumor 
microenvironment are necessary for spindle cells survival and proliferation [Ensoli B et al, 2001]. 
Therefore, it has been proposed a model in which interactions among different factors are 
necessary for KS development: spindle cells produced pro-inflammatory and pro-angiogenic 
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factors that recall inflammatory cells that produce cytokines which in turn promote spindle cells 
survival and growth. In particular, the presence of a state of inflammation seems to play an 
important role in KS development especially in cKS since human aging is characterized by the 
presence of a condition of chronic and low-grade inflammation. 
1.3.2.1.1 Origin of the spindle cells 
The origin of the spindle cells has been investigated for long time and several types of cells have 
been taken into account [Gessain A et al, 2005]. Electron-microscopy analysis was not sufficient to 
define the origin of spindle cells since these cells have some features typical of endothelial cells 
but some particular endothelial marker such as Weible-Palade bodies (storage granules of von 
Willebrand factor) are present only in a small fraction of spindle cells. Moreover, spindle cells are 
characterized by some ultra-structural features typical of other cell types such as fibroblasts, myo-
fibroblats, smooth muscle cells and pericytes. Further immunohystochemical studies did not 
clarify the origin of the spindle cells because they express endothelial markers (including CD31, 
CD34, FVIII and VE-cadherin), markers of monocytes-macrophages (including CD68 and PAM-1) 
and markers of others cell types such as fibroblasts and smooth muscle cells [Browning PJ et al, 
1994]. However, the scientific community reached the consensus on the fact that spindle cells 
derived from the endothelial lineage. In fact, spindle cells express factor VIII which is produced 
exclusively by endothelial cells [Burgdorf WH et al, 1981]. Moreover, spindle cells derived from 
primary KS lesions express several endothelial markers such as CD31, CD34, CD36, CD54, ELAM-1, 
ULEX-1 and do not express markers of other cell types such as CD2 and CD19 [Russell JR et al, 
1995; Browning PJ et al, 1994]. 
Once researches defined that the spindle cells derive from endothelial cells, they investigated 
whether KS spindle cells derived from BECs or LECs. Several studies proposed that they derived 
from lymphatic endothelium because they lack markers preferentially expressed by BEC (vWF, 
PAL-E and Enos) while they express typical lymphatic markers such as podoplanin, LYVE-1 and 
VEGFR-3 [Weninger W et al, 1999; Dupin N et al, 1999; Pyakurel P et al, 2006; Cheung L et al, 
2005]. 
More recent studies supported the hypothesis that BECs latently infected by HHV-8 acquire an 
intermediate phenotype between BECs and LECs by up-regulating the expression of lymphatic 
markers and down-regulating the expression of markers preferentially expressed at high levels in 
BECs as a direct consequence of HHV-8 infection. Wang et al observed by gene expression micro 
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array analysis that cells contained in KS lesions (>80% spindle cells in nodular KS biopsy) were 
more similar to LECs than to BECs [Wang HW et al, 2004]. Hong et al. observed that HHV-8-
infected BECs underwent a lymphatic reprogramming. In particular PROX-1, a transcription factor 
with a key role in lymphatic differentiation, was up-regulated and genes highly expressed on BECs 
were down-regulated [Hong YK et al, 2004]. Carroll et al reported that HHV-8 can infect in vitro 
both BECs and LECs minimizing the difference of gene expressions between the two cell 
populations. They observed that HHV-8-infected immortalized human dermal microvascular cells 
(HDMECs) up-regulated the expression of typical lymphatic endothelium markers such as PROX-1, 
podoplanin, LYVE-1 and VEGFR-3 [Carroll PA et al, 2004; Yoo J et al, 2010]. Moreover, it was 
reported that HHV-8 virion envelope-associated glycoprotein B can activate VEGFR-3 on HDMECs 
[Zhang X et al, 2005]. 
Based on these observations it may be hypothesized that spindle cells may derive from mature 
endothelial cells infected in the site of KS lesions or they may derive from infected EPCs that once 
infected by HHV-8, can acquire an intermediate phenotype between BECs and LECs [Wang HW et 
al, 2004; Hong YK et al, 2004]. However, in this possible scenario, it should still be clarified the 
sites and modality in which EPCs are infected by HHV-8. In fact, EPCs may be infected in the bone 
marrow or in the sites of KS lesions by monocytes or B cells, cell types that are typically infected by 
HHV-8 otherwise they themselves could be latently infected and therefore could enhance KS 
lesions development. The hypothesis that KS lesions develop from dissemination of previously 
infected endothelial precursor cells is supported by several observations; in particular, that pro-
inflammatory micro-environment could promote spindle cells development and proliferation from 
infected endothelial precursor cells. In fact, it has been observed that KS lesions often develop in 
patients with systemic inflammation at sites of previous local inflammation, such as a surgical 
ǁouŶd ;KoeďŶeƌ͛s pheŶoŵeŶoŶͿ [Webster-Cyriaque J et al, 2002]. 
Moreover, Barozzi et al reported that, after kidney transplant, HHV-8 negative recipients 
developed KS and lesions contained neoplastic cells derived from HHV-8-infected donors. Despite 
mature endothelial cells derived from kidney could be the precursors of spindle cells, they are 
terminally differentiated and characterized by a low proliferative potential, therefore, the more 
probable hypothesis is that infected endothelial precursors cells localized in the transplanted 
kidney could disseminate in the immunosuppressed recipients and act as precursors of spindle 
cells [Barozzi P et al, 2003]. 
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1.3.2.1.2 In vitro culture of KS spindle cells 
Several models of spindle cells culture were reported in literature. Spindle cells can be isolated 
from epidermal skin biopsies of KS lesions [Kaaya EE et al, 1995]. Moreover, spindle cells can also 
be cultured from peripheral blood mononuclear cells. In this case spindle cells are cultured in 
medium supplemented with pro-inflammatory cytokines and/or in conditioned medium (CM) 
derived from activated T-cells. In fact, CM contains pro-inflammatory cytokines -such as: IL-2, IL-6, 
TNFα, TNFβ, GM-C“F, PDGF, TGFβ – that in vivo induce KS progression and Barillari et al showed 
that CM is necessary for culturing spindle cells derived from AIDS-associated KS lesions [Barillari G, 
1992]. CM can also induce mature endothelial cells to acquire spindle cell phenotype, to produce 
angiogenic factors and to promote in vitro angiogenesis [Browning PJ et al, 1994]. 
Another important feature of in vitro cultured spindle cells is that, during culture, they lose HHV-8 
episomes [Aluigi MG et al, 1996; Lebbe C et al, 1997]. The reason why, after several passages, 
spindle cells lose HHV-8 episomes in vitro is unknown and this condition does not reflect what 
happens in vivo. In fact, in vivo, spindle cells are always infected by HHV-8 even in late stage KS 
lesions [Sgadari C et al, 2003]. These observations support the hypothesis that lytic replication and 
production of new virions are required for counterbalancing the episomal loss occurring during 
spindle cells proliferation [Grundhoff A et al, 2004]. 
By contrast, HHV-8 infection persists in several B cell lines derived from Primary Effusion 
Lymphoma (PEL), another disease associated with HHV-8 infection. Therefore, at least for B cells, a 
stable latency can be maintained both in vivo and in vitro under standard culture conditions [Pica 
F et al, 2000]. 
1.3.2.2 Histopathological and clinical staging of KS 
In all epidemiological variants, the histopathology of KS is similar. Macroscopically, KS lesions can 
be classified as patch (or macular), plaque and nodule according to their histological features. 
During disease progression KS lesions with different histological features can also co-exist [Gessain 
A et al, 2005]. 
Macular lesions are frequent at the onset of KS and are characterized by spreading through the 
dermis of capillaries and small vessels-like structures - composed by small and irregular 
endothelial cells - by hemosiderin deposition and the presence of little inflammatory infiltrate 
enriched in plasma-cells and lymphocytes [Ackerman AB et al, 1979]. 
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Plaque KS lesions are confluent and palpable since the blood vessels infiltration of dermis 
increases leading to the formation of angiomatoid areas and glomerulous-like vascular structures 
surrounded by spindle cells organized in short fascicles. This kind of lesions can invade all the 
reticular dermis and can also reach subcutaneous fat; moreover they are characterized by the 
presence of perivascular inflammatory infiltrate [Ackerman AB et al, 1979].  
In nodular KS lesions, spindle cells become the predominant component of KS lesions and organize 
in sheets forming large fascicles. The vessels inside the lesion are characterized by fragmented 
basal lamina and irregular endothelial layer. Erythrophagocytosis and endothelial cell necrosis 
were also observed [Regezi JA et al, 1993; Modlin RL et al, 1983]. 
The definition of criteria for clinical staging of patients affected with KS has been a challenge. 
During the years the criteria and the consequent classification, have been changed since new 
hystopathological and clinical aspects were gradually taken into account.  
In particular, in 2003 Brambilla et al proposed one of the most used and accepted KS classification 
[Brambilla L et al, 2003; Cappelletti M et al, 2012]. In this classification the authors introduced new 
clinical parameters such as evolution and the possible presence of complications in order to help 
clinicians in patient management and treatment (Table 1). 
 
Table 1: KS staging according to classification proposed by Brambilla et al.  
In particular, KS classification proposed by Brambilla et al takes into account several aspects: the 
histological features of the lesions (nodular, infiltrative, florid, disseminated, with or without 
visceral involvement), the localization of the lesions (lower limb, limbs ,trunk and head) the clinical 
behaviour (classified as not aggressive, locally aggressive and disseminated aggressive) the rate of 
disease evolution (classified as slow or fast) and the possible presence of complications 
(lymphedema, lymphorragia, hemorrhage, pain, etc.). 
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The rate of disease evolution is defined as fast (B) when one or more new lesions appear or the 
total area of the lesions increases within three months from the last observation. Visceral lesions 
(gastroenteric tract, oral cavity, lymph nodes and lung) are rare and more frequent in late stages 
(III and IV stage) with fast evolution rate [Brambilla L et al, 2003]. 
Therapy able to eradicate HHV-8 is not yet available; anti-herpes drugs, like Cidofovir or 
Ganciclovir, inhibits viral DNA polymerase but are effective only on virus in active replication phase 
but not when virus is in latent phase. KS treatment is personalized and is usually defined on the 
basis of clinical variant, tumor extension and general clinical condition of the patients. Possible 
treatment for KS, whose goal is reduction and control of lesions progression, ranges from 
elastocompression to intralesional chemotherapy and systemic chemotherapy. Small and 
superficial lesions can be surgically excised; sporadic and isolate lesions are usually treated with 
topic and intralesional chemotherapy like vincristine [Brambilla L et al, 2010; Regnier-Rosencher E 
et al, 2013]. Extended superficial lesions are treated with low doses of radiation-therapy (800-
1000 cGy as single dose or 1500-2000 cGy for a week) directed on the lesions and their hedges 
[Fatahzadeh M et al, 2012]. High-doses of radiotherapy or systemic chemotherapy protocols are 
used when KS lesions are deep or in case of visceral involvement [Fatahzadeh M et al, 2012; Vaz P 
et al, 2011]. Anti-angiogenic therapy represents another possible treatment for KS [Coras B et al, 
2004]. cKS and endemic KS are efficiently treated with the methods previously described; 
iatrogenic KS regresses after reduction or suspension of immune-suppressor therapy [Nagy S et al, 
2000] in AIDS-associated KS, treatment is mainly based on HAART therapy that induces KS lesions 
regression by slowing down progression of AIDS [Jones JL et al, 1999]. 
1.3.3 Etiopathogenesis of KS 
HHV-8 is considered the etiological agent of all clinical variants of KS [Gao SJ et al, 1996]. 
Nevertheless, HHV-8 is necessary but not sufficient for KS development. In fact, other factors such 
as immunosuppression and the presence of a pro-inflammatory microenvironment are required. 
1.3.3.1 Human Herpes Virus 8 (HHV-8) 
The herpesvirus HHV-8 was identified for the first time in tissues of a AIDS-associated KS patient 
by Chang et al in 1994 [Chang Y et al, 1994]. Later, HHV-8 infection was also observed in all the 
other KS clinical variants (cKS, endemic KS and iatrogenic KS) [Huang LM et al, 2000]. 
HHV-8, like Epstein-Barr virus (HHV-4) and herpesvirus Saimiri, belongs to the 
gammaherpesvirinae subfamily. Seven different HHV-8 subtypes (A, B, C, D, E, F and Z) have been 
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identified by sequencing ORF K1, a high variable region located at the left extremity of HHV-8 
genome. The subtypes are differently distributed in the world. A and C subtypes are the most 
common in USA, Europe, Middle East and Northern Asia; subtype B is present in Africa and 
subtype D predominated in the Pacific islands; in addition subtypes E, Z and F have been recently 
described respectively in Brazilian Amerindians, Zambian children and Ugandan Bantu tribe. It is 
still unknown whether the different HHV-8 subtypes are associated with different rate of KS 
development and progression [Ouyang X et al, 2014; Cordiali-Fei P et al, 2015]. 
However, evidences reported by Cordilali-Fei et al supported the hypothesis that subjects infected 
with different HHV-8 subtypes may be characterized by different susceptibility to develop KS. In 
fact, in a small group of 27 HHV-8 infected patients all originated from central and south Italy, they 
observed that in both A and C subtypes two main clusters were present and they turned out to be 
distinctively associated to cKS or non-cKS subjects [Cordiali-Fei P et al, 2015]. 
From the inside to the outside, HHV-8 structure is characterized by: an icosadeltahedral caspid 
composed by 162 capsomers that contains viral DNA, the tegument and the envelope composed 
by a double layer of lipids and viral glicoproteins [Edelman DC et al, 2005]. HHV-8 genome is 
composed by a double strand DNA molecule of 165-170 kb. It is linear in the capsid and 
circularizes when is released inside the host cell where it localizes inside the nucleus [Renne R et 
al, 1996]. Viral genome conformation shift from episomal to linear when HHV-8 infection shifts 
from latent to lytic phase. In fact, HHV-8, like the other herpesviruses, is able to establish both 
latent and lytic infection. Some factors such as UV or immunosuppresion can promote the switch 
from latent towards lytic infection. During the latent phase, HHV-8 replicates as closed circular 
episome using host replication machinery. In the lytic phase, HHV-8 replication proceeds on the 
basis of rolling circle model: viral genome is replicated as a linear molecule off from an episome 
[Wen KW et al, 2010]. 
HHV-8  genome encodes for molecules that inhibit apoptosis, favour progression through cell cycle 
and allow viral immune evasion. 
During latency, no-infectious or no-function virions are produced and only few viral molecules are 
expressed. In particular, viral transcripts expressed during the latent phase promote spindle cells 
proliferation and hyperplasia and favour HHV-8 immune evasion.  
The Latency-Associated Nuclear Antigen (LANA) is encoded by ORF73 and plays a crucial role in 
episome persistence; N-terminal LANA binds histones H2A/H2B in mitotic chromosomes and C-
terminal LANA binds HHV-8 terminal repeat (TR) DNA. Thus, LANA tethers the viral genome to host 
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mitotic chromosomes mediating distribution of HHV-8 episomes to daughter nuclei [Ballestas ME 
et al, 1999; Sun Q et al, 2014]. Sun et al, also demonstrated that LANA promotes HHV-8 DNA 
replication recruiting host cell machinery [Sun Q et al, 2014]. Moreover, LANA is able to affect 
gene expression of the host cell recruiting transcription factors [Renne R et al, 2001]. In particular, 
LANA can inhibit RB–E2F tumor suppressor pathways and p53-mediated transcription activity and 
apoptosis both by inhibiting p53 itself and its transcription [Wen KW et al, 2010]. 
viral Cyclin (vCyc) is encoded by ORF72 and is homolog D2 cellular Cyclin. vCyc activates cellular 
cyclin-dependent kinase 6 (CDK6) by promoting cell cycle transition from G1 to S phase. Moreover, 
it is reported to have oncogenic potential [Li M, et al, 1997; Zhi H et al, 2015]. In fact, vCyc acts as 
a pleiotropic cyclin mediating phosphorilation of a higher number of proteins than ones 
phosphorilated by cellular homolog [Chang Y et al, 1996]. 
vBcl-2 is homolog of cellular Bcl-2 and inhibits apoptosis [Sarid R et al, 1997]. It was reported that 
several factors expressed in KS lesions activates vBcl-2. For example, IFN-γ, by promoting the 
expression of CD40, induces the expression of vBcl-2 [Ensoli B et al, 2001]. 
viral FLICE inhibitory protein (vFLIP) is encoded by ORF71 and activates NFkB signaling which is 
involved both in viral latency and oncogenesis. In fact, NFkB signaling activation is important for 
inhibition of lytic replication and for transforming potential of vFLIP. Furthermore, vFLIP inhibits 
apoptosis thus supporting survival of infected cells [Schulz TF et al, 2006; Wen KW et al, 2010]. 
During the lytic phase, other genes are expressed that encode for molecules endowed with 
tumorigenic activities that promote the development of an angiogenic and inflammatory 
microenviroment in KS lesions [Mesri EA et al, 2010]. In particular, viral IL-6 (vIL-6) is encoded by 
ORF K2 and is homolog of human IL-6. vIL-6 acts as an angiogenic factor, also to increase the 
expression and signaling of VEGF and to promote cell proliferation [Suthaus J et al, 2011]. 
In addition, Viral G protein-coupled receptor (VGPCR), encoded by ORF 74, is homolog of human 
IL-8 receptor and binds CXC and CC chemokines. Its activation is constitutive and it induces VEGF 
expression thus promoting angiogenesis. vGPCR is also characterized by a potent oncogenic 
activity [Yang TY et al, 2000]. 
HHV8 infects several different types of cells. In KS patients, HHV-8 was detected by PCR in 95% of 
analysed KS lesions, in all KS clinical variants [Huang LM et al, 2000] both in lathent and lytic phase 
[Polstra AM et al, 2003 a; Polstra AM et al, 2003 b]. HHV-8 infects mainly spindle cells, most of 
them are latently infected whereas only a small percentage are lytically infected [Stürzl M et al, 
1999 a; Stürzl M et al, 1999 b]. 
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Besides KS, two lymphoproliferative diseases – MulticeŶtƌiĐ CastelŵaŶ͛sDisease ;MCDͿ aŶd 
Primary Effusion Lymphoma (PEL) – are associated to HHV-8 infection and derived from infected B-
cells characterized by alteration in their differentiation process [Chadburn A et al, 2008; Gantt S et 
al, 2011]. In fact, T- and B- cells can be infected by HHV-8 [Ensoli B et al, 2001; Nsubuga MM et al, 
2008; Hassman LM et al, 2011; Della Bella S et al, 2010]. Moreover, HHV-8 also infects monocytes 
and macrophages mainly in lytic form [Stürzl M et al, 1999 a; Dupon M et al, 1997; Blasig C et al, 
1997]. 
HHV-8 DNA was also detected in circulating CD34
+
 cells isolated from PBMCs of KS patients [Henry 
M et al, 1999]. Moreover, it has been shown that HHV-8 can infect in vitro CD34
+ 
cells both 
latently and lytically, and infection can persist during in vitro differentiation and also in vivo, after 
injection in NOD/SCID mice [Wu W et al, 2006]. These observations suggest that CD34
+ 
cells could 
be a viral reservoir strengthening the hypothesis that HHV-8 could infect bone-marrow precursors 
from which infection could disseminate to hematopoietic and endothelial progeny. According to 
this hypothesis, Pellet et al. observed that circulating endothelial cells were HHV-8 infected in 50 % 
of KS patients [Pellet C et al, 2006]. Moreover Della Bella et al demonstrated that circulating 
endothelial progenitor cells, isolated and cultured in vitro as ECFCs from peripheral blood of cKS 
patients, are latently infected by HHV-8 and are also able to support lytic viral replication of HHV-8 
[Della Bella S et al, 2008]. 
1.3.3.2 Role of the immune system in KS pathogenesis 
HHV-8, like other herpesviruses, has developed mechanisms to protect itself from the immune 
system control. Latency is a strategy of passive immune evasion; in fact, in the latent phase, 
viruses express few genes thus reducing the expression by infected cells of viral antigens that may 
trigger an immune response [Rezaee SA et al, 2006]. However, lytic replication is necessary for the 
production and release of the virions and the consequent viral dissemination in the host. 
Therefore, HHV-8 has developed also strategies of active immune evasion, as during lytic 
replication several viral proteins are expressed and can be identified by the immune system 
[Coscoy L et al, 2007; Hu Z et al, 2014]. 
In particular, in order to escape mechanisms of the innate immune system, HHV-8 protein KCP 
(KSHV complement-control protein) inhibits the activation of the complement cascade that is 
designated to direct lysis of viral particles and infected cells and to promote their phagocytosis and 
elimination by macrophages [Spiller OB et al, 2003]; the same protein is also able to inhibit type I 
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IFN expression and its signaling cascade thus blocking IFN-mediated anti-viral immunity [Lee HR et 
al, 2015]. 
Apoptosis of infected cells is a commom mechanism involved in blocking viral replication and 
dissemination in the host, as apoptotic cells are phagocyted by macrophages. HHV-8 developed 
several strategies aimed to inhibit apoptosis [Rezaee SA et al, 2006]. In particular, HHV-8 viral 
proteins vFLIP, viral inhibitor of apoptosis protein (vIAP, encoded by ORF K7) and vBcl-2 (encoded 
by ORF 16) promote survival of infected cells by blocking apoptosis. In fact, besides previously 
described vFLIP, vIAP acts by inhibiting capsases, whereas vBcl-2 negatively regulates the release 
and activity of pro-apoptotic molecules [Dourmishev LA et al, 2003]. 
Moreover, HHV-8 developed mechanisms to evade mechanisms of the adaptive immune 
response, too. Viral antigens in association with major histocompatibility complex (MHC) class I 
molecules (HLA-A, B and C) exposed on infected cells can be recognized by cytotoxic CD8
+
 T-cells 
and trigger specific antiviral immune responses. In order to avoid this mechanism, HHV-8 encodes 
for modulator of immune recognition 1 (MIR1) and MIR2. These viral proteins inhibit the 
presentation of viral antigens to cytotoxic T-cells by promoting, in infected cells, the 
internalization of HLA molecules and their subsequent degradation in lysosomes [Coscoy L et al, 
2000]. Moreover MIR1 e MIR2 also inhibits the expression of other molecules that act as co-
stimulatory molecules for T-cells such as CD86 and the adhesion molecule ICAM-1. Down 
regulation of these molecules on HHV-8 infected antigen presenting cells (APCs) - like dendritic 
cells, macrophages and B-cells – impair the proper activation of adaptive immune responses 
[Coscoy L et al, 2001]. 
HHV-8 could also evade from immune system control inducing alterations in dendritic cells (DCs) 
[Campbell DM et al, 2014]. Della Bella et al reported that frequencies of myeloid and plasmacytoid 
DC in patients affected with cKS were lower than in healthy controls. It is possible that alteration 
of DC compartment may represent an immune evasion strategy used by the viruses to establish 
and maintain viral persistence. DC of cKS patients were also characterized by lower production of 
IL-12 – which promotes cell-mediated immune responses - and increased production of IL-6 [Della 
Bella S et al, 2006]. 
Viral chemokines support the development of a microenviroment that promote survival of 
infected cells and consequent viral propagation. In particular, vMIP-I (ORF K6), vMIP-II (ORF K4) 
and vMIP-III (ORF K4.1) selectively chemoattracts CD4
+
 Th2 cells switching the immune response 
towards humoral response thus avoiding the cytotoxic cell mediated response which is deputed to 
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control and elimination of viral infections [Stine JT et al, 2000; Holst PJ et al, 2003]. vMIP-II can 
also impairs Th1 immune responses and inflammatory responses by acting as antagonist of several 
endogenous chemokines, such as RANTES or RANTES o MIP-ϭα [Jensen KK et al, 2004]. 
1.3.3.3 Involvement of the endothelial compartment in KS pathogenesis 
KS development is a multi-step process in which, in addition to HHV-8 infection, alterations of the 
immune system, pro-inflammatory cytokines and angiogenic factors play a crucial role in 
sustaining development and maintenance of KS lesions [Ensoli B et al, 2001]. KS is characterized by 
three parallel processes: a proliferative component (involving chiefly spindle cells), an 
inflammatory component, and an angiogenic component. Typical histological features of KS 
lesions included spindle cell growth, proliferation of endothelial cells that may form dysfunctional 
vessels, extravasated erythrocytes, edema, lymphocytic infiltrate and - in later stages of disease - 
neoangiogenesis.  
Although endothelial proliferation in KS lesions may rely on the acquisition of hallmarks of cancer 
by the spindle cells, several intermediary cytokines and angiogenic factors have been 
demonstrated to play a crucial role in sustaining KS development. In particular, KS lesions are 
characterized by high level of endothelial growth factors such as VEGF, basic fibroblast growth 
factor (bFGF) and fibroblast growth factor 2 (FGF-2) that are necessary for lesion development and 
maintenance [Samaniego F et al, 1998]. In KS lesions, besides angiogenic factors, pro-inflammatory 
cytokines (i.e. IFNγ, TNFα, IL-ϭβ, IL-2, IL-6 and IL-8) are also produced by both spindle cells and 
inflammatory cells like lymphocytes and monocytes-macrophages [Sirianni MC et al, 1998; Monini 
P et al, 1999; Ensoli B et al, 1992]. Such factors promoted, in vitro, endothelial cell migration and 
matrix invasion [Thompson EW et al, 1991] and induced, in vivo, angiogenesis and formation of 
lesions similar to KS [Albini A et al, 1994]. Moreover inflammatory cytokines induce cell 
proliferation in an autocrine and paracrine manner, activate vascular endothelium, recruit other 
inflammatory cells in KS lesions by increasing inflammation and promote the expression of 
adhesion molecules (i.e. ICAM-1, ELAM-1 and V-CAM-1) on inflammatory cells [Fiorelli V et al, 
1998; Sodhi A et al, 2000]. 
VEGF is a prototypical angiogenic factor and it has been detected both in KS lesions and in in vitro 
culture of spindle cells [Cornali E et al, 1996]. Like bFGF, VEGF expression in spindle cells is 
promoted by inflammatory cytokines such as PDGF-β. VEGF aĐts sǇŶeƌgistiĐallǇ ǁith ďFGF 
stimulating endothelial cell growth, angiogenesis and edema formation. 
43 
 
bFGF is involved in the formation of KS lesions. In fact, Ensoli et al observed that bFGF in synergy 
with HIV-1 Tat protein can induce lesions similar to KS in mice [Ensoli B et al, 1994]. They also 
demonstrated that bFGF is produced by spindle cells and support spindle cells and endothelial 
cells proliferation in autocrine and paracrine manner [Ensoli B et al, 1994]. 
PDGF-β is a poteŶt ŵǇtogeŶ pƌoduĐed ďǇ spiŶdle Đells. It aĐts oŶ spiŶdle Đells theŵselǀes iŶ 
paracrine and autocrine manner [Stürzl M et al, 1995]. 
IFN-γ sǇŶeƌgistiĐallǇ aĐts ǁith IL-ϭ aŶd TNFα aŶd iŶduĐes CDϰϬ eǆpƌessioŶ oŶ spiŶdle Đells aŶd 
vascular endothelial cells in the areas proximal to the tumor. CD40 signaling inhibits apoptosis 
probably by inducing the expression of bcl-2 [Pammer J et al, 1996]. Sirianni et al also observed 
that PBMCs in KS patients produced higher levels of IFN-γ thaŶ iŶ healthǇ control. [Sirianni MC et 
al, 1998]. 
IL-1 is produced and released by spindle cells in KS lesions and promotes spindle cells growth in 
autocrine manner. IL-1 acts by interacting with bFGF. Moreover, in association with TNF and IFN-γ, 
IL-1 induces endothelial cell activation, acquisition of the phenotype typical of spindle cells and 
promotes leucocyte recruitment [Ensoli B et al, 1992]. 
IL-8 is a chemokine expressed in KS lesion by spindle cells and activated endothelial cells. IL-8 acts 
as a chemotactic factor for neutrophils [Masood R et al, 2001; Li X et al, 2011]. 
IL-6 is produced in KS lesions by inflammatory cells, spindle cells and activated endothelial cells. IL-
6 promotes angiogenesis and tumor cell growth. Because the vast majority of infected cells 
express IL-6, it was supposed that a viral protein expressed during the latent phase of HHV-8 
infection could induce IL-6 expression. In support to this theory, An et al demonstrated that LANA 
can act as transcription repressor and/or activator. In particular, they observed that LANA by 
interacting with AP1 RE (response elements) present in IL-6 promoters can up-regulate IL-6 
expression. Since AP1 RE are present in several promoters, LANA could induce the expression of 
other factors such as VEGF or other cytokines and molecules that regulate cell growth [An J et al, 
2004]. In addition, HHV-8 genome contains a viral homolog of IL-6 called vIL-6. vIL-6 acts on target 
cells by binding only one subunit of the human IL-6 receptor (gp130) without the need of specific 
IL-6 receptor α (CD126) chain for mediating its effects [Polizzotto MN et al, 2013; Yang J et al, 
1994; Osborne J et al, 1999].  
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These observations support the hypothesis that KS development is based on an inflammatory 
process triggered by HHV-8 infection and reactivated by a proinflammatory microenvironment 
[Ensoli B et al, 1998]. 
1.3.4 EPCs in KS 
Previous studies carried out in our laboratory supported the hypothesis that EPCs could play a role 
in KS pathogenesis. In particular, we analyzed by flow cytometry circulating EPCs in cKS patients 
and reported that circulating EPCs, identified as CD45
low
/CD34
+
/KDR
+
 or 
CD45
low
/CD34
+
/KDR
+
/CD133
+ 
 cells, were increased in cKS patients compared with healthy 
controls. As we did not observed any correlation between the number of EPCs and the plasmatic 
levels of factors such as VEGF, TNF-α and GM-CSF, we hypothesized that circulating EPCs in cKS 
patients may be affected by HHV-8 infection through direct and indirect mechanisms [Taddeo A et 
al, 2008]. Moreover, we demonstrated that ECFCs obtained from cKS patients were HHV-8 
infected [Della Bella S et al, 2008]. By documenting the presence oh HHV-8 DNA in both cells and 
supernatant of ECFCs isolated from cKS patients, we demonstrated that HHV-8 can sustain both 
latent and lytic infection in these cells. The viral infection persisted in long term cultures after 
multiple passages, supporting that ECFCs may represent a HHV-8- reservoir in c KS patients [Della 
Bella S et al, 2008]. Based on this observation, we hypothesized that ECFCs may represent putative 
precursors of spindle cells in KS patients. 
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Kaposi͛s “aƌĐoŵa ;K“Ϳ is a lǇŵphaŶgiopƌolifeƌatiǀe disease ǁhose Đausatiǀe ageŶt is the 
herpesvirus HHV-8 [Chang Y et al, 1994]. KS presents typically with cutaneous lesions but can also 
involve visceral organs and it is characterized by hyperproliferation of HHV-8-infected spindle cells 
- the typical cells of KS lesions. Spindle cells are cells of endothelial origin but it is still unclear if 
they derive from mature endothelial cells infected by HHV-8 in peripheral tissues or whether they 
originate from previously infected circulating cells such as bone-marrow derived endothelial 
progenitor cells (EPCs).  
EPCs play a crucial role in endothelial homeostasis and in vasculogenic processes both in 
physiological and pathological conditions [Urbich C et al, 2004]. Although different types of cells - 
isolated from peripheral blood - have been called EPCs in the past, only endothelial colony-forming 
cells (ECFCs) are considered the true EPCs [Fadini GP et al, 2012]. 
In previous studies, we observed that the number of circulating EPCs, identified by flow cytometry 
as CD45
dim
/CD34
+
/KDR
+
, is increased in patients with classic KS (cKS) when compared with healthy 
controls [Taddeo A et al, 2008]. Moreover, we also observed that ECFCs isolated from cKS patients 
are HHV-8 infected and can act as viral reservoir [Della Bella S et al, 2008]. 
Therefore, in this study we investigated whether ECFCs isolated from cKS patients are endowed 
with features typical of spindle cells in order to evaluate whether they may represent the 
precursors of spindle cells.  
In particular, we compared ECFCs isolated from cKS patients and healthy controls and we 
evaluated the following parameters: 
- during ECFC isolation, we analyzed: 
 the frequency of subjects who gave rise to at least one ECFC colony within 30 days from 
PBMCs seeding 
 the time of ECFC colony appearance 
 the frequency of isolated ECFC colonies  
- during ECFC expansion, we analyzed: 
 the morphology and phenotype of ECFCs 
 ECFC cell senescence and proliferative potential 
 the vasculogenic potential  
 the cytokine production  
 the molecular signature  
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Moreover, several studies reported that spindle cells in KS lesions express LYVE-1, podoplanin and 
VEGFR-3 [Pyakurel P et al, 2006] and that in vitro HHV-8-infected blood endothelial cells (BECs) 
express lymphatic markers including PROX-1 [Hong YK et al, 2004]. Nevertheless, in preliminary 
experiments we observed that LYVE-1 and podoplanin were expressed by ECFCs isolated not only 
from cKS patients but also from healthy controls. 
In the last years, several studies supported the hypothesis that a population of lymphatic 
endothelial progenitor cells (LEPCs) could be involved in lymphangiogenic processes [Park C et al, 
2011]. However, the identity of LEPCs has not yet been fully elucidated.  
Therefore, in this study we investigated the lymphatic differentiative potential of ECFCs and 
whether it could be influenced by the substrate used for ECFC culture. In particular, we evaluated 
the impact of fibronectin compared with collagen, as the presence of fibronectin and its oncofetal 
isoforms (i.e. EDA-FN and EDB-FN) in the tumor microenvironment positively correlates with 
lymphangiogenesis and metastasis [Bae YK et al, 2013; Ou J et al, 2013; Xiang L et al, 2012]. 
Moreover, we evaluated whether migration stimulating factor (MSF), an oncofetal truncated 
isoform of fibronectin typically present in tumor microenvironment [Solinas G et al, 2010], could 
promote the lymphatic differentiation of ECFCs.  
To this aim, we isolated ECFCs from healthy donors and evaluated their lymphatic differentiative 
potential in basal conditions and after MSF stimulation. ECFCs were cultured on either fibronectin 
or collagen and the expression of typical lymphatic markers (PROX-1, podoplanin, LYVE-1 and 
VEGFR-3) was evaluated by: 
 detection of specific transcripts 
 detection of protein expression 
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3. Material and methods 
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3.1 Reagents 
The following reagents were used for PBMCs isolation from peripheral:  
 Heparin sodium, For Hospital s.r.l., Potenza, Italy  
 Falcon 50 ml conical tubes, BD, New Jersey,USA  
 Ficoll-Paque PREMIUM, GE Healthcare, Invitrogen, California, USA  
 HaŶks͛ BalaŶĐed “alt “olution (HBSS) w/o Ca2+ and Mg2+, Lonza, Basel, Switzerland 
 Trypan Blue, Sigma-Aldrich, Missouri, USA 
The following reagents were used for ECFC isolation and expansion: 
 mw6 and mw24 culture plates, BD, New Jersey USA  
 T25, T75 and T175 flasks, BD, New Jersey, USA  
 Tripsin-EDTA, Lonza, Basel, Switzerland  
 Sterile water, Baxter, Rome, Italy 
 Phosphate Buffered Saline (PBS) w/o Ca2+ and Mg2+, Lonza, Basel, Switzerland  
 Acetic acid, Merck Millipore, Billerica, MA, USA  
 Fibronectin from human plasma, Sigma-Aldrich, Missouri, USA  
 Collagen Solution, Type I from rat tail, BD, New Jersey,USA  
 EGM-2 BulletKit ( EBM-2 Basal Medium (500 ml) + EGM-2 SingleQuot Kit Suppl. & Growth 
Factors), Lonza, Basel, Switzerland 
 Fetal Bovin Serum (FBS), Lonza, Basel, Switzerland 
 Trypan Blue, Sigma-Aldrich, Missouri, USA 
The following reagents were used for cytofluorimetric characterization of ECFCs:  
 ACCUTA“E™ “OLUTION, MeƌĐk Millipoƌe, BilleƌiĐa, MA, U“A  
 LIVE ⁄ DEAD® Fiǆaďle AƋua Dead Cell “taiŶ Kit, IŶǀitƌogeŶ, CalifoƌŶia, U“A  
 FACS Tubes, BD, New Jersey, USA  
 Mouse monoclonal antibody anti- human CD14 PerCp Cy5.5-conjugated, BD, New Jersey, 
USA  
 Mouse monoclonal antibody anti- human CD31 FITC-conjugated, BD, New Jersey, USA  
 Mouse monoclonal antibody anti- human CD45 PerCp Cy5.5-conjugated, eBionscience, 
California, USA  
 Mouse monoclonal antibody anti- human CD54 PE-conjugated, R&D, Minnesota, USA  
 Mouse monoclonal antibody anti- human CD144 FITC conjugated, Serotec, Kidlington, UK  
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 Mouse monoclonal antibody anti- human CD146 PE-conjugated, Biocytex, Marseille, France  
 Mouse monoclonal antibody anti- human VEGFR-2 PE-conjugated, R&D, Minnesota, USA  
 Mouse monoclonal antibody anti- human CXCR4 PE Cy7-coniugato, eBioscience, California, 
USA  
 Sterile water, Baxter, Rome, Itay 
 PBS w/o Ca2+ and Mg2+, Lonza, Basel, Switzerland  
 HBSS w/o Ca2+ and Mg2+, Lonza, Basel, Switzerland  
 FBS, Lonza, Basel, Switzerland  
 Stabilizing Fixative, BD, New Jersey, USA  
 Wash buffer solution: HBSS  w/o Ca2+ and Mg2+ + FBS 2% p/v  
The following reagents were used for ECFC characterization by immunofluorescence: 
 EGM-2 BulletKit (EBM-2 Basal Medium (500 ml) + EGM-2 SingleQuot Kit Suppl. & Growth 
Factors), Lonza, Basel, Switzerland 
 mw24 culture plates, BD, New Jersey USA  
 Coverslips, diameter 14 mm, Thermo Scientific, Massachusetts, USA  
 Microscope slides, Thermo Scientific, Massachusetts, USA  
 Sterile water, Baxter, Rome, Italy  
 PFA, Sigma-Aldrich, Missouri, USA 
 PBS w/o Ca2+ and Mg2+ , Lonza, Basel, Switzerland  
 PBS with Ca2+ and Mg2+, Lonza, Basel, Switzerland  
 Dil–labeled acetylated Low-density lipoprotein(Dil-ac-LDL), Molecular Probes, Oregon, USA  
 Lectin from Ulex europaeus (UEA-1) FITC-conjugated, Sigma, Missouri USA  
 DAPI, Invitrogen, California, USA  
 Fluor Preserve Reagent, Calbiochem, California, USA  
 Fixing solution: PBS with Ca2+ and Mg2 + 2% PFA p/v  
The following reagents were used for LANA detection by immunofluorescence: 
 mw24 culture plates, BD, New Jersey USA  
 Coverslips, diameter 14 mm, Thermo Scientific, Massachusetts, USA  
 Microscope slides, Thermo Scientific, Massachusetts, USA  
 Rat monoclonal antibody anti- anti HHV-8 ORF73 (LANA) (Rat IgG2c) Advanced 
Biotechnologies Inc.  
51 
 
 Goat anti-rat IgG (H+L) secondary antibody, Alexa488-conjugated, Invitrogen, California, 
USA  
 DAPI: Nucleic Acid Stain, Invitrogen, California, USA  
 PFA, Sigma-Aldrich, Missouri, USA  
 PBS w/o Ca2+ and Mg2+, EuroClone, UK  
 PBS with Ca2+ and Mg2+, EuroClone, UK  
 Sterile water, Baxter, Rome, Italy  
 Bovine Serum Albumin, fraction V (BSA), Sigma-Aldrich, Missouri, Usa  
 Normal Goat Serum (NGS), Dako, Carpinteria, CA 
 TRITON X100, Sigma-Aldrich, Missouri, Usa  
 Tween20, International PBI, Milan, Italy 
 Wash buffer:Tween20 0.05% in PBS with Ca2+ and Mg2+  
 Permeabilization solution: Triton X-100 0.3% in PBS with Ca2+ and Mg2+ 
 Blocking solution: BSA 2% + NGS 5% in PBS with Ca2+ and Mg2+ 
 Fixing solution: PFA 4% in PBS w/o Ca2+ and Mg2+ 
 Fluor Preserve Reagent, Calbiochem, California, USA  
The following reagents were used for in senescence-assoĐiated β-galactosidase assay: 
 Cellular Senescence Assay Kits, Merck Millipore, Billerica, MA, USA 
 PBS w/o Ca2+ and Mg2+, EuroClone, UK  
 Glycerol, Sigma-Aldrich, Missouri, Usa 
The following reagents were used for in vitro vasculogenic assay: 
 Flat bottom mw96 culture plates, BD, New Jersey, USA  
 Matrigel, BD, New Jersey, USA  
 EGM-2 BulletKit (EBM-2 Basal Medium (500 ml) + EGM-2 SingleQuot Kit Suppl. Growth 
Factors) Lonza, Basel, Switzerland 
The following reagents were used for cytokine detection in ECFC culture supernatant: 
 DuoSet® ELISA Development Systems - R&D Systems, Minnesota, USA  
The following reagents were used for total RNA extraction retrotranscription: 
 RNeasy® Plus Micro kit, Qiagen, California, USA  
 High Capacity cDNA Reverse Transcription kit, Applied Biosystem, California, USA  
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The following reagents were used for gene array analysis: 
 Illumina TotalPrep RNA Amplification kit. Ambion/Applied Biosystems, Texas, USA 
 Illumina HumanHT-12 v4 Expression BeadChip arrays, Illumina Inc., California, USA 
The following reagents were used for evaluation by Q-PCR of the expression of genes encoding for 
lymphatic markers: 
 Sterile water, Baxter, Rome, Italy  
 TaqMan® Universal PCR Master Mix, Applied Biosystem, California, USA  
 TaqMan probe GAPDH FAM, Applied Biosystem, California, USA  
 TaqMan probe PROX-1 FAM, Applied Biosystem, California, USA  
 TaqMan probe podoplanin FAM, Applied Biosystem, California, USA 
 TaqMan probe LYVE-1 FAM Applied Biosystem, California, USA  
 TaqMan probe VEGFR-3 FAM, Applied Biosystem, California, USA  
The following reagents were used for detection of lymphatic markers by immunofluorescence: 
 mw24 culture plates, BD, New Jersey USA  
 Coverslips, diameter 14 mm, Thermo Scientific, Massachusetts, USA  
 Microscope slides, Thermo Scientific, Massachusetts, USA  
 Mouse monoclonal antibody anti- human Podoplanin (IgG1), Serotec, Kidlington, UK  
 Rabbit polyclonal antibody anti- human LYVE-1 Abcam USA  
 Goat polyclonal antibody anti human PROX1, R&D, Minnesota, USA  
 Mouse polyclonal antibody anti human VEGFR-3, R&D, Minnesota, USA  
 Donkey anti-Mouse IgG1 secondary antibody, AlexaFluor488-conjugated, Invitrogen, 
California, USA 
 Donkey anti-Rabbit IgG (H+L) secondary antibody, AlexaFluor568-conjugated, Invitrogen, 
California, USA  
 Donkey anti-Goat IgG (H+L) secondary antibody, AlexaFluor647-conjugated, Invitrogen, 
California, USA  
 DAPI: Nucleic Acid Stain, Invitrogen, California, USA  
 PFA, Sigma-Aldrich, Missouri, USA  
 PBS w/o Ca2+ and Mg2+, EuroClone, UK  
 PBS with Ca2+ and Mg2+, EuroClone, UK  
 Sterile water, Baxter, Rome, Italy  
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 BSA, Sigma-Aldrich, Missouri, Usa  
 TRITON X100, Sigma-Aldrich, Missouri, Usa  
 Human serum (HS) AB, Lonza, Basel, Switzerland  
 Tween20, International PBI, Milan, Italy 
 Wash buffer Tween20 0.05% in PBS with Ca2+ and Mg2+  
 Block-Perm solution: Triton X-100 0.1% + BSA 1% + HS 5% + FBS 5% in PBS with Ca2+ and 
Mg
2+ 
 
 Blocking solution: BSA 1% + HS 5% + 5% FBS in PBS with Ca2+ and Mg2+ 
 Fixing solution: PFA 4% in PBS w/o Ca2+ and Mg2+ 
 Fluor Preserve Reagent, Calbiochem, California, USA  
The following reagent was used for the stimulation of ECFC culture: 
 Migration stimulating factor (MSF), kind gift from Dr. Barbara Bottazzi 
(Immunopharmacology Lab, Istituto Clinico Humanitas) 
The following reagents were used for cell line cultures: 
 Dulbecco's Modified Eagle Medium (DMEM), Sigma-Aldrich, Missouri, USA  
 Endothelial Cell Growth Medium MV2, Promo Cell,Heidelberg, Germany  
 Endothelial Cells Medium, Promo Cell, Heidelberg, Germany 
 RPMI, Lonza. Basel, Switzerland 
3.2 Cell lines 
Besides ECFCs in this study we used other cell types – summarized in Table 2 - as positive and 
negative controls for the optimization of immunofluorescence staining protocols.  
 
Table 2: Summary of cell types used as positive and negative controls for the optimization of the 
immunofluorescence staining protocols. 
54 
 
The body-cavity-based lymphoma cell line BCBL-1 is a commercial cell line established from the 
peritoneal effusion of a 40-year-old man (HIV+) with primary effusion lymphoma (PEL). BCBL-1 
cells were shown to be latently infected by HHV-8, but not by Epstein-Barr virus (EBV). 
BCBL-1 cells grow singly in suspension in RPMI 1640 + FBS (10%) + L-glutammine (3%) + Penicillin-
Streptomycin (1%).  
HDLECs are mature lymphatic endothelial cells isolated from human derma or skin. They grow in 
adhesion and were cultured in Endothelial Cell Growth Medium MV2 (EGM MV2). HDLECs are 
characterized by endothelial morphology and by the expression of the typical lymphatic markers 
such as Podoplanin, PROX-1, LYVE-1 and VEGFR-3.  
Human fibroblasts were a kind gift from Dr. Danese (Istutito Clinico Humanitas). They were 
isolated from colon of healthy subjects. Fibroblasts were seeded at a density of 20.000 cell/cm
2
 
and were cultured in Dulbecco's Modified Eagle Medium (DMEM) + 10% FBS + 1% L-Glutamine + 
1% penicillin-streptomycin. 
HUVECs are mature endothelial cells isolated from Human Umbilical Veins and are one of the most 
used model for the study of endothelium. They grow in adhesion in Endothelial Cell Basal Medium 
additioned with specific endothelial growth factors. HUVEC can be expanded by splitting them 
every 3-4 days and seeding at a density of 8000 cells/cm
2
. 
SW480 cell line is a commercial cell line established from a primary adenocarcinoma of the colon. 
SW480 are characterized by epithelial morphology and grow in adhesion. They were seeded at a 
density of  30.000 cells/cm
2 
and were cultured in
 
DMEM + 10% FBS, 1% L-Glutamine + 1% 
penicillin-streptomycin. 
3.3 Subjects enrolled 
86 healthy controls and 83 patients with cKS were enrolled in this study. All cKS patients were 
followed in the Institute of Dermatological Sciences of the Fondazione IRCCS Ospedale Maggiore 
Policlinico, Mangiagalli e Regina Elena. All cKS patients enrolled had histologically confirmed 
diagnosis of KS, were positive for anti-HHV-8 antibody and were negative for HIV. Patients in 
systemic chemotherapy and patients in treatment with drugs that have been reported to affect 
EPC number and functions (Statins, ACE- Inhibitors, calcium antagonists and metformin) were 
excluded. 
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cKS patients were classified according to the stage of disease. Staging was performed in 
accordance with the classification proposed by Brambilla et al [Brambilla L et al, 2003] that takes 
into account the prevalent type of lesions, localization, clinical behavior, evolutive pattern and 
presence of complications (Table 3). 
 
Table 3: cKS patients enrolled in the study classified on the basis of the stage and the evolutive pattern of 
disease according to the classification proposed by Brambilla et al. 
We collected a sample of heparinized fresh venous blood from all the subjects enrolled in the 
study. A signed informed consent was obtained from all participants. 
3.4 Isolation and expansion of Endothelial Colony Forming Cells (ECFCs)  
ECFCs were isolated and cultured by using a protocol recently optimized in our lab [Colombo et al, 
2013]. In particular, ECFCs were isolated from PBMCs isolated from fresh samples of heparinized 
blood collected from both cKS patients and healthy controls. 
3.4.1 Isolation of Peripheral Blood Mononuclear cells (PBMCs)  
Heparinized blood samples were centrifuged at 1400 rpm for 10 minutes to separate plasma from 
blood cellular components. After plasma removal, blood cellular components were diluted with 
HBSS (ratio of 1:3) and Ficoll-Paque was dispensed. The falcon tubes containing 2 phases -the 
blood cellular components diluted in HBSS on the top and Ficoll-Paque on the bottom of the falcon 
tube- were centrifuged at 400 rcf for 30 minutes. PBMCs were obtained by Ficoll density gradient 
centrifugation. In fact, after centrifugation, starting from the bottom of the tube 4 phases 
containing different cell types can be identified: the bottom layer made up of erytrocytes and 
granulocytes, the layer of Ficoll-Paque, a thin ring composed by PBMCs and - on the top - the 
residual plasma and HHBS used for the dilution of blood cellular components. PBMCs were 
carefully collected and then were washed twice with HBSS. 
PBMCs were then resuspended in EGM-2 + 5% FBS culture medium and were counted in a Burker 
counting chamber. Cell viability was tested with trypan blue. 
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Culture medium Endothelial Growth Medium (EGM-2) was prepared by adding to the Endothelial 
Basal Medium (EBM2) fetal bovine serum (FBS), antibiotics (gentamicin, amphotericin B –GA1000) 
and growth factors that promote endothelial cell differentiation and growth (hydrocortisone, 
hFGF, VEGF, R3-IGF-1, hEGF, heparin and ascorbic acid). The complete cell culture medium EGM-2 
+ 5% FBS was used for ECFC isolation and culture. 
3.4.2 ECFC culture 
3.4.2.1 ECFC isolation 
ECFC colonies were isolated from PBMCs obtained from fresh peripheral blood. Once isolated, 
PBMCs were resuspended in EGM2 + 5% FBS and seeded in mw24 culture plates precoated with 
fibronectin. Fibronectin was diluted in PBS w/o Ca
2+
 and Mg 
2+
 to the final working concentration 
of 1 μg/cm2 and fibronectin coating was incubated for 45 minutes at room temperature to allow 
fibronectin polymerization before cell seeding. PBMCs, seeded at a final density of 2,5 x 10
6
/cm
2
,
 
were cultured at 37°C with 5% CO2. After one day of culture, non-adherent cells and debris were 
removed, adherent cells were washed with EGM-2 + 5% FBS medium and fresh medium was 
added to each well. Medium was changed every 2 days until the first passage. PBMC cultures were 
monitored by daily visual inspection using an inverted microscope in order to detect the initial 
appearance of visible ECFC colonies. ECFC colonies generally appeared 2-3 weeks after PBMC 
seeding and can be identified as well circumscribed monolayers of cobblestone-like cells. 
In order to evaluate the effect of the substrate on the efficiency of ECFC isolation in cKS patients, a 
portion of PBMCs isolated from 4 cKS patients was seeded in mw24 culture plates coated with 
collagen. In particular culture plates were coated with collagen diluted in acid acetic 0,02 N at the 
final working concentration of 50 μg/ml. Collagen coating was incubated for 90 minutes at room 
temperature to allow collagen polymerization. Before cell seeding, the excess fluid was removed 
from the coated surface and the culture plates were washed twice with PBS w/o Ca
2+
 and Mg 
2+
. 
To evaluate the efficiency of ECFC isolation, the number of PBMC seeded, the number of colonies 
isolated and the time of colonies appearance – calculated as the number of days starting from the 
day of PBMCs seeding – were recorded for each subjects enrolled in the study. 
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3.4.2.2 ECFC expansion 
Once identified, ECFC colonies can be detached with Trypsin/EDTA and plated onto 6-well tissue 
culture plates precoated with collagen. Subconfluent cells were further expanded until cell 
senescence. In particular, ECFC were expanded in culture plates coated with collagen, in EGM-2 + 
5% FBS and they were seeded at a density of 5000 cells/cm
2
. 
In order to evaluate whether the substrate used for ECFC culture can affect ECFC lymphatic 
differentiative potential, 15 ECFC colonies isolated from healthy controls were expanded in culture 
plates coated with fibronectin. 
3.4.2.3 ECFC in vitro stimulation with MSF 
In order to evaluate whether MSF could promote the expression of lymphatic markers on ECFCs, 
ECFCs cultured on both fibronectin and collagen were stimulated with MSF.  
In preliminary experiments the optimal MSF concentration and the optimal time of stimulation 
were defined by treating ECFCs with different MSF concentration (10 pg/ml, 100 pg/ml, 10 ng/ml 
and 100 ng/ml) and for different times (6h ,12h, 24h, 48h and 72h).  
Once the optimal MSF concentration and time of incubation have been defined (10 ng/ml for 24 
hours), ECFCs cultured on both fibronectin and collagen were stimulated with MSF to evaluate the 
effect of MSF on the lymphatic differentiative potential of ECFCs. Untreated ECFCs derived from 
the same ECFC colonies were used as basal. 
After stimulation, ECFCs were detached with Trypsin and they were counted in a Burker counting 
chamber. Cell viability was tested with trypan blue. Cell suspensions were transferred in 1.5 ml 
eppendorfs and were then centrifuged (maximum speed for 5 minutes). After centrifuge, 
supernatants were discarded and cell pellets were stored at -80°C for total RNA extraction.  
3.5 ECFC characterization 
3.5.1 ECFC immunophenotype 
3.5.1.1 Evaluation of hematopoietic and endothelial markers expression by flow 
cytometry 
In order to evaluate the immunophenotype of ECFCs isolated from both cKS patients and healthy 
controls, ECFC expression of hematopoietic markers (CD45 and CD14) and endothelial markers 
(CD31, CD54, CD144, CD146 and VEGFR-2) and CXCR4 (SDF-1 receptor) were evaluated by flow 
cytometry. 
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In particular, ECFCs detached with Accutase were counted and stained with Live/Dead – a viability 
dye that allows the identification of dead cells. ECFCs were then washed, resuspended in 100 µl of 
wash buffer (HBBS + 2% FBS) at the final concentration of 1,5x10
6
 cells/ml and were stained with 
the following monoclonal antibodies: anti-CD31 FITC-conjugated, anti-CD54 FITC-conjugated anti-
VEGFR-2 PE-conjugated, anti-CD144 FITC-conjugated, anti-CD146 PE-conjugated, anti-CXCR4 PE 
Cy7-conjugated anti-CD45 PerCp Cy5.5-conjugated, anti-CD14 PerCp Cy5.5- conjugated. Data were 
acquired on a FACSCanto II flow cytometer (Becton-Dickinson) and analysis was performed using 
FlowJo 9.8.5 software (Tristar, Ashland, OR). Cells were electronically gated according to light 
scatter properties to exclude cell debris. 
3.5.1.2 Ulex Europaeus Agglutinin I (UEA I) and Dil-ac-LDL immunofluorescence 
staining 
To further confirm that ECFCs isolated from both cKS patients and healthy controls were endowed 
with the typical features of ECFCs, the ability to up-take Dil-ac-LDL and bind UEA-1 were evaluated 
by immunofluorescence. 
In particular, ECFCs were incubated for 1 hour at 37°C with Dil-ac-LDL (10 µg/m in EGM). After 
incubation, cells were washed twice with PBS with Ca
2+
 and Mg
2+
, fixed for 15 minutes (PFA 2% in 
PBS with Ca
2+
 and Mg
2+
) and incubated for 1 hour at 37°C with UEA-1–FITC conjugated (10 μg/ml). 
cell nuclei were then stained with DAPI. The coverslips with stained cells were mounted onto 
microscope slides. Stained cells were analyzed on a confocal microscope. 
3.5.2 Evaluation of the expression of lymphatic markers  
3.5.2.1 Evaluation of the expression of genes typically expressed by LECs 
The expression of genes encoding for PROX-1, podoplanin, LYVE-1 and VEGFR-3 was evaluated in 
ECFCs by Q-PCR. 
3.5.2.1.1 RNA extraction, quantification and retro-transcription 
Total RNA was extracted from ECFC pellets using a commercial kit (RNeasy® Plus Micro – Qiagen). 
RNA extraction was performed according to the manufacturers' instructions. RNA purity and 
concentration were measured using NanoDrop 1000 UV-VIS Spectrophotometer. 
1 µg of total RNA extracted from ECFCs was retro-transcribed to cDNA using a commercial kit (High 
Capacity cDNA Reverse Transcription kit - Applied Biosystem). In particular, the reverse 
transcription reaction mix has been prepare by combining the components indicated in Table 4. 
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Table 4: Reagents used for the preparation of reverse transcription reaction mix. 
Thermal cycling parameters used for RT-PCR are indicated in Table 5 
 
Table 5: Thermal cycling parameters used for RT-PCR. 
Resulting cDNA was stored at -80°C.  
3.5.2.1.2 Q-PCR 
The expression of genes typically expressed by LECs - PROX-1, podoplanin, LYVE-1 and VEGFR-3 - 
was evaluated on ECFCs by Q-PCR. 
cDNA was used as the template for Q-PCR and in particular, Q-PCR assay employing the TaqMan 
probe was performed. GAPDH was used as housekeeping gene. 
For each analyzed gene, every sample was analyzed in triplicate and the same amount of starting 
cDNA was used in each reaction. In particular, 20 ng of cDNA were used per 10 µl amplification 
reaction. 
The reagents used to prepare the PCR reaction mix are shown in Table 6. 
 
Table 6: Reagents used to prepare the PCR reaction mix. 
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Samples were run on ABI Prism 7900HT system (Applied Biosystem); thermal cycling parameters 
used for Q-PCR are indicated in Table 7. 
 
Table 7: Thermal cycling parameters used for RT-PCR. 
The expression level of each gene was normalized to the GAPDH housekeeping gene and was 
calculated as 2
(- ΔCT)
(X10
6
). 
3.5.2.2 Evaluation of lymphatic markers expression by confocal microscopy 
3.5.2.2.1 Evaluation of PROX-1, Podoplanin and LYVE-1 expression by multicolor 
confocal microscopy 
For the evaluation of PROX-1, podoplanin and LYVE-1 expression, a protocol for by multicolor 
immunofluorescence staining was optimized. Multicolor immunofluorescence staining allowed the 
evaluation of lymphatic markers coexpression. 
Three days before the analysis, 20.000 ECFCs were seeded on coverslips coated with fibronectin or 
collagen. Once confluent, cells were fixed with the fixing solution (4% PFA in PBS w/o Ca
2+
 and 
Mg
2+
) for 20 minutes at room temperature. Therefore, fixed cells were washed twice with PBS 
with Ca
2+
 and Mg
2+
, blocked for 1 hour (blocking solution: BSA 1%, HS 5%, FBS 5% in PBS with Ca
2+
 
and Mg
2+
) and then incubated 2 hours at room temperature with the primary antibodies (Mouse 
anti-human Podoplanin and Rabbit anti-human LYVE-1, both diluted 1:50 in blocking solution).  
After primary antibody incubation, cells were washed three times with the wash buffer (Tween20 
0.05% in PBS with Ca
2+
 and Mg
2+
) and incubated 1 hour at room temperature with the secondary 
antibodies (Donkey-anti-Mouse secondary antibody AlexaFluor488-conjugated and Donkey anti-
Rabbit secondary antibody, AlexaFluor568-conjugate; both secondary antibodies were diluted 
1:1000 in blocking solution). After secondary antibody incubation, cells were washed three times 
with the wash buffer and they were fixed with PFA 1% in PBS w/o Ca
2+
 and Mg
2+
 for 5 minutes.  
After fixation, cells were washed with the wash buffer and were stained for PROX-1. Briefly, cells 
were blocked (blocking solution: BSA 1% in PBS with Ca
2+
 and Mg
2+
, incubated for 20 minutes at 
room temperature), permeabilized (block-perm solution: BSA 1%, FBS 5%, HS 5%, TRITON X100 
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0,01 % in PBS with Ca
2+
 and Mg
2+
, incubated for 30 minutes at room temperature) and incubated 
with the primary antibody (Goat anti human PROX-1, diluted 1:100 in block-perm solution, 
incubated overnight at +4°C).  
After primary antibody incubation, cells were washed three times with the wash buffer and were 
incubated with the secondary antibody (Donkey anti-Goat secondary antibody, AlexaFluor647- 
conjugated, diluted 1:1000 in block-perm solution, incubated 1 hour at room temperature).  
After secondary antibody incubation, cells were washed with the wash buffer, stained with DAPI 
(diluted 1:50000 in water, Incubated 10 minutes at room temperature) and washed three times 
with the wash buffer. The coverslips with stained cells were mounted onto microscope slides. 
Stained cells were analyzed on a confocal microscope. For every sample, 10 casual microscopic 
fields (60x magnification) were acquired and analyzed. 
Cells stained only with the secondary antibody were used to evaluate the background due to the 
aspecific binding of the secondary antibodies and to the cell autofluorescence. HDLECs were used 
as positive control. Fibroblasts were used as negative control for PROX-1 and LIVE-1 staining; 
HUVECs were used as negative control for podoplanin staining. 
3.5.2.2.2 Evaluation of VEGFR-3 expression by confocal microscopy  
For the evaluation of VEGFR-3 expression, 3 days before the analysis, 20.000 ECFCs were seeded 
on coverslips coated with fibronectin or collagen. 
Once confluent, cells were fixed with the fixing solution (4% PFA in PBS w/o Ca 2
+
 and Mg2
+
) for 20 
minutes at room temperature. Therefore, fixed cells were washed twice with PBS with Ca
2+
 and 
Mg
2+
, blocked for 1 hour (blocking solution: BSA 1% in PBS with Ca
2+
 and Mg
2+
), permeabilized for 
30 minutes (BSA 1%, FBS 5%, HS 5%, TRITON X100 0,01% in PBS with Ca
2+
 and Mg
2+
) and incubated 
2 hours at room temperature with the primary antibody (Mouse anti-VEGFR-3, diluted 1:50 in 
blocking solution).  
After primary antibody incubation, cells were washed three times with the wash buffer (Tween20 
0.05% in PBS with Ca
2+
 and Mg
2+
) and incubated 1 hour at room temperature with the secondary 
antibody (Donkey-anti-Mouse AlexaFluor488-conjugated, diluted 1:1000 in blocking solution). 
After secondary antibody incubation, cells were washed three times with the wash buffer, stained 
with DAPI (Incubated 10 minutes at room temperature, diluted 1:50000 in water) and washed 
three times with the wash buffer. The coverslips with the stained cells were mounted onto 
microscope slides. 
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Stained cells were analyzed on a confocal microscope. For every sample, 10 casual microscopic 
fields (60x magnification) were acquired and analyzed 
Cells stained only with the secondary antibody were used to evaluate the background due to 
aspecific binding of the secondary antibody and to cell autofluorescence. HDLECs were used as 
positive control. SW480 cell line – that does not express VEGFR-3 - was used as negative control.  
3.5.3 Evaluation of HHV-8 infection  
In order to evaluate the presence of HHV-8 infection in ECFC colonies, Latency-Associated Nuclear 
Antigen (LANA) was detected by confocal microscopy. 
Cells were fixed with the fixing solution (4% PFA in PBS w/o Ca
2+
 and Mg
2+
) for 15 minutes at room 
temperature. Therefore, fixed cells were washed twice with PBS with Ca
2+
 and Mg
2+
, 
permeabilized (permeabilization solution: TRITON X100 0,3% in PBS with Ca
2+
 and Mg
2+
, incubated 
for 20 minutes at room temperature) blocked (blocking solution: BSA 2%, NGS 5% in PBS with Ca
2+
 
and Mg
2+
, incubated 20 minutes at room temperature) and then incubated with the primary 
antibody (Rat anti-LANA –ORF73, diluted 1:1000 in blocking solution, incubated overnight at +4°C).  
After primary antibody incubation, cells were washed three times with the wash buffer (Tween20 
0.05% in PBS with Ca
2+
 and Mg
2+
) and incubated with the secondary antibody (Goat-anti-Rat 
secondary antibody AlexaFluor488-conjugated diluted 1:1000 in blocking solution, incubated 1 
hour at room temperature). 
After secondary antibody incubation, cells were washed with the wash buffer, stained with DAPI 
(diluted 1:50000 in water, incubated 10 minutes at room temperature) and washed three times 
with the wash buffer. The coverslips with stained cells were mounted onto microscope slides. 
Stained cells were analyzed on a confocal microscope. For every sample, 15 casual microscopic 
fields (60x magnification) were acquired and analyzed 
Cells stained only with the secondary antibody were used to evaluate the background due to the 
aspecific binding of the secondary antibodies and to the cell autofluorescence. BCBL1 cell line was 
used as positive control. 
3.5.4 Cell senescence  
Senescent cells were characterized by low viability – assessed by Trypan Blue exclusion test – and 
altered morphology – assessed by microscopic inspection. Senescence was further confirmed by 
positive staining for senescence-associated ß-galactosidase. Senescence-associated ß-
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galactosidase assay was performed with a commercial kits (Cellular Senescence Assay Kits, Merck 
Millipore) used according to the manufacturers' instructions. Senescent cells were identified by 
observation under an inverted microscope since senescence-associated ß-galactosidase catalyzes 
the hydrolysis of Xgal, which results in the accumulation of a distinctive blue color in senescent 
cells. 
3.5.5 Cell proliferation 
In order to evaluate the proliferative ability of ECFC isolated from healthy controls and cKS 
patients, at each culture passage detached ECFCs were counted and the cell number and the day 
of culture were recorded. 
3.5.6 In vitro vasculogenesis 
Matrigel capillary tube formation assay was performed to evaluate the tubule formation ability of 
ECFCs isolated from cKS patients and healthy controls. 
Matrigel is a commercially available basement membrane preparation - isolated from Engelbreth-
Holm-Swarm (EHS) mouse sarcoma - that allows to mimic in vitro the cell-ECM interaction. 
In Matrigel capillary tube formation assay, 80 μl of Matrigel were added into wells of flat bottom 
96 well culture plates. Plates with Matrigel were incubated at 37°C for 45 minutes to allow matrix 
polymerization into insoluble gels. ECFCs were seeded onto the surface of Matrigel-coated wells at 
a density of 15 × 10
3
cells/well. Each sample was analyzed in triplicate. The plates were incubated 
at 37 °C in the CO2 incubator. After 24 hours, the plates were examined using an inverted phase-
contrast microscope. 5 photographs of different microscopic fields were taken for each well (4x 
magnification). In each photograph, the number of capillary-like structures formed by seeded cells 
was evaluated. 
3.5.7 Cytokine production 
IL-ϲ, VEGF, FGFď, TNFα, IFNγ aŶd IL-3 were quantified in ECFC supernatants by specific enzyme-
linked immunosorbent assay (ELISA). Cytokine concentration was measured with commercial kits 
(R&D Systems, Minneapolis, MN) used according to the manufacturers' instructions. 
At each passage, ECFC supernatants were collected and centrifuged to eliminate debris and death 
cells. Cell-free culture supernatants were filtered and stored at – 20°C. 
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3.5.8 Gene array analysis 
ECFCs isolated from cKS patients and healthy controls were compared for gene expression 
profiling. 
Total RNA was extracted from ECFC pellets using a commercial kit (RNeasy® Plus Micro – Qiagen). 
RNA extraction was performed according to the manufacturers' instructions. RNA purity and 
concentration were measured using NanoDrop 1000 UV-VIS Spectrophotometer, RNA integrity 
was evaluated by using an 2100 BioAnalyzer (Agilent Technologies) and samples with a RNA 
Integrity Number (RIN) lower than 8 were discarded. 
RNA extracted from ECFCs was reverse transcribed using the commercial kit Illumina TotalPrep 
RNA Amplification kit according to the Illumina protocol (Ambion) and cRNA was generated after a 
14 hours of in vitro transcription. Gene expression of ECFCs was analyzed by Illumina direct 
hybridization assays. Washing, staining and hybridization were performed according to the 
standard Illumina protocol. cRNA obtained from each sample was hybridized onto Illumina 
HumanHT-12 v4 Expression BeadChip arrays. Hybridization and scanning were performed 
according to the ŵaŶufaĐtuƌeƌ͛s iŶdiĐatioŶs oŶ aŶ IlluŵiŶa i“ĐaŶ “Ǉsteŵ aŶd data ǁeƌe pƌoĐessed 
with BeadStudio v.3. 
3.6 Statistical analysis 
The frequency of subjects who give rise to at least one ECFC colony was shown as percentage and 
P value was calculated as χc2. 
The time of ECFC colonies appearance and the frequency of ECFC colonies isolated - evaluated 
during ECFC isolation phase - ǁeƌe shoǁŶ as ŵediaŶ ;iŶteƌƋuaƌtile ƌaŶgeͿ aŶd Т ďaƌs ƌepƌeseŶt ϱ 
and 95 percentile. P value calculated by the Mann-Whitney U-test or Wilcoxon signed-rank test, as 
indicated.  
IŶ ECFC eǆpaŶsioŶ phase aŶalǇsis, data ǁeƌe shoǁŶ as as ŵediaŶ ;iŶteƌƋuaƌtile ƌaŶgeͿ aŶd Т ďaƌs 
represent 5 and 95 percentile. P value calculated by the Mann-Whitney U-test or Wilcoxon signed-
rank test, as indicated.  
In the evaluation of ECFC lymphatic differentiative potential, data of gene expression were shown 
as median and interquartile and P value was calculated by the Mann-Whitney U-test or Wilcoxon 
signed-rank test, as indicated whereas the data of lymphatic markers expression were shown as 
peƌĐeŶtage oƌ as ŵediaŶ ;iŶteƌƋuaƌtile ƌaŶgeͿ aŶd Т ďaƌs ƌepƌeseŶt ϱ aŶd 9ϱ peƌĐeŶtile aŶd P 
value was calculated by χc2 or by the Mann-Whitney U-test or Wilcoxon signed-rank test, as 
indicated.  
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4. Results 
 
 
 
 
 
 
 
 
 
 
66 
 
4.1 Comparison between ECFCs isolated from cKS patients and healthy 
controls 
EPCs play a crucial role in endothelial homeostasis and in vasculogenic processes both in 
physiological and pathological conditions [Urbich C et al, 2004]. Although different types of cells - 
isolated from peripheral blood - have been called EPCs in the past, only ECFCs are considered the 
true EPCs. In fact, ECFCs are endowed with high proliferative potential and are able to give raise to 
new vessels in vivo and form capillary-like structures in vitro [Fadini GP et al, 2012]. 
Since in previous studies we demonstrated that circulating EPCs, identified as 
CD45
dim
/CD34
+
/KDR
+
, are increased in cKS patients [Taddeo A et al, 2008] and that in cKS patients 
ECFCs are HHV-8 infected and can act as viral reservoir [Della Bella S et al, 2008], in this project we 
evaluated whether EPCs isolated and cultured as ECFCs from cKS patients are characterized by 
features that resemble the spindle cells, the typical cells of KS lesions. In particular, ECFCs were 
isolated from cKS patients and healthy controls and were analyzed for the parameters described in 
the following chapters. 
4.1.1 Efficiency of ECFC colonies isolation  
In order to assess whether the frequency of ECFCs may be altered in patients with cKS, we 
compared the appearance of ECFC colonies obtained after seeding PBMCs isolated from cKS 
patients and healthy donors, by applying a method recently optimized in our lab [Colombo et al, 
2013]. Briefly, PBMCs isolated from fresh peripheral blood samples were seeded in culture plates 
coated with fibronectin, in EGM-2 medium + 5% FBS, and ECFC colonies were identified as cluster 
of adherent cells with cobblestone-like morphology. Once identified, ECFC colonies were detached 
and further expanded for several passages in culture plates coated with collagen.  
From each subject, PBMCs were isolated from a sample of fresh peripheral blood. PBMC cultures 
were monitored for 30 days starting from PBMCs seeding by visual inspection using an inverted 
microscope, in order to identify the ECFC colonies on the basis of their morphological appearance. 
For each subject, the number of seeded PBMCs, the time of ECFC colonies appearance and the 
number of ECFC colonies obtained were recorded.  
As shown in Figure 6A, the proportion of donors giving rise to at least one ECFC colony was similar 
among cKS patients and healthy controls (cKS vs controls: 80.72% vs 73.26% subjects who give rise 
to at least one ECFC colony, n=83, n=86, P=n.s.).  
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The subjects who gave rise to at least one ECFC colony were further characterized and in 
particular, we evaluated the frequency of ECFC colonies isolated and the time of ECFC colonies 
appearance. As shown in Figure 6B, the frequency of ECFCs was strikingly higher in cKS patients 
than healthy controls (median, cKS vs controls: 15.0 vs 2.6 ECFC colonies/10
8
 seeded PBMCs, n=67, 
n=63, P<0.0001). Moreover, ECFC colonies isolated from cKS patients appeared some days earlier 
than those from healthy controls (median cKS vs controls: 13.6 vs 19.0 days, n=67, n=63, 
P<0.0001) (Figure 6C). 
 
Figure 6: ECFC isolation from healthy controls and cKS patients. (A) Frequency of subjects who gave rise to 
at least one ECFC colony. Percentage of subjects who gave rise to at least one ECFC colony within 30 days 
after PBMC seeding in healthy controls (CTR, white bar) and cKS patients (cKS, gray bar). Data shown as 
percentage. P value calculated by the χc2 test. (B) Frequency of ECFC colonies. Frequency of ECFC colonies 
isolated from healthy controls (CTR, white box) and cKS patients (cKS, gray box). The frequency of ECFC 
colonies isolated was expressed as number of ECFC colonies isolated/10
8
 seeded PBMCs. Data shown as 
median (interquartile range) and Т bars represent 5 and 95 percentile. P value calculated by Mann-Whitney 
test. (C) Time of appearance of ECFC colonies. Time of appearance of ECFC colonies isolated from healthy 
controls (CTR, white box) and cKS patients (cKS, gray box). Data shown as median (interquartile range) and 
Т bars represent 5 and 95 percentile. P value calculated by Mann-Whitney test. 
These findings were relatively stable over time. In fact, 5 cKS patients with a stable stage of 
disease over a period of six months and 5 healthy controls were analyzed for circulating ECFCs at a 
second time point and showed the persistence of similar ECFC frequencies (median in cKS: 14.6 
and 16.8 ECFC colonies/10
8
 PBMCs, n=5, P=n.s.; median in controls: 3.1 and 2.9, n=5, P=n.s.) and 
similar time of appearance (median in cKS: 15.3 and 13.9 days, n=5, P=n.s.; median in controls: 
18.3 and 18.5, n=5, P=n.s.) (Data not shown). 
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Moreover, in the group of cKS patients, we evaluated whether the stage and evolutive pattern of 
disease could influence the efficiency of ECFC isolation. 
As shown in Figure 7, the increased frequency of ECFC colonies was more pronounced in patients 
with rapidly evolving (all stages B) than slowly evolving (all stages A) disease (median in stage B vs 
stage A: 16.3 vs 7.7 ECFC colonies/10
8
 seeded PBMCs, n=46, n=15, P<0.05) (Figure 7A), whereas no 
correlation between the frequency of ECFC colonies and clinical stage (I, II, III, IV) was observed 
(median in stage I-II vs stage III-IV: 15.62 vs 15 ECFC colonies/10
8
 seeded PBMCs, n=46, n=21, 
P=n.s.) (Figure 7B). No correlation between the frequency of subjects who gave rise to at least one 
ECFC colony and clinical stage or evolutive pattern was observed (percentage in stage I-II vs stage 
III-IV: 83.64% vs 75% subjects who give rise to at least one ECFC colony, n=55, n=28, P=n.s.; 
percentage in stage B vs stage A: 80.7% vs 83.3%, n=57, n=18, P=n.s.) (Data not shown). No 
correlation between the time of appearance of ECFC colonies and clinical stage or evolutive 
pattern was observed (median in stage I-II vs stage III-IV: 13.6 vs 13.65 days, n=46, n=21, P=n.s.; 
median in stage B vs stage A: 13.6 vs 13.67, n=46, n=15, P=n.s.) (Data not shown). 
 
Figure 7: Frequency of ECFC colonies isolated from cKS patients stratified on the basis of the evolutive 
pattern and the stage of disease. (A) Frequency of ECFC colonies isolated from cKS patients stratified on the 
basis of the evolutive pattern of disease. Frequency of ECFC colonies isolated from cKS patients with slowly 
evolving disease, stage A (cKS A) and cKS patients with rapidly evolving disease, stage B (cKS B). The 
frequency of ECFC colonies isolated was expressed as number of ECFC colonies isolated/10
8
 seeded PBMCs. 
Data shown as median (interquartile ƌaŶgeͿ aŶd Т ďaƌs ƌepƌeseŶt 5 aŶd ϵ5 peƌĐeŶtile. p ǀalue ĐalĐulated ďǇ 
Mann-Whitney test. (B) Frequency of ECFC colonies isolated from cKS patients stratified on the basis of the 
stage of disease. Frequency of ECFC colonies isolated from cKS patients with early stages of disease, stage I 
and II (cKS I-II) and cKS patients with advanced stages of disease, stage III and IV (cKS III-IV). The frequency 
of ECFC colonies isolated was expressed as number of ECFC colonies isolated/10
8
 seeded PBMCs. Data 
shown as median (interquaƌtile ƌaŶgeͿ aŶd Т ďaƌs ƌepƌeseŶt 5 aŶd ϵ5 peƌĐeŶtile. P ǀalue ĐalĐulated ďǇ 
Mann-Whitney test. 
In order to assess whether the use of collagen rather than fibronectin used for coating plastic 
plates may differently affect the efficiency of ECFC colony isolation from cKS patients, in few 
experiments we compared the appearance of ECFC colonies obtained after seeding PBMCs from 
cKS on either substrate. To this aim, the PBMCs obtained from 4 cKS patients were divided into 
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portions, with half of them seeded on fibronectin-coated plates and the rest seeded on collagen-
coated plates.  
 
Figure 8: Effects of fibronectin and collagen on isolation of ECFC colonies in cKS patients. Time of 
appearance of ECFC colonies obtained from cKS patients whose PBMCs were seeded on fibronectin (cKS FN) 
or collagen–coated culture plates (cKS COLͿ. Data shoǁŶ as ŵediaŶ ;iŶteƌƋuaƌtile ƌaŶgeͿ aŶd Т ďaƌs 
represent 5 and 95 percentile. P value calculated by Wilcoxon signed-rank test. 
Similarly to our previous observation in healthy donors [Colombo et al, 2013], also ECFCs from cKS 
patients were isolated more efficiently when fibronectin was used, as ECFC colonies appeared 
some days earlier when PBMCs were seeded on fibronectin than collagen (median fibronectin vs 
collagen: 14.4 vs 17.1 days, n=4, n=4, P=n.s.) (Figure 8). 
4.1.2 In vitro expansion of ECFCs 
Once isolated, ECFC colonies can be expanded in vitro for several passages allowing their 
phenotypic and functional characterization. 
In particular, we compared ECFCs isolated from cKS patients and healthy controls and we 
evaluated: the immunophenotype and morphology, the life span, the proliferative and in vitro 
vasculogenic potential of ECFCs. Moreover, we evaluated also ECFC cytokine production and ECFC 
molecular signature. 
4.1.2.1 Immunophenotype 
In order to assess whether ECFCs obtained from cKS patients may have a different 
immunophenotype compared with healthy controls, in few cultures we analyzed the expression of 
endothelial and non-endothelial markers. 
As shown in Figure 9, ECFCs isolated from both cKS patients and healthy controls were endowed 
with characteristics typical of ECFCs. In facts, immunophenotyping by flow cytometry revealed 
that ECFCs isolated from both cKS patients and healthy controls did not express the pan-leukocyte 
marker CD45 and the monocyte/macrophage marker CD14 (Figure 9A) whereas they expressed 
typical endothelial cell-surface antigens such as CD31, CD54, CD144, CD146 and VEGFR-2 and 
CXCR4 (SDF-1 receptor) (Figure 9B). In addition, as confirmed by confocal microscopy analysis 
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ECFCs isolated from both cKS patients and healthy controls incorporated Dil-ac-LDL and bound 
lectin UEA- 1 (Figure 9C).  
 
Figure 9: Immunophenotype of ECFCs isolated from healthy controls and cKS patients. (A) CD14 and CD45 
expression and (B) endothelial markes (CD31, CD54, CD144, CD146 and VEGFR-2) and CXCR4 (SDF-1 receptor) 
expression in ECFCs isolated from healthy controls (blue histograms) and cKS patients (red histograms). Data 
shown as flow cytometric histograms. For each marker, representative flow cytometric histograms of one ECFC 
colony isolated from a healthy control and one ECFC colony isolated from a cKS patient are shown. In each flow 
cytometric histogram the overlay of stained (empty curve) and unstained cells (filled curve) is shown. (C) 
Representative immunofluorescence photographs showing the uptake of Dil-ac-LDL (in red) and the binding of 
lectin UEA-1 (in green) in ECFCs isolated from healthy controls and cKS patients. Photographs were obtained 
using an Olympus Fluoview FV1000 confocal microscope, 40x magnification. 
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4.1.2.2 Detection of HHV-8 infection 
In a previous study we reported that ECFCs isolated from cKS were HHV-8-infected as we detected 
HHV-8 DNA in both cells and culture supernatants [Della Bella S et al, 2008]. 
In order to confirm the presence of HHV-8 infection also with a different technique, we 
investigated the presence of LANA - a nuclear antigen typically expressed during the latent phase 
of HHV-8 infection - by immunofluorescence assay. In particular, LANA detection by confocal 
microscopy allowed to evaluate the percentage of HHV-8-infected cells in ECFC cultures and to 
evaluate the antigen localization within the cells.  
We first set up the protocol for LANA detection in ECFC cultures. In particular, we defined the 
optimal concentration and incubation conditions for the primary antibody (diluition 1:1000; final 
working concentration of 1 µg/ml, incubated overnight at +4°C). 
The body-cavity-based lymphoma (BCBL)-1 cell line was used as positive control for LANA staining. 
In fact, BCBL-1 cells are latently infected with HHV-8 and LANA is expressed costitutively in nearly 
all cells. 
 
Figure 10: LANA detection in BCBL-1 cells. Representative immunofluorescence photographs of BCBL-1 cells 
stained for LANA (green). Cells were stained for LANA and cell nuclei were stained with DAPI (blue) 
Photographs were obtained using an Olympus Fluoview FV1000 confocal microscope; photographs at 40x, 
120x and 180x magnification are shown. 
As shown in figure 10, the optimized protocol allowed the detection of LANA that is expressed 
with the typical intranuclear punctate pattern in nearly all BCBL-1 cells. 
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The optimized protocol was used to evaluate LANA expression - and therefore the presence of 
HHV-8 infection - in ECFC colonies isolated from cKS patients and healthy controls.  
 
Figure 11: LANA detection in ECFC cultures. Upper row: representative immunofluorescence photographs 
showing ECFCS isolated from cKS patients stained for LANA; lower row: representative immunofluorescence 
photographs showing ECFCS isolated from HHV-8 seronegative healthy controls stained for LANA. Cells were 
stained for LANA (intranuclear green dots, indicated by white arrows) and cell nuclei were stained with DAPI 
(blue). Photographs were obtained using an Olympus Fluoview FV1000 confocal microscope; photographs at 
120x magnification. 
As shown in figure 11, confocal analysis for LANA expression revealed that all the screened ECFC 
colonies isolated from cKS patients expressed LANA antigen thus confirming that they were HHV-8 
infected. Notably, the expression level of LANA was lower in KS-ECFCs than in BCBL-1 and only a 
portion of cells of each screened ECFC colony expressed LANA. The percentage of LANA
+ 
cells was 
variable among the analyzed colonies, ranging from 5% to 20% of total cells (ECFC colonies 
analyzed n=6). As expected, all the screened ECFC colonies isolated from HHV-8 seronegative 
healthy controls were negative for LANA expression (ECFC colonies analyzed n=5).  
4.1.2.3 Senescence  
In order to evaluate the senescence of ECFC colonies, we identified as senescent cells those with 
low viability (viable cells <60%) and altered morphology. Cell senescence was further confirmed by 
the β-galactosidase assay, based on the expression of high levels of the senescence-associated 
enzyme β-galactosidase by senescent cells (Figure 12). 
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Figure 12: Senescence evaluation in ECFC cultures. Representative photographs of viable cells characterized 
with typical cobblestone-like morphology and absence of senescence-assoĐiated β-galactosidase activity 
(left column); representative photographs of senescent cells characterized by altered morphology and 
expression of high levels of senescence-assoĐiated β-galactosidase, as indicated by the presence of 
blue/green precipitate (right column). Photographs were obtained using an Olympus inverted microscope 
IX51, 4x and 10x magnification. 
Similarly to ECFCs isolated from healthy controls, ECFCs obtained from cKS patients maintained 
stable endothelial morphology and exhibited features of primary cells by ultimately becoming 
senescent after long term culture as confirmed by seŶesĐeŶĐe assoĐiated β-galactosidase assay 
(median cKS vs controls: 7 vs 6 passage, n=45, n=45, P=n.s.) (data not shown). 
4.1.2.4 Proliferative potential 
In order to assess whether ECFCs obtained from cKS patients may have an in vitro behaviour that 
may evoke the in vivo behaviour of KS spindle cells, we analyzed the proliferation curves of ECFC 
colonies obtained from cKS and healthy donors. To this aim, we analyzed and compared 45 
consecutive ECFC colonies obtained from each group. 
 
Figure 13: Proliferative potential of ECFCs isolated from healthy controls and cKS patients. (A) Ex vivo 
expansion of ECFCs isolated from healthy controls (CTR) and cKS patients (cKS). Data shown as median 
curves. P values calculated by Mann-Whitney test (*P<0.05, 
#
P<0.01, 
§
P<0.001. (B) Maximum cell yield 
obtained after ex vivo expansion of ECFCs isolated from healthy controls (CTR) and cKS patients (cKS). Data 
shoǁŶ as ŵediaŶ ;iŶteƌƋuaƌtile ƌaŶgeͿ aŶd Т ďaƌs ƌepƌeseŶt 5 aŶd ϵ5 peƌĐeŶtile. P ǀalue ĐalĐulated ďǇ 
Mann-Whitney test. 
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ECFCs isolated from cKS patients were endowed with a higher proliferative potential than ECFCs 
isolated from healthy controls. Median curves which described the cell yield at each passage of 
ECFC cultures are reported in Figure 13A. Despite the cell number increased with increasing days 
of culture in ECFCs isolated from both groups, the cell yield was higher in cultures of ECFCs 
isolated from cKS patients at each time point (<10 days of culture: n=60 vs 54, P<0.05; 10-14 days: 
n=67 vs 57, P<0.05; 15-19 days: n= 40 vs 34, P<0.05; 20-24 days: n=35 vs 28, P<0.05; 25-29 days: 
n=25 vs 23, P<0.05; 30-34 days: n=13 vs 9, P=n.s.; 35-39 days: n=8 vs 6, P=n.s.; 40-49 days: n=6 vs 
12, P=n.s.; 50-59 days: n= 2 vs 3, P=n.s.). Accordingly, also the maximum cell yield obtained after 
ECFC ex vivo expansion was higher in cultures of ECFCs isolated from cKS patients than healthy 
controls (median cKS vs controls: 69.55 vs 5.58 number of cells x10
6
, n=45 vs 45, P<0.05) (Figure 
13B). 
To further confirm the higher proliferative ability observed in ECFC colonies isolated from cKS 
patients, we evaluated the proliferation rate of ECFCs isolated from both cKS patients and healthy 
controls. 
 
Figure 14: Proliferation rate of ECFCs isolated from healthy controls and cKS patients. Proliferation rate of ex 
vivo expanded ECFCs isolated from healthy controls (CTR) and cKS patients (cKS). Data shown as median 
curves of day of culture at each culture passage. P values calculated by Mann-Whitney test (*P<0.05, 
#
P<0.01, 
§
P<0.001). 
As shown in Figure 14, ECFCs isolated from cKS patients proliferated faster than ECFCs isolated 
from healthy controls. In fact, ECFCs isolated from cKS patients reached late passages earlier than 
ECFCs isolated from healthy donors (cKS vs controls: n=28 vs 28, passage 1: P=n.s.; passage 2: 
P<0.001; passage 3: P=<0.001; passage 4: P=<0.001; passage 5: P=<0.01; passage 6: P=<0.01; 
passage 7: P=<0.01). 
Moreover, in the group of cKS patients, we evaluated whether the stage and the evolutive pattern 
of disease could influence the proliferative potential of ECFCs isolated from cKS patients. No 
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correlation between the proliferative potential and clinical stage (I, II, III, IV) or evolutive pattern 
(A,B) of disease was observed (data not shown).  
4.1.2.5 In vitro vasculogenic potential 
In order to evaluate whether ECFCs isolated from cKS patients were characterized by a higher 
vasculogenic potential than ECFCs isolated from healthy controls, we performed Matrigel capillary 
tube formation assay. In particular, we evaluated the ability of ECFCs to form capillary-like 
structures when seeded in Matrigel matrix (Figure 15). 
 
Figure 15: Matrigel capillary tube formation assay. Representative phase-contrast photographs showing the 
capillary-like structures formed by ECFCs seeded in Matrigel matrix. Photographs were obtained using an 
Olympus inverted microscope IX51, 4X magnification. 
Although ECFCs isolated from both cKS patients and healthy controls were able to form capillary-
like structures when seeded in Matrigel matrix, ECFCs isolated from cKS patients were endowed 
with a higher vasculogenic potential than ECFCs isolated from healthy controls. 
 
Figure 16: Vasculogenic potential of ECFCs isolated from healthy controls and cKS patients. The capillary-like 
structure formation was evaluated 24h after ECFC seeding in Matrigel matrix by observation with inverted 
microscopy. (A) Number of capillary-like structures formed by ECFCs isolated from healthy controls (CTR, 
white box) and cKS patients (cKS, gray box). Data shown as median (interquaƌtile ƌaŶgeͿ aŶd Т ďaƌs 
represent 5 and 95 percentile. p value calculated by Mann-Whitney test. (B) Vasculogenic potential 
evaluated at different time points in ECFCs isolated from healthy controls (CTR) and cKS patients (cKS). Data 
shown as median curves. p values calculated by Mann-Whitney test. 
As shown in Figure 16A, ECFCs isolated from cKS patients formed a significantly higher number of 
capillary–like structures than ECFCs isolated from healthy controls (median cKS vs controls: 30 vs 
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15.8 capillary-like structures/field, n=19, n=15, P<0.001). To evaluate whether the vasculogenic 
potential of ECFCs may vary during ex vivo expansion, the angiogenic potential of 4 ECFC colonies 
isolated from healthy controls and 4 ECFC colonies isolated from cKS patients was assessed at 
different time point during the ex vivo expansion .As shown in Figure 16B, ECFCs isolated from cKS 
patients - after 24 hours of culture in Matrigel - displayed a higher vasculogenic potential at each 
analyzed time point (median number of capillary-like structures/field, cKS vs controls, at day 7: 
33.43 vs 23.89, P<0.05.; at day 14: 37.17 vs 20.28, P<0.01; at day 21: 35 vs 21, P<0.05). 
We further evaluated whether the stage and the evolutive pattern of disease could influence the 
angiogenic potential of ECFCs isolated from cKS patients. No correlation between the angiogenic 
ability of ECFCs and the stage or the evolutive pattern of disease was observed (data not shown). 
4.1.2.6 Cytokine production 
To investigate the mechanisms possibly involved in sustaining the higher proliferative and 
vasculognic potential observed in ECFCs isolated from cKS patients than healthy controls, we 
evaluated the cytokine production of ECFCs. In particular, we analyzed in our cultures the main 
proangiogenic cytokines secreted by endothelial progenitor cells [Krenning G et al, 2009] and the 
cytokines typically present in KS lesions [Sirianni MC et al, 1998]. To this aim, we measured by 
ELISA assay the levels of IL-6, IL-3, IFNγ, TNFα, FGFb and VEGF in the supernatants recovered from 
each ECFC culture just before cell passaging. VEGF, IFNγ, TNFα and IL-3 were undetectable at any 
passage in ECFCs isolated from both healthy controls and cKS patients, in accordance with a 
previous study [Hur J et al, 2004]. 
FGFb was detectable in ECFC cultures isolated from both healthy controls and cKS patients but no 
differences in FGFb concentration were observed between the two groups (data not shown). 
As shown in Figure 17, IL-6 was detectable in ECFCs isolated from both healthy controls and cKS 
patients. Moreover, IL-6 concentration - expressed as pg/10
5
 cells – increased during ECFC ex vivo 
expansion (Figure 17A) and was higher in culture supernatants of ECFCs isolated from cKS patients 
than healthy controls at each time point analyzed (cKS vs controls, <10 days of culture: n=34 vs 33, 
P=n.s.; 10-14 days: n=40 vs 37, P<0.05; 15-19 days: n=19 vs 35, P<0.05; 20-24 days: n=14 vs 30, 
P<0.05; 25-29 days: n=8 vs 16, P<0.05; 30-34 days: n=5 vs 7, P<0.05; 35-39 days: n=4 vs 7, P<0.05; 
40-49 days: n= 3 vs 9, P<0.05; 50-59 days: n=3 vs 3, P=n.s.). In addition, the maximum levels of IL-6 
detected in the supernatants of ECFC cultures were significantly higher in ECFCs isolated from cKS 
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patients than healthy controls (median cKS vs controls: 2467.48 vs 847.37 IL-6 pg/10
5
 cells, n=29, 
n=40, P<0.05) (Figure 17B). 
 
Figure 17: IL-6 production by ECFCs. (A) IL-6 levels, expressed as pg/10
5
 cells, were measured in culture 
supernatants of ECFCs isolated from healthy controls (CTR, gray dashed line) and cKS patients (cKS, black 
line). Data shown as median curves. P values calculated by Mann-Whitney test (*P<0.05, 
#
P<0.01, 
§
P<0.001). (B) Maximum levels of IL-6, expressed as pg/10
5
 cells, detected in culture supernatants of ECFCs 
isolated from healthy controls (CTR, white box) and cKS patients (cKS, gray box). Data shown as median 
;iŶteƌƋuaƌtile ƌaŶgeͿ aŶd Т ďaƌs represent 5 and 95 percentile. P value calculated by Mann-Whitney test. 
We also evaluated whether stage and evolutive pattern of disease could influence IL-6 production 
of ECFCs isolated from cKS patients. No correlation between the levels of IL-6 produced by ECFCs 
and the stage or evolutive pattern of disease was observed (data not shown). 
4.1.2.7 Gene array analysis 
In order to investigate the molecular pathways possibly involved in the different behaviour of 
ECFCs isolated from cKS patients, we performed a gene-array analysis comparing the molecular 
signature of ECFC isolated from cKS patients and healthy controls.  
ECFCs isolated from 3 healthy controls and 3 cKS patients were analyzed by gene array. Total RNA 
isolated from ECFCs was reverse-transcribed and cRNA was hybridized onto Illumina Human HT-12 
v4 Expression BeadChip arrays. 
Preliminary analysis revealed that, as shown in the heat map in Figure 18A, patients and healthy 
controls segregated by clustering, thus confirming that gene expression profile differs between 
ECFCs isolated from cKS patients and healthy donors. 
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Figure 18: Gene expression profile of ECFCs isolated from healthy controls and cKS patients. (A) Hierarchical 
clustering of samples and transcripts. The heat map shows the relative expression levels of each transcript 
(rows) in each sample (column). Rows and columns are hierarchically clustered. (B) List of upregulated genes 
in ECFCs isolated from cKS patients compared with healthy controls (fold change >1.5 and P<0.05.)  
In particular, as shown in Figure 18B, 16 genes were found to be upregulated (fold change >1.5 
and P<0.05) in ECFCs isolated from cKS patients compared to ECFCs isolated from healthy controls. 
More detailed analysis are still in progress in order to evaluate the possible role of the genes that 
have been found to be differentially expressed in determining the typical behavior observed in 
ECFCs isolated from cKS. In particular, deubiquitinase PSMD14 - whose expression was significantly 
up-regulated in ECFCs isolated from cKS patients - was reported to be involved in regulation of cell 
proliferation. In fact, Byrne et al documented that knockdown of human PSMD14 induced cell 
cycle arrest and senescence in carcinoma cell lines [Byrne A et al, 2010]. 
Moreover, gene set enrichment analysis (GSEA) will be performed to evaluate whether specific 
gene-sets are differentially expressed by ECFCs isolated from cKS patients. In particular, genes 
specifically involved in angiogenesis, cell proliferation, IL-6 pathway and VEGFR-3 pathway and 
genes that are differentially expressed by BECs and LECs will be evaluated. 
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4.2 Evaluation of lymphatic differentiative potential of ECFCs 
Several studies reported that spindle cells in KS lesions express the lymphatic markers LYVE-1, 
podoplanin and VEGFR-3 [Pyakurel P, 2006] and in vitro HHV-8-infected BECs upregulate the 
expression of lymphatic markers including PROX-1 [Hong YK et al, 2004]. Therefore, we initially 
planned to evaluate the expression of LYVE-1 and podoplanin in ECFCs isolated from cKS patients 
and healthy controls. Unexpectedly, in preliminary experiments performed in few ECFC cultures 
analyzed by immunofluorescence microscopy, we observed that podoplanin and LYVE-1 were 
expressed not only by ECFCs isolated from cKS patients but also by ECFCs isolated from healthy 
controls (Figure 19). 
 
Figure 19: ECFCs isolated from cKS patients and healthy controls stained for podoplanin and LYVE-1. (A) 
representative photographs showing immunofluorescence staining for podoplanin (green) in ECFCs isolated 
from cKS patients (cKS) and healthy controls (CTR); (B) representative photographs showing 
immunofluorescence staining for LYVE-1 (green) in ECFCs isolated from cKS patients (cKS) and healthy 
controls (CTR). Cell nuclei were stained with DAPI (blue). Photographs were obtained using an Olympus 
Fluoview FV1000 confocal microscope, 60X magnification. 
These results were totally unexpected, as the expression of lymphatic markers by ECFCs had never 
been reported. Moreover, in recent years several studies supported the hypothesis that a 
population of lymphatic endothelial progenitor cells (LEPCs) could be involved in lymphangiogenic 
processes [Park C. et al, 2011]. Nevertheless, the identity of LEPCs has not yet been fully 
elucidated.  
Therefore, we studied the expression of lymphatic markers on ECFCs isolated from healthy 
controls.  
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4.2.1 Evaluation of lymphatic differentiative potential of ECFCs in basal conditions 
In order to investigate the lymphatic differentiative potential of ECFCs, the expression of mRNA 
encoding for PROX-1, Podoplanin, LYVE-1 and VEGFR-3 in ECFCs was investigated by Q-PCR. We 
further confirmed the expression of the lymphatic markers by confocal microscopy. 
Moreover, we evaluated whether fibronectin – an ECM protein commonly used as substrate for 
ECFC culture – may foster ECFC differentiation toward the lymphatic phenotype. In fact, several 
clinical studies reported that the presence of fibronectin in tumor stroma correlates with 
lymphangiogenesis and lymph node metastases [Bae YK et al, 2013; Ou J et al, 2013]. Therefore, 
we compared the expression of PROX-1, Podoplanin, LYVE-1 and VEGFR-3 between ECFCs cultured 
on fibronectin and ECFCs cultured on collagen – another ECM protein commonly used as a 
substrate for ECFC culture. 
4.2.1.1 Detection of mRNA encoding for lymphatic markers by Q-PCR 
The expression of mRNA encoding for PROX-1, Podoplanin, LYVE-1 and VEGFR-3 was investigated in 
ECFCs by Q-PCR. GAPDH was used as the housekeeping and the expression level of each marker was 
shown as 2
-ΔCT
 (X10
6
). 
ECFCs cultured both on fibronectin and collagen expressed the transcripts encoding PROX-1, LYVE-1 
and VEGFR-3. Also podoplanin was expressed by ECFCs but this lymphatic marker was expressed only 
by some of the ECFC colonies screened and the percentage of ECFC colonies that expressed 
podoplanin was similar between ECFC colonies cultured on fibronectin and on collagen (fibronectin vs 
collagen: 72.73% vs 54.5% of ECFC colonies that expressed podoplanin, P=n.s.) (Data not shown). 
 
Figure 20: Expression of mRNA encoding for PROX-1, podoplanin, LYVE-1 and VEGFR-3 evaluated by Q-PCR. 
The expression of (A) PROX-1, (B) podoplanin, (C) LYVE-1 and (D) VEGFR-3 was assessed in ECFCs cultured on 
fibronectin (FN, white bar) or collagen (COL, gray bar). GAPDH was used as the housekeeping and the 
expression level of each marker was shown as 2
-ΔCT
 (X10
6
). Data shown as median±interquartile range. P 
value calculated by Mann-Whitney test. 
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Moreover, the expression levels of the analyzed markers were variable between colonies. As shown in 
figure 20, ECFCs cultured on fibronectin and collagen expressed PROX-1, podoplanin, LYVE-1 and 
VEGFR-3 at similar levels (median 2
-ΔCT
(X10
6
) on fibronectin vs collagen, PROX-1: 35.84 vs 27.31, n=11 
vs 11, P=n.s.; podoplanin: 8.31 vs 7.57, n=8 vs 6, P=n.s.; LYVE-1: 11406 vs 3431, n=11 vs 11, P=n.s.; 
VEGFR-3: 4010 vs 2219, n=11 vs 11, P=n.s.). 
In order to evaluate whether ECFCs isolated from cKS patients express the lymphatic markers – a 
typical feature of KS spindle cells [Pyakurel P, 2006] and in vitro HHV-8-infected BECs [Hong YK et 
al, 2004] - and in order to confirm our previous experiments performed by immunofluorescence, 
we evaluated by Q-PCR the expression of genes encoding for PROX-1, podoplanin, LYVE-1 and 
VEGFR-3 also in ECFCS isolated from cKS patients.  
 
Figure 21: Expression of mRNA encoding for lymphatic markers evaluated by Q-PCR in ECFC isolated from 
cKS patients compared with healthy controls.The expression of PROX-1, podoplanin, LYVE-1 and VEGFR-3 - 
expressed as 2
-ΔCT
(X10
6
) - was assessed in 2 ECFCs colonies isolated from cKS patients (respectively cKS#1 
cKS#2). Data shown as median±SD. 
As shown in Figure 19, in preliminary experiments performed in 2 ECFC colonies isolated from cKS 
patients, we observed that ECFCs isolated from cKS patients expressed the lymphatic markers 
PROX-1, podoplanin, LYVE-1 and VEGFR-3. Moreover, ECFC colonies isolated from cKS patients 
expressed the lymphatic markers at similar levels of ECFC colonies isolated from healthy controls. 
Further experiments are still in progress in order to evaluate whether the lymphatic marker 
expression is similar or it is increased in ECFCs isolated from cKS patients compared to ECFCs 
isolated from healthy controls. 
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4.2.1.2 Detection of lymphatic markers by confocal microscopy 
To confirm the results observed at the transcriptional level by Q-PCR, we further analyzed the 
expression of PROX-1, Podoplanin, LYVE-1 and VEGFR-3 by confocal microscopy. In particular, we 
analyzed ECFCs colonies cultured on both fibronectin and collagen. 
4.2.1.2.1 Optimization of protocols for lymphatic markers detection by confocal 
microscopy 
In order to evaluate by confocal microscopy the lymphatic marker expression on ECFCs, we first 
optimized the staining protocols. HDLECs were used as positive controls, as they express all the 
lymphatic markers investigated at high levels [Johnson LA et al, 2013]. Moreover, different negative 
controls were used to verify staining specificity. In particular, cell types that do not express lymphatic 
markers were used as negative controls [Leclers D et al, 2006, Norgall S et al, 2007, Lorusso B et al, 
2015] 
 
Figure 22: HDLECs and fibroblasts, used as positive and negative controls, respectively, stained for PROX-1. 
(A) representative photographs showing immunofluorescence staining for PROX-1 in HDLECs and 
fibroblasts; (B) representative immunofluorescence photographs of HDLECs and fibroblasts stained only 
with the secondary antibody. Cells were stained for PROX-1 (white) and with DAPI for nuclear staining 
(blue). Photographs were obtained using an Olympus Fluoview FV1000 confocal microscope, 60X 
magnification. 
As shown in Figure 22, the optimized protocol allowed the specific staining of PROX-1. In fact, PROX-1 
signal localized in the nuclei of HDLECs, whereas PROX-1 signal was absent in fibroblasts and in HDLECs 
stained only with the secondary antibody. 
 
 
 
83 
 
 
Figure 23: HDLECs and HUVECs, used as positive and negative controls, respectively,stained for podoplanin. 
(A) representative photographs showing immunofluorescence staining for podoplanin in HDLECs and 
HUVECs; (B) representative immunofluorescence photographs of HDLECs and HUVECs stained only with the 
secondary antibody. Cells were stained for podoplanin (green) and with DAPI for nuclear staining (blue). 
Photographs were obtained using an Olympus Fluoview FV1000 confocal microscope, 60X magnification. 
As shown in Figure 23, the optimized protocol allowed the specific staining of podoplanin. In fact, 
podoplanin signal localized on the membrane of HDLECs whereas podoplanin signal was absent in 
HUVECs and in HDLECs stained only with the secondary antibody. 
 
Figure 24: HDLECs and fibroblasts, used as positive and negative controls, respectively, stained for LYVE-1. 
(A) representative photographs showing immunofluorescence staining for LYVE.1 in HDLECs and fibroblasts; 
(B) representative immunofluorescence photographs of HDLECs and fibroblasts stained only with the 
secondary antibody. Cells were stained for LYVE-1 (green) and with DAPI for nuclear staining (blue). 
Photographs were obtained using an Olympus Fluoview FV1000 confocal microscope, 60X magnification. 
As shown in Figure 24, the optimized protocol allowed the specific staining of LYVE-1. In fact, LYVE-
1 signal localized on the membrane of HDLECs whereas it was absent in fibroblasts and in HDLECs 
stained only with the secondary antibody. 
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Figure 25: HDLECs and SW480 cell line, used as positive and negative controls, respectively, stained for 
VEGR-3. (A) representative photographs showing immunofluorescence staining for VEGFR-3 in HDLECs and 
SW480; (B) representative immunofluorescence photographs of HDLECs and SW480 stained only with the 
secondary antibody. Cells were stained for VEGFR-3 (green) and with DAPI for nuclear staining (blue). 
Photographs were obtained using an Olympus Fluoview FV1000 confocal microscope, 60X magnification. 
As shown in Figure 25, the optimized protocol allowed the specific staining of VEGFR-3. In fact, 
VEGFR-3 signal localized on the membrane of HDLECs whereas it was absent in fibroblasts and in 
HDLECs stained only with the secondary antibody. 
4.2.1.2.2 Lymphatic markers detection in ECFCs by confocal microscopy 
In order to confirm the expression of lymphatic markers by ECFCs at the protein level, we 
evaluated the expression of PROX-1, podoplanin, LYVE-1 and VEGFR-3 on ECFCs by using the 
optimized protocol and analyzing cells by confocal microscopy. 
 
Figure 26: PROX-1 expression in ECFCs cultured on fibronectin and collagen: (A) ECFCs cultured on 
fibronectin and collagen stained for PROX-1. Representative photographs showing immunofluorescence 
staining for PROX-1 in ECFCs cultured on fibronectin (upper row) and collagen (lower row). ECFCs were 
stained for PROX-1 (white) and with DAPI (blue). ECFCs stained only with the secondary antibody were used 
as negative control (right column). Photographs were obtained using an Olympus Fluoview FV1000 confocal 
microscope, 60X magnification (B) Percentage of PROX-1
+ 
ECFC colonies in ECFC colonies cultured on either 
fibronectin (FN, white bar) or collagen (COLL, gray bar). Data shown as percentage. P ǀalue ĐalĐulated ďǇ χc2 
test. (C) Percentage of PROX-1
+
 cells within ECFC colonies cultured on fibronectin (FN, white box) or collagen 
(COLL, gray box). Data shown as median (interquartile rangeͿ aŶd Т ďaƌs represent 5 and 95 percentile. P 
values calculated by Mann-Whitney test. 
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As shown in Figure 26A, ECFC colonies cultured on both fibronectin and collagen expressed the 
transcription factor PROX-1. We also observed that the intensity of PROX-1 expression was highly 
variable among PROX-1
+
 cells of the same colony and among different ECFC colonies. We 
evaluated the percentage of ECFC colonies positive for PROX-1 expression and the percentage of 
PROX-1
+
 cells within ECFC colonies. As shown in Figure 26B, all the screened ECFC colonies were 
positive for PROX-1 expression both on fibronectin and collagen (fibronectin vs collagen: 100% vs 
100%, n=5, n=5, P=n.s.). Moreover, we observed that PROX-1 was expressed only by a proportion 
of cells and that the percentage of PROX-1
+
 cells was similar in ECFC colonies cultured on either 
fibronectin or collagen (median fibronectin vs collagen: 51.19 vs 38.92 percentage of PROX-1
+
 
cells, n=5, n=5, P=n.s.) (Figure 26C). 
Similar results were observed also when podoplanin (fibronectin vs collagen: 80% vs 80% 
percentage of podoplanin
+ 
colonies n=5 vs 5, P=n.s.; median 19.5 vs 24.48 percentage of 
podoplanin
+
 cells, n=4 vs 4, P=n.s.) and LYVE-1 (fibronectin vs collagen: 100% vs 100% percentage 
of LYVE-1
+ 
colonies, n=5 vs 5, P=n.s.; median 22.9% vs 26.3% percentage of LYVE-1
+
 cells, n=5 vs 5, 
P=n.s.) expression was analyzed (Figure 27 and 28). 
 
Figure 27: Podoplanin expression in ECFCs cultured on fibronectin and collagen: (A) ECFCs cultured on 
fibronectin and collagen stained for podoplanin. Representative photographs showing immunofluorescence 
staining for podoplanin in ECFCs cultured on fibronectin (upper row) and collagen (lower row). ECFCs were 
stained for podoplanin (green) and with DAPI (blue). ECFCs stained only with the secondary antibody were 
used as negative control (right column). Photographs were obtained using an Olympus Fluoview FV1000 
confocal microscope, 60X magnification (B) Percentage of podoplanin
+ 
ECFC colonies in ECFC colonies 
cultured on either fibronectin (FN, white bar) or collagen (COLL, gray bar). Data shown as percentage. p 
ǀalue ĐalĐulated ďǇ χc2 test. (C) Percentage of podoplanin+ cells within ECFC colonies cultured on fibronectin 
(FN, white box) or collagen (COLL, gray box). Data shown as ŵediaŶ ;iŶteƌƋuaƌtile ƌaŶgeͿ aŶd Т ďaƌs 
represent 5 and 95 percentile. P values calculated by Mann-Whitney test. 
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Figure 28: LYVE-1 expression in ECFCs cultured on fibronectin and collagen: (A) ECFCs cultured on fibronectin 
and collagen stained for LYVE-1. Representative photographs showing immunofluorescence staining for 
LYVE-1 in ECFCs cultured on fibronectin (upper row) and collagen (lower row). ECFCs were stained for LYVE-1 
(green) and with DAPI (blue). ECFCs stained only with the secondary antibody were used as negative control 
(right column). Photographs were obtained using an Olympus Fluoview FV1000 confocal microscope, 60X 
magnification (B) Percentage of LYVE-1
+ 
ECFC colonies in ECFC colonies cultured on either fibronectin (FN, 
white bar) or collagen (COLL, gray bar). Data shown as percentage. p ǀalue ĐalĐulated ďǇ χc2 test. (C) 
Percentage of LYVE-1
+
 cells within ECFC colonies cultured on fibronectin (FN, white box) or collagen (COLL, 
gray box). Data shown as ŵediaŶ ;iŶteƌƋuaƌtile ƌaŶgeͿ aŶd Т ďaƌs represent 5 and 95 percentile. P values 
calculated by Mann-Whitney test. 
In addition, as shown in Figure 29, all the screened ECFC colonies cultured both on fibronectin and 
collagen expressed VEGFR-3 (fibronectin vs collagen: 100% vs 100%, n=5 vs 5, P=n.s.) and VEGFR-3 
was expressed by all the cells of the screened ECFC colonies cultured on either fibronectin or 
collagen (fibronectin vs collagen: 100% vs 100% percentage of VEGFR-3
+
 cells, n=5, n=5, P=n.s.) 
(Data not shown). 
 
Figure 29: VEGFR-3 expression in ECFCs cultured on fibronectin and collagen: ECFCs cultured on fibronectin 
and collagen stained for VEGFR-3. Representative photographs showing immunofluorescence staining for 
VEGFR-3 in ECFCs cultured on fibronectin (upper row) and collagen (lower row). ECFCs were stained for 
VEGFR-3 (green) and with DAPI (blue). ECFCs stained only with the secondary antibody were used as 
negative control (right column). Photographs were obtained using an Olympus Fluoview FV1000 confocal 
microscope, 60X magnification. 
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4.2.1.2.3 Evaluation of lymphatic markers coexpression in ECFCs 
As the lymphatic markers PROX-1, podoplanin and LYVE-1 were expressed only by a proportion of the 
cells that composed the ECFC colonies, we evaluated their coexpression on ECFCs by multicolor 
immunofluorescence staining. 
The staining protocol was optimized on HDLECs which were used as positive control; afterwards the 
optimized protocol was used to evaluate the coexpression of PROX-1, podoplanin and LYVE-1on ECFCs 
cultured on both fibronectin and collagen (Figure 30). 
  
Figure 30: Analysis of lymphatic markers coexpression. Upper row row representative photographs showing 
HDLECs and ECFCs cultured on fibronectin and collagen stained for PROX-1, podoplanin and LYVE-1; lower 
row: representative immunofluorescence photographs of HDLECs and ECFCs cultured on fibronectin and 
collagen stained only with the secondary antibodies. Cells were stained for PROX-1 (white), podoplanin 
(green) and LYVE-1 (red). Cell nuclei were stained with DAPI (blue). Photographs were obtained using an 
Olympus Fluoview FV1000 confocal microscope, 60X magnification. 
As shown in Table 8, ECFCs cultured on both fibronectin and collagen expressed PROX-1, podoplanin 
and LYVE-1 in different combinations. In fact, the three markers were not always coexpressed and 
within the same ECFC colony it was possible to observe cells which expressed the three markers in 
different combinations. 
 
Table 8: Lymphatic marker coexpression in ECFCs. Frequency of cells positive for lymphatic marker 
expression analyzed in different combinations in ECFCs cultured on both fibronectin and collagen. Data 
shown as median±SD. P value calculated by Mann-Whitney test.  
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4.2.2 Evaluation of lymphatic differentiation of ECFCs upon stimulation with MSF 
In clinical studies, it has been reported that also the levels of some oncofetal isoforms of 
fibronectin – namely EDA-FN and EDB-FN - promote lymphangiogensis [Xiang L et al, 2012]. 
Therefore, we evaluated whether the lymphatic differentiative potential of ECFCs could be 
fostered by stimulating the cultures with an oncofetal isoform of fibronectin. In particular we 
stimulated ECFCs - isolated from healthy controls and cultured on both fibronectin and collagen – 
with MSF, a soluble oncofetal truncated isoform of fibronectin typically present in tumor 
microenvironment [Solinas G et al, 2010]. 
4.2.2.1 Optimization of ECFC stimulation with MSF  
As the possible role of MSF in promoting lymphatic differentiation of endothelial cells has never 
been investigated so far, we first performed preliminary experiments in order to define the 
optimal MSF concentration and time of stimulation. 
To define the optimal MSF concentration, ECFCs colonies – cultured on both fibronectin and 
collagen - were stimulated for 24 hours with different concentrations of MSF. After MSF 
stimulation, the expression of mRNA encoding for PROX-1, podoplanin, LYVE-1 and VEGFR-3 in 
ECFCs was investigated by Q-PCR. 
 
Figure 31 Expression of mRNA encoding for lymphatic markers in ECFCs treated with different 
concentrations of MSF. The expression levels of (A) PROX-1, (B) podoplanin, (C) LYVE-1 and (D) VEGFR-3 
were assessed by Q-PCR. The expression levels of a representative ECFC colony treated with increasing 
concentrations of MSF was shown. The expression level of each gene was normalized to the GAPDH internal 
control and was shown as 2
-ΔCT
 (X10
6
). 
As shown in Figure 31, ECFCs upregulated the expression of the genes encoding for all the 
lymphatic markers after treatment with MSF. The effect of MSF was similar in ECFCs cultured on 
fibronectin and collagen. In particular, the maximum stimulation of lymphatic marker expression 
was observed when ECFCs were treated with MSF at the concentration of 10 ng/ml. 
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Once defined the optimal MSF concentration for ECFC stimulation, we defined the optimal time of 
stimulation. To do that, ECFCs colonies cultured on both fibronectin and collagen were treated 
with MSF (10 ng/ml) for different times. 
 
Figure 32: Expression of mRNA encoding for lymphatic markers in ECFCs treated with MSF for different 
times. The expression levels of (A) PROX-1, (B) podoplanin, (C) LYVE-1 and (D) VEGFR-3 were assessed by Q-
PCR. The expression levels of a representative ECFC colony treated with MSF (10 ng/ml) for different times 
was shown. The expression level of each gene was normalized to the GAPDH internal control and was shown 
as 2
-ΔCT
 (X10
6
). 
As shown in Figure 32, ECFCs upregulated the expression of genes encoding for lymphatic markers 
after treatment with MSF for different times (6, 12, 24, 48 and 72 hours) and the effect of MSF 
was similar in ECFCs cultured on fibronectin and collagen. In addition, since the four analyzed 
marker were characterized by different kinetics of upregulation upon MSF stimulation, we decided 
to stimulate ECFCs for 24 hours in the following experiments. In fact, the upregulation of all four 
analyzed lymphatic markers can be appreciated in ECFCs stimulated with MSF (10 ng/ml) for 24 
hours.  
4.2.2.2 Detection of mRNA encoding for lymphatic markers in ECFC colonies 
stimulated with MSF 
The expression of mRNA encoding for PROX-1, Podoplanin, LYVE-1 and VEGFR-3 in ECFCs was 
investigated by Q-PCR in ECFCs cultured on both fibronectin and collagen both in basal conditions 
and after MSF stimulation. In particular, ECFC colonies were treated for 24 hours with MSF at the 
final concentration of 10 ng/ml in order to evaluate the effect of MSF in fostering the lymphatic 
differentiation of ECFCs.. 
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Figure 33: Expression of mRNA encoding for lymphatic markers in ECFCs treated with MSF. The expression 
levels of genes encoding for (A) PROX-1, (B) podoplanin (C) LYVE-1 and (D) VEGFR-3 were assessed by Q-PCR 
in ECFCs colonies (fibronectin + collagen) in basal condition (Basal) and after stimulation with MSF (+MSF). 
The expression level of each gene was normalized to the GAPDH internal control and was shown as 2
-ΔCT
 
(X10
6
). Data shown as median±interquartile range. P value was calculate by Wilcoxon signed-rank test. 
MSF treatment upregulated the expression of lymphatic markers in ECFCs cultured either on 
fibronectin and collagen (PROX-1: median fibronectin vs collagen: 38.42 vs 20.39 2
-ΔCT
(X10
6
), n=4, 
n=5, P=n.s.; LYVE-1: median fibronectin vs collagen: 27493 vs 34666 2
-ΔCT
 (X10
6
), n=4, n=5, P=n.s.; 
VEGFR-3: median fibronectin vs collagen: 6481 vs 4320 2
-ΔCT
 (X10
6
), n=4, n=5, P=n.s.) (Data not 
shown). As shown in Figure 33, the expression of lymphatic markers was significantly higher in 
ECFCs treated with MSF compared to untreated cultures. (PROX-1: median basal vs MSF 
stimulated: 13.26 vs 28.68 2
-ΔCT
 (X10
6
), n=9, n=9, P<0.01.; LYVE-1: median basal vs MSF stimulated: 
6067 vs 31478 2
-ΔCT
 (X10
6
), n=9, n=9, P<0.01.; VEGFR-3: median basal vs MSF stimulated: 3972 vs 
5280 2
-ΔCT
 T(X10
6
), n=9, n=9, P<0.01). Moreover, podoplanin was expressed only by a portion of 
ECFC colonies screened (fibronectin vs collagen: 25% vs 40% percentage of podoplanin
+
 colonies, 
n=4, n=5 p=n.s.) (Data not shown) and MSF stimulation did not induce de novo expression of 
podoplanin but induced the upregulation of podoplanin expression in ECFC colonies that already 
expressed podoplanin in basal conditions (podoplanin: median basal vs MSF stimulated: 4.61 vs 
22.44 2
-ΔCT
 (X10
6
), n=3, n=3, P=n.s.) (Figure 33B). 
4.2.2.3 Lymphatic markers detection by confocal microscopy in ECFCs stimulated 
with MSF 
To further confirm the ability of MSF to induce the lymphatic differentiation of ECFCs at the 
protein level, the expression of PROX-1, podoplanin and LYVE-1 was also evaluated - in ECFCs in 
basal conditions and stimulated with MSF -by confocal microscopy. 
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Figure 34: Analysis of lymphatic marker expression in ECFCs stimulated with MSF. (A) Left columns: 
representative photographs showing ECFCs cultured in basal conditions stained for PROX-1, podoplanin and 
LYVE-1; right columns: representative immunofluorescence photographs of ECFCs stimulated with MSF 
stained for PROX-1, podoplanin and LYVE-1. Cells were stained for PROX-1 (white), podoplanin (green) and 
LYVE-1 (red). Cell nuclei were stained with DAPI (blue). Photographs were obtained using an Olympus 
Fluoview FV1000 confocal microscope, 60X magnification. 
Immunofuorescence analysis confirmed the results observed at the transcriptional level by Q-PCR. 
In fact, as shown in Figure 34, immunofuorescence analysis showed that the expression of PROX-1, 
podoplanin and LYVE-1 was increased in ECFCs treated with MSF. 
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5. Discussion 
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EPCs were described for the first time in 1997 by Asahara [Asahara T et al, 1997]. Since that time, 
everal studies demonstrated that EPCs play a crucial role in endothelial homeostasis and in 
vasculogenic processes both in physiological and pathological conditions [Urbich C et al, 2004].  
In the past, several cell types – isolated from the peripheral blood with different methods and 
endowed with endothelial features - have been called EPCs. Among these cell populations, only 
endothelial colony-forming cells (ECFCs) are considered the true EPCs. [Fadini GP et al, 2012]. In 
fact, only ECFCs are endowed with all the typical features of EPCs. In particular, ECFCs express 
endothelial markers while lacking hematopoietic markers, are characterized by a high proliferative 
potential [Mead LE et al, 2008] and have the unique ability to display in vivo vasculogenic activity 
when implanted into immunodeficient mice [Foubert P et al, 2007; Yoder MC et al, 2007]. 
Kaposi͛s “aƌĐoŵa ;K“Ϳ is a lǇŵphaŶgiopƌolifeƌatiǀe disease ǁhiĐh pƌeseŶts tǇpiĐallǇ ǁith ĐutaŶeous 
lesions but can also involve visceral organs. KS is characterized by the hyperproliferation of the 
spindle cells, the typical cells of KS lesions. Spindle cells are cells of endothelial origin which are 
infected by HHV-8 – the herpersvirus which is the causative agent of KS [Chang Y et al, 1994] –but 
it is still unclear if they derive from mature endothelial cells infected by HHV-8 in peripheral tissues 
or whether they originate from previously infected circulating cells such as bone-marrow derived 
endothelial progenitor cells (EPCs).  
In previous studies, we observeed that the number of circulating EPCs, identified by flow 
cytometry as CD45
dim
/CD34
+
/KDR
+
, is increased in cKS patients [Taddeo A et al, 2008]. Moreover, 
we reported that ECFCs isolated from cKS patients are HHV-8 –infected and support viral 
productive replication and may therefore act as potential virus reservoirs [Della Bella S et al, 
2008].  
Therefore, in this study we characterized the ECFCs isolated from cKS patients in order to evaluate 
whether these cells have features similar to the spindle cells in KS lesions. ECFCs were isolated and 
cultured by using a protocol recently optimized in our lab [Colombo E et al, 2013]. Moreover, we 
enrolled in the study only patients with the Mediterranean variant of KS – also called classic KS 
(cKS). This clinical variant of KS represents a useful model of virus-associated tumor since it is 
characterized by the absence of confounding factors such as iatrogenic immunosuppression or co-
infection with other viruses (i.e. HIV). 
During ECFC isolation we evaluated the frequency of subjects who gave rise to at least one ECFC 
colony, the time of ECFC colonies appearance and the frequency of ECFC colonies isolated. 
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The frequency of subjects who gave rise to at least one ECFC colony was similar in cKS patients and 
healthy controls whereas the time of ECFC colonies appearance was reduced in cKS patients. Since 
ECFC colonies were identified by daily culture observation of PBMC cultures using an inverted 
microscope, the reduced time of appearance reported in cKS patients could be due to a higher cell 
proliferation rate that may support a faster growth of ECFC colonies that therefore reach earlier a 
size that allows their identification. 
The frequency of ECFC colonies isolated was strikingly higher in cKS patients than in healthy 
controls. In fact, the frequency of ECFC colonies isolated was about 5-fold higher in cKS patients. 
This observation may suggest the presence, in the group of cKS patients, of higher levels of 
circulating cells able to give rise to ECFCs in vitro. Moreover, the higher number of ECFC colonies 
observed in cKS patients is in accordance with our previous study in which we reported that 
circulating EPCs, identified as CD45
dim
/CD34
+
/KDR
+ 
 were increased in cKS patients [Taddeo A et al, 
2008]. Nevetheless, the cell population identified as CD45
dim
/CD34
+
/KDR
+
 contained not only the 
cells from which ECFCs originate in vitro but also hematopoietic cells that promote angiogenesis 
with paracrine mechanisms. In fact, Case et al demonstrated that only the rare CD45
-
 
subpopulation of CD34
+
/CD133
+
/KDR
+
 cells in the blood is not endowed with hematopoietic 
activity and should therefore represent the true EPCs [Case J. et al, 2007]. Although in this study 
we did not investigate the mechanisms underlying the increased frequency of ECFCs in the blood 
of KS patients, it could be argued that HHV-8 infection could foster cell proliferation and therefore 
could sustain the reduced time of appearance of ECFC colonies and the increased frequency of 
ECFCs isolated from cKS patients. 
Moreover, in order to evaluate whether ECFC isolated from cKS patients were characterized by the 
expression of different integrins and adhesion molecules, we assessed whether fibronectin and 
collagen – the substrate typically used for ECFC culture - may differently affect the efficiency of 
ECFC isolation from cKS patients. ECFCs were isolated both on fibronectin- and collagen-coated 
culture plates but, similarly to our previous observation in healthy donors (Colombo et al, 2013), 
ECFCs from cKS patients were isolated more efficiently when fibronectin was used.  
cKS patients can be classified according to the stage and the evolutive pattern of disease. In our 
study, cKS patients were classified according to the classification proposed by Brambilla et al 
[Brambilla L et al, 2003] and we therefore evaluated whether the stage or the evolutive pattern of 
disease could influence the efficiency of ECFC isolation. In particular, the frequency of ECFCs 
isolated was higher in cKS patients with rapidly evolving disease (stage B) than cKS patients with 
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slowly evolving disease (stage A). This observation may support the hypothesis that circulating 
HHV-8 – infected EPCs could be involved in the pathogenesis of KS. The higher number of cells 
giving origin to ECFCs in vitro that has been detected in cKS patients with stage B disease could 
explain, at least in part, the rapid evolution of disease observed in this group of patients that 
developed new KS lesions within three months from the last observation. These data are in 
contrast with our previous study in which we reported that circulating EPCs identified as 
CD45
dim
/CD34
+
/KDR
+ 
 are significantly reduced in cKS patients with rapidly evolving disease than 
patients with slowly evolving disease [Taddeo A et al, 2008]. This could be due to the fact that, as 
discussed above, CD45
dim
/CD34
+
/KDR
+
 cells and ECFCs are different populations of EPCs. 
Once isolated, ECFCs were expanded for further characterization. ECFCs isolated from both cKS 
patients and healthy controls possessed all the typical characteristics of ECFCs. In fact they were 
characterized by a cobblestone-like morphology, did not express the hematopoietic markers CD45 
and CD14 and expressed endothelial markers typically used for ECFC characterization. In particular 
ECFCs isolated from both cKS patients and healthy controls expressed CD31, CD54, CD144, CD146, 
and VEGRF2 and SDF-1 receptor CXCR4, internalized Dil-ac-LDL and bound UEA-1 [Ingram DA et al, 
2004]. 
The possible presence of HHV-8 infection was evaluated by immunofluorescent detection of the 
latent phase antigen LANA by confocal microscopy. All the screened ECFC colonies isolated from 
cKS patients were positive for LANA staining thus confirming that ECFCs isolated from cKS patients 
were HHV-8 infected. These data are in accordance with our previous study in which HHV-8 DNA 
was detected by PCR analysis in both ECFCs isolated from cKS patients and their culture 
supernatants [Della Bella S et al, 2008]. Moreover, immunofluorescence analysis of LANA 
expression allowed to observe that - within the analyzed colonies - only a proportion of cells 
expressed LANA and iwas therefore HHV-8-infected (5%-20% of total cells). The low percentage of 
HHV-8 infected cells detected is in accordance with our previous study in which we reported that 
ECFCs harbor moderate amounts of viral genome [Della Bella S et al, 2008] and it may be partly 
related to the fact that the patients enrolled in the study were affected by cKS. In fact, cKS is the 
less aggressive variant of KS and it is characterized by a poorly aggressive course and a relatively 
low viral load [Pellet C et al, 2006; Antman K et al, 2000]. 
ECFCs expanded ex vivo were characterized in order to evaluate whether ECFCs obtained from cKS 
patients may have an in vitro behaviour that may evoke the in vivo behaviour of KS spindle cells.  
96 
 
ECFCs isolated from both cKS patients and healthy controls maintained stable endothelial 
morphology and exhibited features of primary cells. In fact they could be expanded for a limited 
number of passages before they reached a senescent state as confirmed by senescence-associated 
β-galactosidase assay These results are in line with those of our previous study in which we 
reported that ECFC colonies isolated from healthy controls can be expanded for several passages 
by ultimately becoming senescent after long term culture [Colombo E et al, 2013]. Moreover, the 
observation that ECFCs isolated from cKS patients exhibited features of primary cells is in 
agreement with the fact that also HHV-8-infected spindle cells derived from KS lesions are not 
immortalized. In fact, as shown in in vivo studies, spindle cells injected in nude mice survived for a 
short period of time and formed only transient tumors [Mutlu AD et al, 2007]. 
Moreover, ECFCs isolated from cKS were endowed with a higher proliferative potential than ECFCs 
isolated form healthy controls. In fact, ECFCs isolated from cKS patients proliferated faster than 
ECFCs isolated from healthy controls and higher cell yields were obtained at the end of the 
cultures when ECFCs were isolated from cKS patients than healthy controls. 
The increased proliferative ability of ECFCs isolated from cKS patients could be explained by the 
presence of HHV-8 infection. In fact, previous studies have documented that HHV-8 infection 
promotes cell proliferation of infected cells. In particular, Flore et al demonstrated that HUVECs 
infected in vitro by HHV-8 were characterized by increased proliferation. In this model, only a 
proportion of the cultured cells were HHV-8-infected (about 5%) and the authors demonstrated 
that HHV-8 infection fostered also the proliferation of uninfected cells through paracrine 
mechanisms [Flore O et al, 1998]. In fact, many studies reported that several viral molecules 
expressed in the latent phase of HHV-8 infection (i.e. LANA, vCyc, vBcl-2 and vFLIP) act on 
pathways involved in cell proliferation and survival both directly (i.e. regulating cell cycle) and 
through paracrine mechanisms by inducing the production of soluble factors that can promote cell 
survival and proliferation also in adjacent uninfected cells [Ganem D et al, 2010]. In KS lesions, the 
microenvironment is enriched in cytokines and growth factors produced by HHV-8-infected 
spindle cells themselves and by the inflammatory cells recruited within the lesions. Such soluble 
factors play a crucial role in promoting spindle cell survival and growth. In particular, one of the 
mechanisms used by HHV-8 to promote cell proliferation consists in promoting IL-6 production by 
infected cells. In fact, HHV-8 in vitro infection induced an increase in IL-6 production in human 
microvascular endothelial cells (HMECs) [Speciale L et al, 2006]. In addition, An et al demonstrated 
that, during the latent phase of HHV-8 infection, LANA can up-regulate IL-6 expression by 
97 
 
interacting with AP1 RE (response elements) present in IL-6 promoters [An J et al, 2004]. In turn, 
IL-6 produced by infected cells promotes cell proliferation also in uninfected cells. Moreover, also 
vIL6 –a lytic phase HHV-8 viral molecule, homolog of human IL-6- was documented to induce IL-6 
production in several cell types [Mori Y et al, 2000]. These evidence support the hypothesis that IL-
6 pathway can play an important role in KS pathogenesis fostering cell proliferation and survival of 
spindle cells in KS lesions. 
To evaluate whether IL-6 may play a role in the increased proliferation observed in ECFCs cultures 
obtained from cKS patients, we measured the levels of IL-6 in ECFC culture supernatants. ECFCs 
isolated from cKS patients produced higher levels of IL-6 than ECFCs isolated from healthy 
controls, thus supporting the hypothesis that, in ECFCs isolated from cKS patients, HHV-8 infection 
could promote IL-6 production which in turn may foster cell proliferation. Our results are also in 
accordance with our previous study demonstrating that IL-6 can sustain ECFC proliferation 
[Colombo et al, 2013].  
In addition, we measured in ECFC supernatants the levels of other cytokines typically present in KS 
lesions. [Sirianni MC et al, 1998]. FGFb was detectable in supernatant of ECFs isolated from both 
healthy controls and cKS patients but no differences in FGFb concentration were observed 
between the two groups, whereas VEGF, IFNγ, TNFα and IL-3 were undetectable at any passage in 
ECFCs isolated from both healthy controls and cKS patients. Our results are in accordance with a 
previous study in which other authors reported that unstimulated ECFCs produce low amount of 
these cytokines [Hur J et al, 2004]. In addition, it is possible that the increased cytokine production 
and proliferative potential observed in ECFCs isolated from cKS patients could be further enhanced 
upon ECFC stimulation with proinflammatory cytokine or culturing ECFCs in hypoxic conditions 
since proinflamatory cytokines and hypoxia are typical features of KS lesions microenvironment.  
Our results further demonstrated that ECFCs isolated from cKS patients were endowed with higher 
vasculogenic ability, as shown by in vitro matrigel tubulogenesis assay. It is possible that the higher 
proliferative potential displayed by ECFCs isolated from cKS patients and sustained by increased IL-
6 production, may explain at least in part their enhanced ability to form capillary-like structures 
when seeded in Matrigel.  
In order to investigate the molecular pathways possibly involved in the different behavior of ECFCs 
isolated from cKS patients and healthy controls, we performed a gene-array analysis to compare 
the molecular signature of ECFCs isolated from the two groups. Preliminary analysis revealed that 
patients and healthy donors segregated by clustering, thus confirming that gene expression profile 
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differs between ECFC isolated from cKS patients and healthy donors. Moreover, 16 genes were 
upregulated in ECFC isolated from cKS patients compared to healthy controls. In particular, the 
deubiquitinase PSMD14 - whose expression was significantly upregulated in ECFCs isolated from 
cKS patients - was reported to be involved in regulation of cell proliferation. In fact, Byrne et al 
documented that knockdown of human PSMD14 induced cell cycle arrest and senescence in 
carcinoma cell lines [Byrne A et al, 2010]. Therefore, it is possible that the increased expression of 
PSMD14 observed in ECFC colonies isolated from cKS patients may have a role in supporting ECFC 
proliferation. More detailed analysis will be performed in order to investigate the possible role of 
the diffentially expressed genes in determining the characteristic behavior observed in ECFCs 
isolated from cKS patients. In addition, gene set enrichment analysis (GSEA) will be performed in 
order to evaluate whether genes specifically involved in angiogenesis, cell proliferation, IL-6 
pathway and VEGFR-3 pathway are differentially expressed by ECFCs isolated from cKS patients 
Spindle cells are characterized by the expression of both BEC and LEC markers. In particular, 
spindle cells in KS lesions express the lymphatic markers VEGFR-3, LYVE-1 and podoplanin [Dupin 
N et al, 2006]. To further evaluate whether ECFCs obtained from cKS patients may have features 
that resembled KS spindle cells, in preliminary experiments we evaluated whether ECFCs isolated 
from cKS patients expressed the lymphatic markers LYVE-1 and podoplanin. 
Surprisingly, in those preliminary experiments we observed that LYVE-1 and podoplanin were 
expressed not only by ECFCs isolated from cKS patients but also by ECFCs isolated from healthy 
controls. These results were unexpected, as ECFCs have been always considered as the true EPCs 
involved in vasculogenesis but no one had investigated their potential involvement also in 
lymphangiogenesis as putative LEPCs. Therefore, we investigated the lymphatic differentiative 
potential of ECFCs evaluating the expression of four typical lymphatic markers – namely PROX-1, 
podoplanin, LYVE-1 and VEGFR-3 - both at the transcriptional and protein levels. We observed, 
indeed, that ECFCs isolated from the peripheral blood of adult healthy controls expressed the 
lymphatic markers PROX-1, podoplanin, LYVE-1 and VEGFR-3 whose expression was confirmed by 
Q-PCR and confocal microscopy.  
In 2 ECFC colonies isolated from cKS patients we further confirmed our preliminary results by 
reporting that also ECFCs isolated from cKS patients expressed the lymphatic markers PROX-1, 
podoplanin, LYVE-1 and VEGFR-3. Our results are in accordance with previous studies that showed 
that KS spindle cells and in vitro HHV-8 infected cells BECs are characterized by the expression of 
lymphatic markes such as podoplanin, LYVE-1 and VEGFR-3 [Dupin N et al, 2006; Hong YK et al, 
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2004]. Further experiments will be performed in order to evaluate whether the expression levels 
of lymphatic markers in ECFCs are increased in cKS patients. 
VEGFR-3 was expressed by the totality of the cells in all the screened colonies isolated from 
healthy controls. Our results were in line with a previous study in which Huang et al documented 
the expression of VEGFR-3 in ECFCs isolated from cord blood [Huang L et al, 2011]. The high levels 
of VEGFR-3 expression on ECFCs may depend on the fact that ECFCs are endothelial progenitors. In 
fact, in early stages of development, VEGFR-3 is expressed on both BECs and LECs and only in the 
late stage of development and in adulthood its expression is downregulated in BEC and becomes 
restricted to LECs [Dumont D.J. et al, 1998]. 
Moreover, PROX-1, podoplanin and LYVE-1 were expressed with variable intensity only by a 
proportion of cells in the screened ECFC colonies. By multicolor immunofluorescence analysis we 
observed that PROX-1, podoplanin and LYVE-1 were expressed by ECFCs in different combinations. 
In fact, the three markers were not always coexpressed and cells which expressed the three 
markers in different combinations could be identified within the same ECFC colony. In particular 
we identified cells that were PROX-1
-
 /podoplanin
+
 and this is in contrast with the most accepted 
model for lymphatic vascular system development, according to which it derives from committed 
PROX-1
+
 cells and podoplanin expression is acquired only in later stages [Oliver G et al, 2004]. The 
presence of PROX-1
-
/podoplanin
+
 cells may suggest that the lymphatic differentiation process in 
adults may differ from the model proposed for the development of the lymphatic vascular system 
during embryogenesis. In addition, also PROX-1
-
/LYVE
+
 cells have been identified in our ECFC 
cultures. This is in accordance with the most accepted model for lymphatic vascular system 
development in embryogenesis since several studies reported that LYVE-1 is expressed in the early 
stages of lymphatic differentiation in endothelial cells of the embryonic cardinal veins prior to the 
induction of Prox-1 [Tammela T et al, 2010].  
Starting from 2003, several studies have proposed that lymphvasculogenesis may also occur in 
adulthood thus contributing to lymphatic neovasculaziation processes. [Kerjaschki D. et al, 2006; 
Maruyama K. et al, 2005] In addition, it was hypothesized that bone-marrow derived precursors 
could participate in lymphatic vessel formation by acting as lymphatic endothelial progenitor cells 
(LEPCs). Nevertheless, the identity and the characteristics of LEPCs have not yet been clearly 
defined and several cell populations have been described as putative LEPCs. In 2010, Lee at al 
identified a population of podoplanin
+
/CD11b
+
 macrophages derived from the bone marrow that 
contribute to lymphatic neovascularization both by transdifferentiating in lymphatic endothelial 
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cells and by producing VEGF-C and other lymphangiogenic factors that promote proliferation of 
local pre-existent LECs. [Lee JY et al, 2010] In other studies, LEPCs have been identified in the 
peripheral blood as cells that express CD34 in combination with the lymphatic markers VEGFR-3. 
In particular, in 2003 Salven et al first described in human fetal liver the presence of a 
CD34
+
/VEGFR-3
+
/CD133
+
 sub-population that in vitro was characterized by a high proliferative 
potential and the expression of both lymphatic and blood vascular markers [Salven P. et al, 2003]. 
Tan et al reported that CD34
+
/VEGFR-3
+
 cells isolated by fluorescence-activated cell sorting from 
human cord blood mononuclear cells, acquired - after two weeks of culture in presence of VEGF-C 
- a lymphatic phenotype [Tan YZ et al, 2014]. The identification of lymphatic markers on ECFCs 
supported the hypothesis that the cell population that in vitro gives origin to ECFCs could 
differentiate towards both BECs and LECs thus acting not only as EPCs but also as LEPCs. Our 
results are in accordance with a recent study - that has been published online during the late 
writing phases of this thesis - in which the Authors reported that ECFCs express also markers 
specific of lymphatic endothelium: PROX-1, podoplanin, LYVE-1 and VEGFR-3 [DiMaio TA et al, 
2015]. 
In adulthood, cancer represents a major cause of lymphangiogenesis. [Alitalo A et al, 2012]. 
Therefore we evaluated whether the lymphatic differentiative potential of ECFCs could be 
fostered by component of tumor microenvironment which are known to promote tumor 
associated lymphangiogenesis and metastasis. Since ECFCs were cultured in culture plates coated 
with ECM protein – typically fibronectin and collagen – we first evaluated whether the substrate 
used for ECFCs culture could affect their lymphatic differentiative potential. In fact, as reported in 
several clinical studies, the presence of fibronectin in the tumor stroma correlates with 
lymphovascular invasion, lymph node metastasis in breast cancer and other human tumors [Bae 
YK et al, 2013; Ou J et al, 2013]. We observed that ECFCs cultured on both fibronectin and collagen 
expressed PROX-1, podoplanin, LYVE-1 and VEGFR-3. Moreover, the analyzed lymphatic markers 
were similarly expressed in ECFCs cultured on the two substrates. We hypothesized that the 
reason why we did not observed difference between ECFCs cultured on fibronectin and on 
collagen may depend on the fact that the fibronectin used for plate coating was a soluble form 
derived from human plasma - that therefore differs from fibronectin present in tumor ECM since 
plasma fibronectin and cellular fibronectin possess distinct structures and rates of assembly into 
three-dimensional matrices [To WS et al, 2011]. 
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Several clinical studies reported that also some alternatively spliced oncofetal isoforms of 
fibronectin (i.e. EDA-fibronectin and EDB-fibronectin) promote lymphangiogensis. In particular, 
EDA-fibronectin expression correlates with distant metastasis in colorectal carcinoma [Xiang L et 
al, 2012]. Therefore, we evaluated whether the stimulation with migration stimulator factor (MSF) 
– an oncofetal truncated isoform of fibronectin - could foster ECFC differentiation towards a 
lymphatic phenotype. MSF has been cloned in 2003 by Schor and colleagues [Schor SL et al, 2003]. 
It is expressed during wound healing and it is strongly overexpressed in a wide range of common 
human cancers [Schor SL et al, 2003]. In particular, MSF was known to be produced by fetal skin 
keratinocytes, neoplastic cells, tumor-associated vascular endothelial cells and tumor associated 
macrophages (TAM) [Solinas G et al, 2010]. MSF was first identified by its motogenic activity. In 
fact, it is characterized by a strong chemotactic activity for monocytes and tumor cells [Solinas G 
et al, 2010] Moreover, it was reported to be a potent stimulator of angiogenesis [Schor SL et al, 
2003] but its potential role in inducing lymphatic differentiation has never been investigated. 
Our study revealed that MSF induced the expression of lymphatic markers in ECFCs. In particular, 
MSF stimulation induced an upregulation of PROX-1, podoplanin, LYVE-1 and VEGFR-3 in ECFCs 
cultured on both fibronectin and collagen. The upregulation was confimed by Q-PCR and by 
confocal microscopy. 
Our results seem to suggest for the first time that also MSF, like other oncofetal isoforms of 
fibronectin (EDA-fibronectin and EDB-fibronectin), may play a role in promoting lymphatic 
differentiation and lymphangiogenesis. 
In conclusion, in this study we characterized ECFCs isolated from cKS patients and in particular, we 
observed that ECFCs isolated from cKS patients were endowed with features typical of KS spindle 
cells. Our results support the hypothesis that ECFCs could be involved in the phathogenesis of KS 
as precursors of spindle cells. Our hypothesis is also supported by the observation that ECFCs 
isolated from cKS patients expressed typical lymphatic markers such as PROX-1, podoplanin, LVYE-
1 and VEGFR-3. In fact, spindle cells in KS lesions are characterized by a typical intermediate 
phenotype between BECs and LECs [Dupin N et al, 2006]. 
Moreover, in our study we described that also ECFCs isolated from healthy controls expressed the 
typical lymphatic markers PROX-1, podoplanin, LYVE-1 and VEGFR-3. In addition we reported that 
the expression of lymphatic markers in ECFCs can be promoted by stimulation with MSF, an 
oncofetal truncated isoform of fibronectin. Our observation seems to suggest that ECFCs can 
differentiate towards both BECs and LECs thus supporting the hypothesis that ECFCs can act not 
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only as EPCs but also as LEPCs. The identification of lymphatic markers on ECFCs has an important 
biological relevance since ECFCs are considered the true EPCs, are used as non-invasive tool for 
the study of the endothelial compartment in both physiological and pathological conditions and 
they are considered a promising candidate cells for endothelial regenerative medicine. Therefore, 
a more detailed study of the lymphatic differentiative potential of ECFCs, with particular attention 
to the identification of the stimuli that can induce the differentiation of ECFCs to LECs and the 
evaluation of the possible involvement of ECFCs in lymphangiogenic processes, will be required.  
In addition, since MSF ability to induce lymphatic differentiation has never been described also the 
role of MSF in promoting lymphatic differentiation and lymphangiogenesis deserve to be 
investigated in more depth. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
103 
 
 
 
 
 
 
 
 
 
6. References 
 
 
 
 
 
 
 
104 
 
- Achen MG, McColl BK, Stacker SA. "Focus on lymphangiogenesis in tumor metastasis". Cancer 
Cell, 7, 2005, pp. 121–7. 
- Ackerman AB. ͞Subtle clues to diagnosis by conventional microscopy. The patch stage of Kaposi's 
sarcoma͟. Am J Dermatopathol, 1(2), 1979, pp. 165-72. 
- Adams RH, Alitalo K. ͞Molecular regulation of angiogenesis and lymphangiogenesis͟. Nat Rev Mol 
Cell Biol., 8(6), 2007, pp. 464-78. 
- Aicher A, Heeschen C, Mildner-Rihm C, Urbich C, Ihling C, Technau-Ihling K, Zeiher AM, Dimmeler 
S. ͞Essential role of endothelial nitric oxide synthase for mobilization of stem and progenitor cells͟. 
Nat Med, 9(11), 2003, pp. 1370–76. 
- Alam A, Blanc I, Gueguen-Dorbes G, Duclos O, Bonnin J, Barron P, Laplace MC, Morin G, 
Gaujarengues F, Dol F, Hérault JP, Schaeffer P, Savi P, Bono F. ͞SAR131675, a potent and selective 
VEGFR-3-TK inhibitor with antilymphangiogenic, antitumoral, and antimetastatic activities͟. Mol 
Cancer Ther, 11(8), 2012. Pp. 1637-49. 
- Albini A, Fontanini G, Masiello L, Tacchetti C, Bigini D, Luzzi P, Noonan DM, Stetler-Stevenson 
WG. ͞Angiogenic potential in vivo by Kaposi's sarcoma cell-free supernatants and HIV-1 tat 
product: inhibition of KS-like lesions by tissue inhibitor of metalloproteinase-2͟. AIDS, 8(9), 1994, 
pp. 1237-44. 
- Alitalo A, Detmar M. "Interaction of tumor cells and lymphatic vessels in cancer progression". 
Oncogene, 31(42), 2012, pp. 4499-508. 
- Alitalo AK, Proulx ST, Karaman S, Aebischer D, Martino S, Jost M, Schneider N, Bry M, Detmar 
M."VEGF-C and VEGF-D blockade inhibits inflammatory skin carcinogenesis". Cancer Res, 73(14), 
2013, pp. 4212-21. 
- Alitalo K, Tammela T, Petrova TV. ͞Lymphangiogenesis in development and human disease͟. 
Nature, 438(7070), 2005, pp. 946.53. 
- Alitalo K. ͞The lymphatic vasculare in disease͟. Nat Med, 17(11), 2011, pp. 1371-80. 
- Alitalo K, Detmar M. ͞Interaction of tumor cells and lymphatic vessels in cancer progression͟. 
Oncogene, 31(42), 2012, pp. 4499-508. 
- Aluigi MG, Albini A, Carlone S, Repetto L, De Marchi R, Icardi A, Moro M, Noonan D, Benelli R. 
͞KSHV sequences in biopsies and cultured spindle cells of epidemic, iatrogenic and Mediterranean 
foƌŵs of Kaposi͛s saƌĐoŵa͟. Res Virol, 147(5), 1996, pp. 267-75. 
- Andreoni M, Sarmati L, Nicastri E, El Sawaf G, El Zalabani M, Uccella I, Bugarini R, Parisi SG, Rezza 
G. ͞Primary human herpesvirus 8 infection in immunocompetent children͟. JAMA, 287(10), 2002, 
pp. 1295-300. 
105 
 
- Anghelina M, Krishnan P, Moldovan L, Moldovan NI. ͞Monocytes/macrophages cooperate with 
progenitor cells during neovascularization and tissue repair: conversion of cell columns into 
fibrovascular bundles͟. Am J Pathol, 168, 2006, pp. 529–41. 
- An J, Sun Y, Rettig MB. ͞Transcriptional coactivation of c-Jun by the KSHV-encoded LANA͟. Blood, 
103(1), 2004, pp. 222-8. 
- Antman K, Chang Y. ͞Kaposi's Sarcoma͟. N Engl J Med, 342, 2000, pp. 1027-38. 
- Armyra K, Kouris A, Xanthinaki A, Stratigos A, Potouridou I. ͞Faŵilial Kaposi͛s “aƌĐoŵa: A ‘epoƌt 
of Five Cases from Greece͟. Case Rep Dermatol Med, 2014, 671631. 
- Asahara T, Murohara T, Sullivan A, Silver M, van der Zee R, Li T, Witzenbichler B, Schatteman G, 
Isner JM. ͞Isolation of putative progenitor endothelial cells for angiogenesis͟. Science, 275(5302), 
1997, pp. 964-7. 
- Asahara T, Masuda H, Takahashi T Kalka C, Pastore C, Silver M, Kearne M, Magner M, Isner JM. 
͞Bone marrow origin of endothelial progenitor cells responsible for postnatal vasculogenesis in 
physiological and pathological neovascularization͟. Circ Res, 85, 1999, pp. 221–28. 
- Asahara T, Kawamoto A, Masuda H. ͞Concise review: Circulating endothelial progenitor cells for 
vascular medicine͟. Stem Cells, 29, 2011, pp. 1650–55. 
- Ascoli V, Minelli G, Kanieff M, Crialesi R, Frova L, Conti S. ͞Cause-specific mortality in classic 
Kaposi's sarcoma: a population-based study in Italy (1995–2002)͟. Br J Cancer, 101(7), 2009,pp. 
1085–90. 
- Bae YK, Kim A, Kim MK, Choi JE, Kang SH, Lee SJ. ͞Fibronectin expression in carcinoma cells 
correlates with tumor aggressiveness and poor clinical outcome in patients with invasive breast 
cancer͟. Hum Pathol, 44(10), 2013, pp. 2028-37. 
- Ballestas ME, Chatis PA,Kaye KM.͞Efficient persistence of extrachromosomal KSHV DNA mediated 
by latency-associated nuclear antigen͟. Science, 284, 1999, pp. 641-44. 
- Banerji S, Ni J, Wang SX, Clasper S, Su J, Tammi R, Jones M, Jackson DG. ͞LYVE-1, a new 
homologue ofthe CD44 glycoprotein, is a lymph-specific receptor for hyaluronan͟. J Cell Biol, 144, 
1999, pp. 789–801. 
- Barillari G, Buonaguro L, Fiorelli V, Hoffman J, Michaels F, Gallo RC, Ensoli B. ͞Effects of cytokines 
from activated immune cells on vascular cell growth and HIV-1 gene expression. Implications for 
AIDS-Kaposi's sarcoma pathogenesis͟. J Immunol, 149(11), 1992, pp. 3727-34. 
- Barozzi P, Luppi M, Facchetti F, Mecucci C, Alù M, Sarid R, Rasini V, Ravazzini L, Rossi E, Festa S, 
Crescenzi B, Wolf DG, Schulz TF, Torelli G. ͞Post-transplant Kaposi sarcoma originates from the 
seeding of donor-derived progenitors͟. Nat Med, 9(5), 2003, pp. 554-61. 
106 
 
- Basile DP, Yoder MC. ͞Circulating and tissue resident endothelial progenitor cells͟. J Cell Physiol, 
229(1), 2014, pp. 10-6. 
- Bertolini F, Shaked Y, Mancuso P, Kerbel RS. ͞The multifaceted circulating endothelial cell in 
cancer: towards marker and target identification͟. Nat Rev Cancer, 6(11), 2006, pp. 835-45. 
- Björndahl MA, Cao R, Burton JB, Brakenhielm E, Religa P, Galter D, Wu L, Cao Y. ͞Vascular 
endothelial growth factor-A promotes peritumoral lymphangiogenesis and lymphatic metastasis͟. 
Cancer Res, 65(20), 2005, pp. 9261-8. 
- Blasig C, Zietz C, Haar B, Neipel F, Esser S, Brockmeyer NH, Tschachler E, Colombini S, Ensoli B, 
Stürzl M. ͞MonocǇtes iŶ Kaposi͛s saƌĐoŵa lesioŶs aƌe pƌoduĐtiǀelǇ iŶfeĐted ďǇ huŵaŶ heƌpesǀiƌus 
8͟. J Virol, 71(10), 1997, pp. 7963-68. 
- Brambilla L, Boneschi V, Taglioni M, Ferrucci S. ͞Staging of classic Kaposi's sarcoma: a useful tool 
for therapeutic choices͟. Eur J Dermatol, 13(1), 2003, pp. 83-86. 
- Brambilla L, Bellinvia M, Tourlaki A, Scoppio B, Gaiani F, Boneschi V. ͞Intralesional vincristine as 
first-line therapy for nodular lesions in classic Kaposi sarcoma: a prospective study in 151 patients͟. 
Br J Dermatol, 162(4), 2010, pp. 854-59. 
- Braun M. ͞Classics in Oncology. Idiopathic multiple pigmented sarcoma of the skin by Kaposi͟. CA 
Cancer J Clin, 32(6), 1982, pp. 340-7. 
- Breiteneder-Geleff S, Matsui K, Soleiman A, Meraner P, Poczewski H, Kalt R, Schaffner G, 
Kerjaschki D. ͞Podoplanin, novel 43-kd membrane protein of glomerular epithelial cells, is down-
regulated in puromycin nephrosis͟. Am J Pathol, 151(4), 1997, pp. 141-52. 
- Breiteneder-Geleff S, Soleiman A, Kowalski H, Horvat R, Amann G, Kriehuber E, Diem K, Weninger 
W, Tschachler E, Alitalo K, Kerjaschki D. ͞Angiosarcomas express mixed endothelial phenotypes of 
blood and lymphatic capillaries: podoplanin as a specific marker for lymphatic endothelium͟. Am J 
Pathol, 154(2), 1999, pp. 385-94. 
- Browning PJ, Sechler JM, Kaplan M, Washington RH, Gendelman R, Yarchoan R, Ensoli B, Gallo 
RC. ͞Identification and culture of Kaposi's sarcoma-like spindle cells from the peripheral blood of 
human immunodeficiency virus-1-infected individuals and normal controls͟. Blood, 84(8), 1994, pp. 
2711-20. 
- Burgdorf WH, Mukai K, Rosai J. ͞Immunohistochemical identification of factor VIII-related antigen 
in endothelial cells of cutaneous lesions of alleged vascular nature͟. Am J Clin Pathol, 75(2), 1981, 
pp. 167-71. 
- Burton JB, Priceman SJ, Sung JL, Brakenhielm E, An DS, Pytowski B, Alitalo K, Wu L. ͞Suppression 
of prostate cancer nodal and systemic metastasis by blockade of the lymphangiogenic axis͟. 
Cancer Res, 68(19), 2008 , pp. 7828-37. 
107 
 
- Byrne A, McLaren RP, Mason P, Chai L, Dufault MR, Huang Y, Liang B, Gans JD, Zhang M, Carter K, 
Gladysheva TB, Teicher BA, Biemann HP, Booker M,Goldberg MA, Klinger KW, Lillie J, Madden SL, 
Jiang Y. ͞Knockdown of human deubiquitinase PSMD14 induces cell cycle arrest and senescence͟. 
Exp Cell Res, 316(2), 2010, pp. 258-71. 
- Calcaterra F, Taddeo A, Colombo E, Cappelletti M, Martinelli A, Calabrese S, Mavilio D, Cetin I, 
Della Bella S. ͞Reduction of maternal circulating endothelial progenitor cells in human pregnancies 
with intrauterine growth restriction͟. Placenta, 35(7), 2014, pp. 431-6. 
- Campbell DM, Rappocciolo G, Jenkins FJ, Rinaldo CR. ͞Dendritic cells: key players in human 
herpesvirus 8 infection and pathogenesis͟. Front Microbiol, 5, 2014, pp. 452. 
- Cappelletti M, Taddeo A, Colombo E, Brambilla L, Bellinvia M, Pregliasco F, Villa ML, Della Bella S. 
͞Immunogenicity and safety of seasonal influenza vaccination in patients with classic Kaposi's 
sarcoma͟. J Invest Dermatol, 132(10), 2012, pp. 2414-21. 
- Carmeliet P. ͞Angiogenesis in health and disease͟. Nat Med, 9(6), 2003, pp. 653-60. 
- Carroll PA, Brazeau E, Lagunoff M. ͞Kaposi's sarcoma-associated herpesvirus infection of blood 
endothelial cells induces lymphatic differentiation͟. Virology, 328(1), 2004, pp. 7-18. 
- Case J, Mead LE, Bessler WK, Prater D, White HA, Saadatzadeh MR, Bhavsar JR, Yoder MC, 
Haneline LS, Ingram DA. ͞Human CD34+AC133+VEGFR-2+ cells are not endothelial progenitor cells 
but distinct, primitive hematopoietic progenitors͟. Exp Hematol, 35(7), 2007, pp. 1109-18. 
- Chadburn A, Hyjek EM, Tam W, Liu Y, Rengifo T, Cesarman E, Knowles DM. ͞Immunophenotypic 
analysis of the Kaposi sarcoma herpesvirus (KSHV; HHV-8)- infected B cells in HIV+ multicentric 
Castleman disease (MCD)͟. Histopathology, 53(5), 2008, pp. 513-24. 
- Chang Y, Cesarman E, Pessin MS, Lee F, Culpepper J, Knowles DM, Moore PS. ͞Identification of 
herpesvirus-like DNA sequences in AIDS-associated Kaposi's sarcoma͟. Science, 266(5192), 1994, 
pp. 1865-69. 
- Chang Y, Moore PS, Talbot SJ, Boshoff CH, Zarkowska T, Godden-Kent, Paterson H, Weiss RA, 
Mittnacht S. ͞Cyclin encoded by KS herpesvirus͟. Nature, 382, 1996, pp. 410-11. 
- Chavakis E, Aicher A, Heeschen C, Sasaki K, Kaiser R, El Makhfi N, Urbich C, Peters T, Scharffetter-
Kochanek K, Zeiher AM, Chavakis T, Dimmeler S. ͞Role of beta2-integrins for homing and 
neovascularization capacity of endothelial progenitor cells͟. J Exp Med, 201(1), 2005, pp. 63-72. 
- Chen J, Alexander JS, Orr AW. ͞Integrins and their extracellular matrix ligands in 
lymphangiogenesis and lymph node metastasis͟. Int J Cell Biol,  2012, 2012, 853703. 
- Cheung L, Rockson SG. ͞The lymphatic biology of Kaposi's sarcoma͟. Lymphat Res Biol, 3(1), 
2005, pp. 25-35. 
108 
 
- Colombo E, Calcaterra F, Cappelletti M, Mavilio D, Della Bella S. ͞Comparison of fibronectin and 
collagen in supporting the isolation and expansion of endothelial progenitor cells from human 
adult peripheral blood͟. PLoS One, 8(6), 2013, e66734.  
- Coras B, Hafner C, Reichle A, Hohenleutner U, Szeimies RM, Landthaler M, Vogt T. 
͞Antiangiogenic therapy with pioglitazone, rofecoxib, and trofosfamide in a patient with endemic 
kaposi sarcoma͟. Arch Dermatol, 140(12), 2004, pp. 1504-07.  
- Corbeil J, Evans LA, Vasak E, Cooper DA, Penny R. ͞Culture and properties of cells derived from 
Kaposi sarcoma͟. J Immunol, 146(9), 1991, pp. 2972-76. 
- Cordiali-Fei P, Trento E, Giovanetti M, Lo Presti A, Latini A, Giuliani M, D'Agosto G, Bordignon V, 
Cella E, Farchi F, Ferraro C, Lesnoni La Parola I, Cota C, Sperduti I, Vento A, Cristaudo A, Ciccozzi M, 
Ensoli F. ͞Analysis of the ORFK1 hypervariable regions reveal distinct HHV-8 clustering in Kaposi's 
sarcoma and non-Kaposi's cases͟. J Exp Clin Cancer Res, 34, 2015, pp. 1. 
- Cornali E, Zietz C, Benelli R, Weninger W, Masiello L, Breier G, Tschachler E, Albini A, Stürzl M. 
͞Vascular endothelial growth factor regulates angiogenesis and vascular permeability in Kaposi's 
sarcoma͟. Am J Pathol, 149(6), 1996, pp. 1851-69. 
- Coscoy L, Ganem D. ͞Kaposi͛s saƌĐoŵa-associated herpesvirus encodes two proteins that block 
cell surface display of MHC class I chains by enhancing their endocytosis͟. Proc Natl Acad Sci USA, 
97, 2000, pp. 8051-56. 
- Coscoy L, Ganem D. ͞A viral protein that selectively downregulates ICAM-1 and B7-2 and 
modulates T cell costimulation͟. J Clin Invest, 107, 2001, pp. 1599-606. 
- Coscoy L.͞IŵŵuŶe eǀasioŶ ďǇ Kaposi͛s saƌĐoŵa-associated herpesvirus͟. Nat Rev Immunol, 7, 
2007, pp. 391-401. 
- Coultas L, Chawengsaksophak K, Rossant J. ͞Endothelial cells and VEGF in vascular development͟. 
Nature, 438(7070), 2005, pp. 937-45. 
- Critser PJ, Mervin C, Yoder MC. ͞Endothelial Colony Forming Cell role in neoangiogenesis and 
tissue repair͟. Curr Opin Organ Transplant, 15(1), 2010, pp. 68–72. 
- Crosby JR, Kaminski WE, Schatteman G, Martin PJ, Raines EW, Seifert RA, Bowen-Pope DF. 
͞Endothelial cells of hematopoietic origin make a significant contribution to adult blood vessel 
formation͟. Circ Res, 87(9), 2000, pp. 728-30. 
- Davis DA, Rinderknecht AS, Zoeteweij JP, Aoki Y, Read-Connole EL, Tosato G, Blauvelt A, Yarchoan 
R. ͞Hypoxia induces lytic replication of Kaposi sarcoma-associated herpesvirus͟. Blood, 97(10), 
2001, pp. 3244-50. 
- Della Bella S, Nicola S, Brambilla L, Riva A, Ferrucci S, Presicce P, Boneschi V, Berti E, Villa ML. 
͞Quantitative and functional defects of dendritic cells in classic Kaposi's sarcoma͟. Clin Immunol, 
119(3), 2006, pp. 317-29. 
109 
 
- Della Bella S, Taddeo A, Calabrò ML, Brambilla L, Bellinvia M, Bergamo E, Clerici M, Villa ML. 
͞Peripheral blood endothelial progenitors as potential reservoirs of Kaposi's sarcoma-associated 
herpesvirus͟. PLoS One, 3(1), 2008, e1520. 
- Della Bella S, Taddeo A, Colombo E, Brambilla L, Bellinvia M, Pregliasco F, Cappelletti M, Calabrò 
ML, Villa ML. ͞Human herpesvirus-8 infection leads to expansion of the preimmune/natural 
effector B cell compartment͟. PLoS One, 5(11), 2010, e15029. 
- De Palma M, Venneri MA, Naldini L. ͞In vivo targeting of tumor endothelial cells by systemic 
delivery of lentiviral vectors͟. Hum Gene Ther, 14(12), 2003, pp. 1193-206. 
- DiMaio TA, Wentz BL, Lagunoff M. ͞Isolation and characterization of circulating lymphatic 
endothelial colony forming cells͟. Exp Cell Res, 2015, pii: S0014-4827(15)30159-2. 
- Dimmeler S, Aicher A, Vasa M, Mildner-Rihm C, Adler K,Tiemann M, Rütten H, Fichtlscherer S, 
Martin H, Zeiher AM. ͞HMG-CoA reductase inhibitors (statins) increase endothelial progenitor cells 
via the PI 3-kinase/Akt pathway͟. J Clin Invest, 108(3), 2001, pp. 391-7. 
- Dourmishev LA, Dourmishev AL, Palmeri D, Schwartz RA and Lukac DM. ͞Molecular Genetics of 
Kaposi͛s saƌĐoŵa-associated herpesvirus (human herpesvirus-8) epidemiology and pathogenesis͟. 
Microbiol Mol Biol Rev, 67(2), 2003, pp. 175-212.  
- Dumont DJ, Jussila L, Taipale J, Lymboussaki A, Mustonen T, Pajusola K, Breitman M, Alitalo K. 
͞Cardiovascular failure in mouse embryos deficient in VEGF receptor-3͟. Science, 282(5390), 1998, 
pp. 946-9. 
- Dupin N, Fisher C, Kellam P, Ariad S, Tulliez M, Franck N, van Marck E, Salmon D, Gorin I, Escande 
JP, Weiss RA, Alitalo K, Boshoff C. ͞Distribution of human herpesvirus-8 latently infected cells in 
Kaposi's sarcoma, multicentricCastleman's disease, and primary effusion lymphoma͟. Proc Natl 
Acad Sci USA, 96(8), 1999, pp. 4546-51. 
- Dupin N, Grange PA. ͞Looking for the target cell of Kaposi's sarcoma-associated herpesvirus͟. J 
Invest Dermatol, 126(3), 2006, pp. 545-7. 
- Dupon M, Masquelier B, Cazorla C, Chêne G, Dumon B, Ragnaud JM, de Barbeyrac B, Bébéar C, 
Lacut JY, Fleury HJ. ͞Acquired immunodeficiency syndrome-associated Kaposi's sarcoma and 
human herpesvirus 8 DNA detection in serial peripheral blood mononuclear cell samples͟. Res 
Virol, 148(6), 1997, pp. 417-25. 
- Duprez R, Lacoste V, Brière J, Couppié P, Frances C, Sainte-Marie D, Kassa-Kelembho E, Lando MJ, 
Essame Oyono JL, Nkegoum B, Hbid O, Mahé A, Lebbé C, Tortevoye P, Huerre M, Gessain A. 
͞Evidence for a multiclonal origin of multicentric advanced lesions of Kaposi sarcoma͟. J Natl 
Cancer Inst, 99(14), 2007, pp. 1086-94. 
- Dzierzak E, Medvinsky A, de Bruijn M. ͞Qualitative and quantitative aspects of haematopoietic 
cell development in the mammalian embryo͟. Immunol Today, 19(5), 1998, pp. 228-36. 
110 
 
- Edelman DC. ͞Human herpesvirus 8-a novel human pathogen͟. Virol J, 2, 2005, pp. 2-78. 
- Ensoli B, Barillari G, Gallo RC. ͞Cytokines and growth factors in the pathogenesis of AIDS-
associated Kaposi's sarcoma͟. Immunol Rev, 127, 1992, pp. 147-55. 
- Ensoli B, Gendelman R, Markham P, Fiorelli V, Colombini S, Raffeld M, Cafaro A, Chang HK, Brady 
JN, Gallo RC. ͞Synergy between basic fibroblast growth factor and HIV-1 Tat protein in induction of 
Kaposi's sarcoma͟. Nature, 371(6499), 1994, pp. 674-80. 
- Ensoli B, Sirianni MC. ͞Kaposi's sarcoma pathogenesis: a link between immunology and tumor 
biology͟. Crit Rev Oncog, 9(2), 1998, pp. 107-24. 
- Ensoli B, Sgadari C, Barillari G, Sirianni MC, Stürzl M, Monini P. ͞Biology of Kaposi's sarcoma͟. Eur 
J Cancer, 37(10), 2001, pp. 1251-69 
- Fadini GP, Sartore S, Albiero M, Baesso I, Murphy E, Menegolo M, Grego F, Vigili de Kreutzenberg 
S, Tiengo A, Agostini C, Avogaro A. ͞Number and function of endothelial progenitor cells as a 
marker of severity for diabetic vasculopathy͟. Arterioscler Thromb Vasc Biol, 26(9), 2006 a, pp. 
2140-6.  
- Fadini GP, Sartore S, Baesso I, Lenzi M, Agostini C, Tiengo A, Avogaro A. ͞Endothelial progenitor 
cells and the diabetic paradox͟. Diabetes Care, 29, 2006 b, pp.714-16.  
- Fadini GP, Losordo D, Dimmeler S. ͞Critical reevaluation of endothelial progenitor cell phenotypes 
for therapeutic and diagnostic use͟. Circ Res, 110(4), 2012, pp. 624-37. 
- Fang D, Xiao-qin H. ͞Effect of endothelial progenitor cells in neovascularization and their 
application in tumor therapy͟. Chin Med J, 123(17), 2010, pp. 2454-60. 
- Fang S, Wei J, Pentinmikko N, Leinonen H, Salven P. ͞Generation of functional blood vessels from 
a single c-kit+ adult vascular endothelial stem cell͟. PLoS Biol, 10(10), 2012, e1001407. 
- Fatahzadeh M. ͞Kaposi sarcoma: Review and medical management update͟. Oral Surg Oral Med 
Oral Pathol Oral Radiol, 113(1), 2012, pp. 2-16. 
- Fiorelli V, Gendelman R, Sirianni MC, Chang HK, Colombini S, Markham PD, Monini P, Sonnabend 
J, Pintus A, Gallo RC, Ensoli B. ͞gamma-Interferon produced by CD8+ T cells infiltrating Kaposi's 
sarcoma induces spindle cells with angiogenic phenotype and synergy with human 
immunodeficiency virus-1 Tat protein: an immune response to human herpesvirus-8 infection?͟. 
Blood, 91(3), 1998, pp. 956-67. 
- Floƌe O, ‘afii “, ElǇ “, O͛LeaƌǇ JJ, HǇjek EM, CesaƌŵaŶ E. ͞Transformation of primary human 
eŶdothelial Đells ďǇ Kaposi͛s saƌĐoŵa-associated herpesvirus͟. Nature, 394(6693), 1998, pp. 588-
92. 
 
111 
 
- Foubert P, Silvestre JS, Souttou B, Barateau V, Martin C, Ebrahimian TG, Leré-Déan C, Contreres 
JO, Sulpice E, Levy BI, Plouët J, Tobelem G, Le Ricousse-Roussanne S. ͞PSGL-1- mediated activation 
of EphB4 increases the proangiogenic potential of endothelial progenitor cells͟. J Clin Invest, 
117(6), 2007, pp. 1527-37. 
- François M, Caprini A, Hosking B, Orsenigo F, Wilhelm D, Browne C, Paavonen K, Karnezis T, 
Shayan R, Downes M, Davidson T, Tutt D, Cheah KS, Stacker SA, Muscat GE, Achen MG, Dejana E, 
Koopman P. ͞Sox18 induces development of the lymphatic vasculature in mice͟. Nature, 
456(7222), 2008, pp. 643-7. 
- Fuchs S, Motta A, Migliaresi C, Kirkpatrick CJ. ͞Outgrowth endothelial cells isolated and expanded 
from human peripheral blood progenitor cells as a potential source of autologous cells for 
endothelization of silk fibroin biomaterials͟. Biomaterials, 27, 2006, pp.5399–408. 
- Fujiyama S, Amano K, Uehira K, Yoshida M, Nishiwaki Y, Nozawa Y, Jin D, Takai S, Miyazaki M, 
Egashira K, Imada T, Iwasaka T, Matsubara H. ͞Bone marrow monocyte lineage cells adhere on 
injured endothelium in a monocyte chemoattractant protein-1-dependent manner and accelerate 
reendothelialization as endothelial progenitor cells͟. Circ Res, 93(10), 2003, pp. 980-9. 
- Gale NW, Prevo R, Espinosa J, Ferguson DJ, Dominguez MG, Yancopoulos GD, Thurston G, and 
Jackson DG. ͞Normal lymphatic development and function in mice deficient for the lymphatic 
hyaluronan receptor LYVE-1͟. Mol Cell Biol, 27, 2007, pp. 595–604. 
- Ganem D. ͞KSHV and the pathogenesis of Kaposi sarcoma: listening to human biology and 
medicine͟. J Clin Invest, 120, 2010, pp. 939–49. 
- Gantt S, Casper C. ͞Human herpesvirus 8-associated neoplasms: the roles of viral replication and 
antiviral treatment͟. Curr Opin Infect Dis, 24(4), 2011, pp. 295-301. 
- Gao D, Nolan D, McDonnell K, Vahdat L, Benezra R, Altorki N, Mittal V. ͞Bone marrow-derived 
endothelial progenitor cells contribute to the angiogenic switch in tumor growth and metastatic 
progression͟. Biochim Biophys Acta, 1796(1), 2009, pp. 33-40. 
- Gao SJ, Kingsley L, Li M, Zheng W, Parravicini C, Ziegler J, Newton R, Rinaldo CR, Saah A, Phair J, 
Detels R, Chang Y, Moore PS. ͞KSHV antibodies among Americans, Italians and Ugandans with and 
without Kaposi's sarcoma͟. Nat Med, 2(8), 1996, pp. 925-28. 
- Gessain A, Duprez R. ͞Spindle cells and their role in Kaposi's sarcoma͟.Int J Biochem Cell Biol, 
37(12), 2005, pp.2457-65. 
- Gill PS, Tsai YC, Rao AP, Spruck CH 3rd, Zheng T, Harrington WA Jr, Cheung T, Nathwani B, Jones 
PA. ͞EǀideŶĐe foƌ ŵultiĐloŶalitǇ iŶ ŵultiĐeŶtƌiĐ Kaposi͛s saƌĐoŵa͟. Proc Natl Acad Sci USA, 95, 
1998, pp. 8257–61. 
112 
 
- Gulati R, Jevremovic D, Peterson TE, Chatterjee S, Shah V, Vile RG, Simari RD. ͞Diverse origin and 
function of cells with endothelial phenotype obtained from adult human blood͟. Circ Res, 93(11), 
2003, pp.1023-25. 
- Gunsilius E, Duba H-C, Petzer AL, Kähler CM, Grünewald K, Stockhammer G, Gabl C, Dirnhofer S, 
Clausen J, Gastl G. ͞Evidence from a leukaemia model for maintenance of vascular endothelium by 
bone-marrow-derived endothelial cells͟. Lancet, 355(9216), 2000, pp. 1688-91. 
- Grundhoff A, Ganem D. ͞Inefficient establishment of KSHV latency suggests an additional role for 
continued lytic replication in Kaposi sarcoma pathogenesis͟. J Clin Invest, 113(1), 2004, pp. 124-36. 
- Haque M, Davis DA, Wang V, Widmer I, Yarchoan R. ͞Kaposi's sarcoma-associated herpesvirus 
(human herpesvirus 8) contains hypoxia response elements: relevance to lytic induction by 
hypoxia͟. J Virol, 77(12), 2003, pp. 6761-8. 
- Hassman LM, Ellison TJ, Kedes DH. ͞KSHV infects a subset of human tonsillar B cells, driving 
proliferation and plasmablast differentiation͟. J Clin Invest, 121(2), 2011, pp. 752-68. 
- Heeschen C, Aicher A, Lehmann R, Fichtlscherer S, Vasa M, Urbich C, Mildner-Rihm C, Martin H, 
Zeiher AM, Dimmeler S. ͞Erythropoietin is a potent physiologic stimulus for endothelial progenitor 
cell mobilization͟. Blood, 102(4), 2003, pp. 1340–46. 
- Heissig B, Hattori K, Dias S, Friedrich M, Ferris B, Hackett NR, Crystal RG, Besmer P, Lyden D, 
Moore MA, Werb Z, Rafii S. ͞Recruitment of stem and progenitor cells from the bone marrow niche 
requires MMP-9 mediated release of kit-ligand͟. Cell, 109(5), 2002, pp. 625-37. 
- Hengge UR, Ruzicka T, Tyring SK, Stuschke M, Roggendorf M, Schwartz RA, Seeber S. ͞Update on 
Kaposi's sarcoma and other HHV8 associated diseases. Part 1: epidemiology, environmental 
predispositions, clinical manifestations, and therapy͟. Lancet Infect Dis, 2(5), 2002, pp. 281-92. 
- Henry M, Uthman A, Geusau A, Rieger A, Furci L, Lazzarin A, Lusso P, Tschachler E. ͞Infection of 
circulating CD34+ cells by HHV-8 in patients with Kaposi's sarcoma͟. J Invest Dermatol, 113(4), 
1999, pp. 613–6. 
- Herndier BG, Werner A, Arnstein P, Abbey NW, Demartis F, Cohen RL, Shuman MA, Levy JA. 
͞Characterization of a human Kaposi's sarcoma cell line that induces angiogenic tumors in 
animals͟. AIDS, 8(5), 1994, pp. 575-81. 
- He Y, Rajantie I, Ilmonen M, Makinen T, Karkkainen MJ, Haiko P, Salven P, Alitalo K. ͞Preexisting 
lymphatic endothelium but not endothelial progenitor cells are essential for tumor 
lymphangiogenesis and lymphatic metastasis͟. Cancer Res, 64(11), 2004, pp. 3737-40. 
- Hill JM, Zalos G, Halcox JPJ, Schenke WH, Waclawiw MA, Quyyumi AA, Finkel T. ͞Circulating 
Endothelial Progenitor Cells, Vascular Function, and Cardiovascular Risk͟. N Engl J Med, 348(7), 
2003, pp. 593–600. 
113 
 
- Hirschi KK, Ingram DA, Yoder MC. ͞Assessing identity, phenotype, and fate of endothelial 
progenitor cells͟. Arterioscler Thromb Vasc Biol, 28, 2008, pp. 1584–95. 
- Holst PJ, Luttichau HR, Schwartz TW and Rosenkilde MM. ͞Virally encoded chemokines and 
chemokine receptors in the role of viral infections͟. Contrib Microbiol, 10, 2003, pp. 232-52. 
- Hong KH, Ryu J, Han KH. ͞Monocyte chemoattractant protein-1-induced angiogenesis is mediated 
by vascular endothelial growth factor-A͟. Blood, 105, 2005, pp. 1405–7. 
- Hong YK, Foreman K, Shin JW, Hirakawa S, Curry CL, Sage DR, Libermann T, Dezube BJ, Fingeroth 
JD, Detmar M. ͟Lymphatic reprogramming of blood vascular endothelium by Kaposi sarcoma-
associated herpesvirus͟. Nat Genet, 36(7), 2004, pp. 683-5. 
- Hoshida T, Isaka N, Hagendoorn J, di Tomaso E, Chen YL, Pytowski B, Fukumura D, Padera TP, Jain 
RK. ͞Imaging steps of lymphatic metastasis reveals that vascular endothelial growth factor-C 
increases metastasis by increasing delivery of cancer cells to lymph nodes: therapeutic 
implications͟. Cancer Res, 66(16), 2006, pp. 8065-75. 
- Hosseini-Moghaddam SM, Soleimanirahbar A, Mazzulli T, Rotstein C, Husain S. ͟Post renal 
transplantation Kaposi's sarcoma: a review of its epidemiology, pathogenesis, diagnosis, clinical 
aspects, and therapy͟. Transpl Infect Dis, 14(4), 2012, pp. 338-45. 
- Huang LM, Huang SY, Chen MY, Chao MF, Lu CY, Tien HF, Lee CY, Jeang KT. ͞Geographical 
differences in human herpesvirus 8 seroepidemiology: a survey of 1,201 individuals in Asia͟. J Med 
Virol, 60(3), 2000, pp. 290-3. 
- Huang L, Critser PJ., Grimes BR, Yoder CM. ͞Human Umbilical Cord Blood Plasma Can Replace 
Fetal Bovine Serum (FBS) for in vitro Expansion of Functional Human Endothelial Colony Forming 
Cells (ECFC)͟. Cytotherapy, 13(6), 2011, pp. 712–21. 
- Huntington GS, McClure CFW. ͞The anatomy and development of the jugular lymph sac in the 
domestic cat (Felis domestica)͟. Am J Anat, 10, 1910, pp. 177–311. 
- Hur J, Yoon CH, Kim HS, Choi JH, Kang HJ, Hwang KK, Oh BH, Lee MM, Park YB. ͞Characterization 
of two types of endothelial progenitor cells and their different contributions to neovasculogenesis͟. 
Arterioscler Thromb Vasc Biol, 24(2), 2004, pp. 288–93. 
- Hu Z, Usherwood EJ. ͟IŵŵuŶe esĐape of γ-herpesviruses from adaptive immunity͟. Rev Med 
Virol, 24(6), 2014, pp. 365-78. 
- Imanishi T, Hano T, Nishio I. ͞Estrogen reduces endothelial progenitor cell senescence through 
augmentation of telomerase activity͟. J Hypertens, 23(9), 2005, pp. 1699–706. 
- Ingram DA, Mead LE, Tanaka H, Meade V, Fenoglio A, Mortell K, Pollok K, Ferkowicz MJ, Gilley D, 
Yoder MC. ͞Identification of a novel hierarchy of endothelial progenitor cells using human 
peripheral and umbilical cord blood͟. Blood, 104(9), 2004, pp. 2752-60. 
114 
 
- Ingram DA, Mead LE, Moore DB, Woodard W, Fenoglio A, Yoder MC. ͞Vessel wall-derived 
endothelial cells rapidly proliferate because they contain a complete hierarchy of endothelial 
progenitor cells͟. Blood, 105(7), 2005, pp. 2783-6. 
- Ishihara A, Yoshida T, Tamaki H, Sakakura T. ͞Tenascin expression in cancer cells and stroma of 
human breast cancer and its prognostic significance͟. Clin Cancer Res, 1(9), 1995, pp. 1035-41. 
- Iscovich J, Boffetta P, Franceschi S, Azizi E, Sarid R. ͟ Classic kaposi sarcoma: epidemiology and 
risk factors͟. Cancer, 88(3), 2000, pp. 500-17. 
- Ishikawa M, Asahara T. ͞Endothelial progenitor cell culture for vascular regeneration͟. Stem Cells 
Dev, 13(4), 2004, pp. 344-9. 
- Jackson DG. ͞Biology of the lymphatic marker LYVE-1 and applications in research into lymphatic 
trafficking and lymphangiogenesis͟. APMIS, 112(7-8), 2004, pp. 526-38. 
- Jackson KA, Majka SM, Wang H, Pocius J, Hartley CJ, Majesky MW, Entman ML, Michael LH, 
Hirschi KK, Goodell MA. ͞Regeneration of ischemic cardiac muscle and vascular endothelium by 
adult stem cells͟. J Clin Invest, 107(11), 2001, pp. 1395-402. 
- Jaipersad AS, Lip GYH, Silverman S, Shantsila E. ͞The Role of Monocytes in Angiogenesis and 
Atherosclerosis͟. J Am Coll Cardiol. 63(1), 2014, pp. 1-11. 
- Jensen KK and Lira S. ͞CheŵokiŶes aŶd Kaposi͛s saƌĐoŵa͟. Semin.Cancer Biol, 14, 2004, pp. 187-
194. 
- Johnson LA, Jackson DG. ͞The chemokine CX3CL1 promotes trafficking of dendritic cells through 
inflamed lymphatics͟. J Cell Sci. 126(Pt 22), 2013, epub: 5259-70.  
- Jodon de Villeroche V, Avouac J, Ponceau A, Ruiz B, Kahan A, Boileau C, Uzan G, Allanore Y. 
͞Enhanced late-outgrowth circulating endothelial progenitor cell levels in rheumatoid arthritis and 
correlation with disease activity͟. Arthritis Res Ther, 12(1), 2010, R27. 
- Jones JL, Hanson DL, Dworkin MS, Ward JW, Jaffe HW. ͞Effect of antiretroviral therapy on recent 
trends in selected cancers among HIV-infected persons.Adult/Adolescent Spectrum of HIV Disease 
Project Group͟. J Acquir Immune Defic Syndr., 21(1), 1999, pp. S11-7. 
- Kaaya EE, Parravicini C, Ordonez C, Gendelman R, Berti E, Gallo RC, Biberfeld P. ͞Heterogeneity of 
spindle cells in Kaposi's sarcoma: comparison of cells in lesions and in culture͟. J Acquir Immune 
Defic Syndr Hum Retrovirol, 10(3), 1995, pp. 295-305. 
- Kalka C, Masuda H, Takahashi T, Kalka-Moll WM, Silver M, Kearney M, Li T, Isner JM, Asahara T. 
͞Transplantation of ex vivo expanded endothelial progenitor cells for therapeutic 
neovascularization͟. Proc Natl Acad Sci USA, 97(7), 2000, pp. 3422-27. 
115 
 
- Karkkainen MJ, Ferrell RE, Lawrence EC, Kimak MA, Levinson KL, McTigue MA, Alitalo K, Finegold 
DN. ͞Missense mutations interfere with VEGFR-3 signaling in primary lymphoedema͟. Nat Genet, 
25(2), 2000, pp. 153-9. 
- Karkkainen MJ, Saaristo A, Jussila L, Karila KA, Lawrence EC, Pajusola K, Bueler H, Eichmann A, 
Kauppinen R, Kettunen MI, Yla-Herttuala S, Finegold DN, Ferrell RE, Alitalo K. ͞A model for gene 
therapy of human hereditary lymphedema͟. Proc Natl Acad Sci U S A, 98(22), 2001, pp. 12677-82. 
- Karkkainen MJ, Haiko P, Sainio K, Partanen J, Taipale J, Petrova TV, Jeltsch M, Jackson DG, Talikka 
M, Rauvala H, Betsholtz C, Alitalo K. ͟Vascular endothelial growth factor C is required for sprouting 
of thefirst lymphatic vessels from embryonic veins͟. Nat Immunol, 5(1), 2004, pp. 74-80. 
- Karpanen T, Egeblad M, Karkkainen MJ, Kubo H, Ylä-Herttuala S, Jäättelä M, Alitalo K. ͞Vascular 
endothelial growth factor C promotes tumor lymphangiogenesis and intralymphatic tumor 
growth͟. Cancer Res, 61(5), 2001, pp. 1786–90. 
- Karpanen T, Alitalo K. ͞Molecular biology and pathology of lymphangiogenesis͟. Annu Rev Pathol, 
3, 2008, pp. 367-97. 
- Kaushal S, Amiel GE, Guleserian KJ, Shapira OM, Perry T, Sutherland FW, Rabkin E, Moran AM, 
Schoen FJ, Atala A, Soker S, Bischoff J, Mayer JE Jr. ͞Functional small-diameter neovessels created 
using endothelial progenitor cells expanded ex vivo͟. Nat Med, 7(9), 2001, pp. 1035-40. 
- Kedes DH, Operskalski E, Busch M, Kohn R, Flood J, Ganem D. ͞Theseroepidemiology of human 
heƌpesǀiƌus ϴ ;Kaposi͛s saƌĐoŵa-associatedherpesvirus): distribution of infection in KS risk groups 
and evidence forsexual transmission͟. Nat Med, 2, 1996, pp. 918–24. 
- Kerjaschki D. "The crucial role of macrophages in lymphangiogenesis". J Clin Invest, 115(9), 2005, 
pp. 2316-19. 
- Kerjaschki D, Huttary N, Raab I, Regele H, Bojarski-Nagy K, Bartel G, Kröber SM, Greinix H, 
Rosenmaier A, Karlhofer F, Wick N, Mazal PR. ͞Lymphatic endothelial progenitor cells contribute to 
de novo lymphangiogenesis in human renal transplants͟. Nat Med, 12(2), 2006, pp. 230-4. 
- Kramer RH, Fuh GM, Hwang CB, Conant MA, Greenspan JS. ͟Basement membrane and connective 
tissue proteins in early lesions of Kaposi's sarcoma associated with AIDS͟. J Invest Dermatol, 84(6), 
1985, pp. 516-20. 
- Krenning G, van Luyn MJ, Harmsen MC. ͞Endothelial progenitor cell-basedneovascularization: 
implications for therapy͟. Trends Mol Med, 15, 2009, pp. 180–89. 
- Kukk E, Lymboussaki A, Taira S, Kaipainen A, Jeltsch M, Joukov V, Alitalo K. ͞VEGF-C receptor 
binding and pattern of expression with VEGFR-3 suggests a role in lymphatic vascular 
development͟. Development, 122(12), 1996, pp. 3829-37. 
116 
 
- Lebbe C, de Cremoux P, Millot G, Podgorniak MP, Verola O, Berger R, Morel P, Calvo F. 
͞Characterization of in vitro culture of HIV-Ŷegatiǀe Kaposi͛s saƌĐoŵa-derived cells.In vitro 
responses to alfa interferon͟. Arch Dermatol Res, 289(7), 1997, pp. 421–28. 
- Leclers D, Durand K, Cook-Moreau J, Rabinovitch-Chable H, Sturtz FG, Rigaud M. ͞VEGFR-3, VEGF-
C and VEGF-D mRNA quantification by RT-PCR in different human cell types͟. Anticancer Res, 
26(3A), 2006, pp. 1885-91. 
- Lee HR, Amatya R, Jung JU. ͞Multi-step regulation of innate immune signaling by Kaposi's 
sarcoma-associated herpesvirus͟.Virus Res, 209, 2015, pp. 39-44. 
- Lee JY, Park C, Cho YP, Lee E, Kim H, Kim P, Yun SH, Yoon Y. "Podoplanin-expressing Cells Derived 
from Bone Marrow Play a Crucial Role in Postnatal Lymphatic Neovascularization". Circulation, 
122(14), 2010, pp. 1413–25. 
- Lee PS, Poh KK. ͞Endothelial progenitor cells in cardiovascular diseases͟. World J Stem Cells, 6(3), 
2014, pp. 355-66. 
- Leicht SF, Schwarz TM, Hermann PC, Seissler J, Aicher A, Heeschen C. ͞Adiponectin pretreatment 
counteracts the detrimental effect of a diabetic environment on endothelial progenitors͟. Diabetes, 
60(2), 2011, pp. 652–61. 
- Ligi I, Simoncini S, Tellier E, Vassallo PF, Sabatier F, Guillet B, Lamy E, Sarlon G, Quemener C, 
Bikfalvi A, Marcelli M, Pascal A, Dizier B, Simeoni U, Dignat-George F, Anfosso F. ͞A switch toward 
angiostatic gene expression impairs the angiogenic properties of endothelial progenitor cells in low 
birth weight preterm infants͟. Blood, 118(6), 2011, pp. 1699–709. 
- Li M, Lee H, Yoon DW, Albrecht JC, Fleckenstein B, Neipel F and Jung JU. ͞Kaposi͛s saƌĐoŵa-
associated herpesvirus encodes a functional cyclin͟. J. Virol, 71, 1997, pp. 1984-91. 
- Li T, Yang J, Zhou Q, He Y. ͞Molecular regulation of lymphangiogenesis in development and tumor 
microenvironment͟. Cancer Microenviron, 5(3), 2012, pp. 249-60. 
- Li X, Liang D, Lin X, Robertson ES, Lan K. ͞Kaposi's sarcoma-associated herpesvirus-encoded 
latency-associated nuclear antigen reduces interleukin-8 expression in endothelial cells and impairs 
neutrophil chemotaxis by degrading nuclear p65͟. J Virol, 85(17), 2011, pp. 8606-15 
- Lorusso B, Falco A, Madeddu D, Frati C, Cavalli S, Graiani G, Gervasi A, Rinaldi L, Lagrasta C, 
Maselli D, Gnetti L, Silini EM, Quaini E, Ampollini L, Carbognani P, Quaini F. ͞Isolation and 
Characterization of Human Lung Lymphatic Endothelial Cells͟. Biomed Res Int, 2015, Epub 747864.  
- Lund AW, Duraes FV, Hirosue S, Raghavan VR, Nembrini C, Thomas SN, Issa A, Hugues S, Swartz 
MA. ͞VEGF-C promotes immune tolerance in B16 melanomas and cross-presentation of tumor 
antigen by lymph node lymphatics͟. Cell Rep, 1(3), 2012, pp. 191-9. 
117 
 
- Luppi M, Barozzi P, Guaraldi G, Ravazzini L, Rasini V, Spano C, Riva G, Vallerini D, Pinna AD, Torelli 
G. ͞Human herpesvirus 8-associated diseases in solid-organ transplantation: importance of viral 
transmission from the donor͟. Clin Infect Dis, 37(4), 2003, pp. 606-7. 
- Lyden D, Hattori K, Dias S, Costa C, Blaikie P, Butros L, Chadburn A, Heissig B, Marks W, Witte L, 
Wu Y, Hicklin D, Zhu Z, Hackett NR, Crystal RG, Moore MA, Hajjar KA, Manova K, Benezra R, Rafii S. 
͞Impaired recruitment of bone-marrow-derived endothelial and hematopoietic precursor cells 
blocks tumor angiogenesis and growth͟. Nat Med. 7(11), 2001, pp. 1194-201. 
- Madonna R, De Caterina R. ͞Circulating endothelial progenitor cells: Do they live up to their 
name?͞. Vascul Pharmacol, 67-69, 2015, pp. 2-5. 
- Mancuso R, Brambilla L, Agostini S. Biffi R, Hernis A, Guerini FR, Agliardi C, Tourlaki A, Bellinvia M, 
Clerici M. ͞Intrafamiliar transmission of Kaposi's sarcoma associated herpes virus and seronegative 
infection in family members of classic Kaposi's sarcoma patients͟. J Gen Virol, 92(4), 2011, pp. 
744–51. 
- Marçola M, Rodrigues CE. ͞Endothelial progenitor cells in tumor angiogenesis: another brick in 
the wall͟. Stem Cells Int, 2015, 832649.  
- Martin JN, Ganem DE, Osmond DH, Page-Shafer KA, Macrae D, Kedes DH. ͞Sexual transmission 
and the natural history of human herpesvirus 8infection͟. N Engl J Med, 338, 1998, pp. 948–54. 
- Maruyama K, Ii M, Cursiefen C, Jackson DG, Keino H, Tomita M, Van Rooijen N, Takenaka H, 
D'Amore PA, Stein-Streilein J, Losordo DW, Streilein JW. ͞Inflammation-induced 
lymphangiogenesis in the cornea arises from CD11b-positive macrophages͟. J Clin Invest, 115(9), 
2005, pp. 2363–72. 
- Masood R, Cai J, Tulpule A, Zheng T, Hamilton A, Sharma S, Espina BM, Smith DL, Gill PS. 
͞Interleukin 8 is an autocrine growth factor and a surrogate marker for Kaposi's sarcoma͟. Clin 
Cancer Res, 7(9), 2001, pp. 2693-702. 
- Mead LE, Prater D, Yoder MC, Ingram DA. ͞Isolation and characterization of endothelial 
progenitor cells from human blood͟. Curr Protoc Stem Cell Biol, 2(2C.1), 2008. Chapter 2:Unit 2C.1 
- MediŶa ‘J, O͛Neill CL, “ǁeeŶeǇ M, GuduƌiĐ-Fuchs J, Gardiner TA, Simpson DA, Stitt AW. 
͞Molecular analysis of endothelial progenitor cell (EPC) subtypes reveals two distinct cell 
populations with different identities͟. BMC Med Genomics, 3, 2010, 18. 
- Meneveau N, Deschaseaux F, Seronde MF, Chopard R, Schiele F, Jehl J, Tiberghien P, Bassand JP, 
Kantelip JP, Davani S. ͞Presence of endothelial colony-forming cells is associated with reduced 
microvascular obstruction limiting infarct size and left ventricular remodeling in patients with 
acute myocardial infarction͟. Basic Res Cardiol, 106(6), 2011, pp. 1397–410. 
- Mesri EA, Cesarman E, Boshoff C. ͞Kaposi's sarcoma and its associated herpesvirus͟. Nat Rev 
Cancer, 10(10), 2010, pp.707-19. 
118 
 
- Michowitz Y, Goldstein E, Wexler D, Sheps D, Keren G, George J. ͟Circulating endothelial 
progenitor cells and clinical outcome in patients with congestive heart failure͟. Heart, 93, 2007, pp. 
1046-50. 
- Modlin RL, Hofman FM, Kempf RA, Taylor CR, Conant MA, Rea TH. ͞Kaposi's sarcoma in 
homosexual men: an immunohistochemical study͟. J Am AcadDermatol, 8(5), 1983, pp. 620-7. 
- Monini P, Colombini S, Stürzl M, Goletti D, Cafaro A, Sgadari C, Buttò S, Franco M, Leone P, Fais S, 
Leone P, Melucci-Vigo G, Chiozzini C, Carlini F. ͞Reactivation and persistence of human 
herpesvirus-8 infection in B cells and monocytes by Th-1 cytokines increased in Kaposi's sarcoma͟. 
Blood, 93(12), 1999, pp. 4044-58.  
- Mori Y, Nishimoto N, Ohno M, Inagi R, Dhepakson P, Amou K, Yoshizaki K, Yamanishi K. ͞Human 
herpesvirus 8-encoded interleukin-6 homologue (viral IL-6) induces endogenous human IL-6 
secretion͟. J Med Virol, 61(3), 2000, pp. 332-5. 
- Mutlu AD, Cavallin LE, Vincent L, Chiozzini C, Eroles P, Duran EM, Asgari Z, Hooper AT, La Perle 
KM, Hilsher C, Gao SJ, Dittmer DP, Rafii S, Mesri EA. ͞In vivo-restricted and reversible malignancy 
induced by human herpesvirus-8 KSHV: a cell and animal model of virally induced Kaposi's 
sarcoma͟. Cancer Cell, 11(3), 2007, pp. 245-58. 
- Nagy S, Gyulai R, Kemeny L, Szenohradszky P, Dobozy A. ͞Iatrogenic Kaposi's sarcoma: HHV8 
positivity persists but the tumors regress almost completely without immunosuppressive therapy͟. 
Transplantation, 69(10), 2000, pp. 2230-1. 
- Neuchrist C, Erovic BM, Handisurya A, Fischer MB, Steiner GE, Hollemann D, Gedlicka C, Saaristo 
A, Burian M. "Vascular endothelial growth factor C and vascular endothelial growth factor receptor 
3 expression in squamous cell carcinomas of the head and neck". Head & neck, 25(6), 2003, pp. 
464-74. 
- Nicenboim J, Malkinson G, Lupo T, Asaf L, Sela Y, Mayseless O, Gibbs-Bar L, Senderovich N, 
Hashimshony T, Shin M, Jerafi-Vider A, Avraham-Davidi I, Krupalnik V, Hofi R, Almog G, Astin JW, 
Golani O, Ben-Dor S, Crosier PS, Herzog W, Lawson ND, Hanna JH, Yanai I, Yaniv K. ͞Lymphatic 
vessels arise from specialized angioblasts within a venous niche͟. Nature, 522(7554), 2015, pp. 56-
61. 
- Nonaka-Sarukawa M, Yamamoto K, Aoki H, Nishimura Y, Tomizawa H, Ichida M, Eizawa T, Muroi 
K, Ikeda U, Shimada K. ͟Circulating endothelial progenitor cells in congestive heart failure͟. Int J 
Cardiol, 119, 2007,pp. 344-48. 
- Norgall S, Papoutsi M, Rössler J, Schweigerer L, Wilting J, Weich HA. ͞Elevated expression of 
VEGFR-3 in lymphatic endothelial cells from lymphangiomas͟. BMC Cancer, 7, 2007, 105. 
- Nsubuga MM, Biggar RJ, Combs S, Marshall V, Mbisa G, Kambugu F, Mehta M, Biryahwaho B, 
Rabkin CS, Whitby D, Mbulaiteye SM. ͞Human herpesvirus 8 load and progression of AIDS-related 
Kaposi sarcoma lesions͟. Cancer Lett, 263(2), 2008, pp. 182-8. 
119 
 
- Ny A, Koch M, Schneider M, Neven E, Tong RT, Maity S, Fischer C, Plaisance S, Lambrechts D, 
Héligon C, Terclavers S, Ciesiolka M, Kälin R, Man WY, Senn I, Wyns S, Lupu F, Brändli A, Vleminckx 
K, Collen D, Dewerchin M, Conway EM, Moons L, Jain RK, Carmeliet P. ͞A genetic Xenopus laevis 
tadpole model to study lymphangiogenesis͟. Nature Med, 11(9), 2005, pp. 998–1004. 
- O͛BƌieŶ T‘, Kedes D, GaŶeŵ D, MaĐƌae D‘, ‘oseŶďeƌg P“, MoldeŶJ,Goedeƌt JJ. ͞Evidence for 
concurrent epidemics of human herpesvirus 8and human immunodeficiency virus type 1 in US 
homoseǆual ŵeŶ:ƌates, ƌisk faĐtoƌs, aŶd ƌelatioŶship to Kaposi͛s saƌĐoŵa͟. J Infect Dis, 180, 1999, 
pp. 1010–17. 
- Oliver G. ͞Lymphatic vasculature development͟. Nat Rev Immunol, 4(1), 2004, pp.35-45. 
- Osborne J, Moore PS, Chang Y. ͞KSHV-encoded viral IL-6 activates multiple human IL-6 signaling 
pathways͟. Hum Immunol, 60(10), 1999, pp. 921-7. 
- Ou J, Deng J, Wei X, Xie G, Zhou R, Yu L, Liang H. ͞Fibronectin extra domain A (EDA) sustains 
CD133(+)/CD44(+) subpopulation of colorectal cancer cells͟. Stem Cell Res, 11(2), 2013, pp.820-33. 
- Ouyang X, Zeng Y, Fu B, Wang X, Chen W, Fang Y, Luo M, Wang L. ͞GeŶotǇpiĐ AŶalǇsis of Kaposi͛s 
Sarcoma-AssoĐiated Heƌpesǀiƌus fƌoŵ PatieŶts ǁith Kaposi͛s “aƌĐoŵa iŶ XiŶjiaŶg͟. China Viruses, 
6(12), 2014, pp. 4800–10. 
- Pammer J, Weninger W, Mazal PR, Horvat R, Tschachler E. ͞Expression of the CD40 antigen on 
normal endothelial cells and in benign and malignant tumours of vascular origin͟. Histopathology, 
29(6), 1996, pp. 517-24. 
- Park C, Lee JY, Yoon Y. ͞Role of bone marrow-derived lymphatic endothelial progenitor cells for 
lymphatic neovascularization͟. Trends Cardiovasc Med, 21(5), 2011, pp. 135–40. 
- Pearson JD. ͞Endothelial progenitor cells-an evolving story͟. Microvasc Res, 79(3), 2010, pp. 162-
68. 
- Peichev M, Naiyer AJ, Pereira D, Zhu Z, Lane WJ, Williams M, Oz MC, Hicklin DJ, Witte L, Moore 
MA, Rafii S. ͞Expression of VEGFR-2 and AC133 by circulating human CD34(+) cells identifies a 
population of functional endothelial precursors͟. Blood, 95(3), 2000, pp. 952-8. 
- Pellet C, Kerob D, Dupuy A, Carmagnat MV, Mourah S, Podgorniak MP, Toledano C, Morel P, 
Vérola O, Dosquet C, Hamel Y, Calvo F, Rabian C, Lebbé C. ͞Kaposi's sarcoma-associated 
herpesvirus viremia is associated with the progression of classic and endemic Kaposi's sarcoma͟. J 
Invest Dermatol, 126(3), 2006, pp. 621-7. 
- Pelosi E, Valtieri M, Coppola S, Botta R, Gabbianelli M, Lulli V, Marziali G, Masella B, Müller R, 
Sgadari C, Testa U, Bonanno G, Peschle C. ͞Identification of the hemangioblast in postnatal life͟. 
Blood, 100(9), 2002, pp. 3203-8. 
120 
 
- Peters BA, Diaz LA, Polyak K, Meszler L, Romans K, Guinan EC, Antin JH, Myerson D, Hamilton SR, 
Vogelstein B, Kinzler KW, Lengauer C. ͞Contribution of bone marrow-derived endothelial cells to 
human tumor vasculature͟. Nat Med, 11(3), 2005, pp. 261-2. 
- Petrova TV, Mäkinen T, Mäkelä TP, Saarela J, Virtanen I, Ferrell RE, Finegold DN, Kerjaschki D, Ylä-
Herttuala S, Alitalo K. ͞Lymphatic endothelial reprogramming of vascular endothelial cells by the 
Prox-1 homeobox transcription factor͟. EMBO J, 21(17), 2002, pp. 4593-9. 
- Piaggio G, Rosti V, Corselli M, Bertolotti F, Bergamaschi G, Pozzi S, Imperiale D, Chiavarina B, 
Bonetti E, Novara F, Sessarego M, Villani L, Garuti A, Massa M,Ghio R, Campanelli R, Bacigalupo A, 
Pecci A, Viarengo G, Zuffardi O, Frassoni F, Barosi G. ͞Endothelial colony-forming cells from 
patients with chronic myeloproliferative disorders lack the disease-specific molecular clonality 
marker͟. Blood, 114, 2009, pp. 3127–30. 
- Pica F, Volpi A, Serafino A, Fraschetti M, Franzese O, Garaci E. ͞Autocrine nerve growth factor is 
essential for cell survival and viral maturation in HHV-8-infected primary effusion lymphoma cells͟. 
Blood, 95(9), 2000, pp. 2905-12. 
- Piselli P, Busnach G, Citterio F, Frigerio M, Arbustini E, Burra P, Pinna AD, Bresadola V, Ettorre 
GM, Baccarani U, Buda A, Lauro A, Zanus G, Cimaglia C, Spagnoletti G, Lenardon A, Agozzino M, 
Gambato M, Zanfi C, Miglioresi L, Di Gioia P, Mei L, Ippolito G, Serraino D. ͞Immunosuppression 
and Cancer Study Group.Risk of Kaposi sarcoma after solid-organ transplantation: multicenter 
study in 4,767 recipients in Italy, 1970-2006͟.Transplant Proc, 41(4), 2009, pp. 1227-30. 
- Plancoulaine S, Abel L, van Beveren M, Trégouët DA, Joubert M, Tortevoye P, de Thé G, Gessain 
A. ͞Human herpesvirus 8 transmission from mother to child and between siblings in an endemic 
population͟. Lancet, 356(9235), 2000, pp. 1062-5. 
- Polizzotto MN, Uldrick TS, Wang V, Aleman K, Wyvill KM, Marshall V, Pittaluga S, O'Mahony D, 
Whitby D, Tosato G, Steinberg SM, Little RF, Yarchoan R. ͞Human and viral interleukin-6 and other 
cytokines in Kaposi sarcoma herpesvirus-associated multicentric Castleman disease͟. Blood, 
122(26), 2013, pp. 4189-98. 
- Polstra AM, Van Den Burg R, Goudsmit J, Cornelissen M. ͞Human herpesvirus 8 load in matched 
serum and plasma samples of patients with AIDS-associated Kaposi's sarcoma͟. J Clin Microbiol, 
41(12), 2003 a, pp. 5488-91. 
- Polstra AM, Goudsmit J, Cornelissen M. ͞Latent and lytic HHV-8 mRNA expression in PBMCs and 
Kaposi's sarcoma skin biopsies of AIDS Kaposi's sarcoma patients͟. J Med Virol, 70(4), 2003 b, pp. 
624-7. 
- Prater DN, Case J, Ingram DA, Yoder MC. ͞Working hypothesis to redefine endothelial progenitor 
cells͟. Leukemia, 21(6), 2007, pp. 1141-9. 
- Prevo R, Banerji S, Ferguson D, Jackson DG. Mouse. ͞LYVE-1 is an endocytic receptor for 
hyaluronan in lymphatic endothelium͟. J Biol Chem, 276, 2001, pp. 19420–30. 
121 
 
- Prokopi M, Pula G, Mayr U, Devue C, Gallagher J, Xiao Q, Boulanger CM, Westwood N, Urbich C, 
Willeit J, Steiner M, Breuss J, Xu Q, Kiechl S, Mayr M. ͞Proteomic analysis reveals presence of 
platelet microparticles in endothelial progenitor cell cultures͟. Blood, 114, 2009, pp. 723–32. 
- Psaltis PJ, Simari RD. ͞Vascular wall progenitor cells in health and disease͟. Circ Res, 116(8), 2015, 
pp. 1392-412. 
- Purhonen S, Palm J, Rossi D, Kaskenpää N, Rajantie I, Ylä-Herttuala S, Alitalo K, Weissman IL, 
Salven P. ͞Bone marrow-derived circulating endothelial precursors do not contribute to vascular 
endothelium and are not needed for tumor growth͟. Proc Natl Acad Sci USA, 105(18), 2008, pp. 
6620-5. 
- Pyakurel P, Pak F, Mwakigonja AR, Kaaya E, Heiden T, Biberfeld P. ͞Lymphatic and vascular origin 
of Kaposi's sarcoma spindle cells during tumor development͟. Int J Cancer, 119(6), 2006, pp. 1262-
7. 
- Qian CN, Berghuis B, Tsarfaty G, Bruch M, Kort EJ, Ditlev J, Tsarfaty I, Hudson E, Jackson DG, 
Petillo D, Chen J, Resau JH, Teh BT. ͞Preparing the "soil": the primary tumor induces vasculature 
reorganization in the sentinel lymph node before the arrival of metastatic cancer cells͟. Cancer 
Res., 66(21), 2006, pp. 10365-76. 
- Regezi JA, MacPhail LA, Daniels TE, DeSouza YG, Greenspan JS, Greenspan D. ͞Human 
immunodeficiency virus-associated oral Kaposi's sarcoma. A heterogeneous cell population 
dominated by spindle-shaped endothelial cells͟. Am J Pathol, 143(1), 1993, pp. 240-9. 
- Regnier-Rosencher E, Guillot B Dupin N. ͞Treatments for classic Kaposi sarcoma: A systematic 
review of the literature͟. J Am Acad Dermatol, 68(2), 2013, pp.313-31. 
- Rehman J, Li J, Orschell CM, March KL. ͞Peƌipheƌal ďlood ͚eŶdothelial pƌogeŶitoƌ Đells͛ aƌe deƌiǀed 
from monocyte/macrophages and secrete angiogenic growth factors͟. Circulation, 107, 2003, pp. 
1164–69. 
- Religa P, Cao R, Bjorndahl M, Zhou Z, Zhu Z, Cao Y. ͞Presence of bone marrow-derived circulating 
progenitor endothelial cells in the newly formed lymphatic vessels͟. Blood, 106(13), 2005, pp. 
4184–90. 
- Renne R, Lagunoff M, Zhong W, Ganem D. ͞The size aŶd ĐoŶfoƌŵatioŶ of Kaposi͛s saƌĐoŵa-
associated herpesvirus (human herpesvirus 8) DNA in infected cells and virions͟. J Virol, 70, 1996, 
pp. 8151-54. 
- Renne R, Barry C, Dittmer D, Compitello N, Brown PO, Ganem D. ͞Modulation of cellular and viral 
gene expression by the latency-associated nuclear antigen of Kaposi's sarcoma-associated 
herpesvirus͟. J Virol, 75(1), 2001, pp. 458-68. 
- Rezaee SA, Cunningham C, Davison AJ and Blackbourn DJ. ͞Kaposi͛s saƌĐoŵa -associated 
herpesvirus immune modulation: an overview͟. J Gen Virol, 87, 2006, pp. 1781-1804. 
122 
 
- Rohner E, Wyss N, Heg Z, Faralli Z, Mbulaiteye SM, Novak U, Zwahlen M, Egger M, Bohlius J. ͞HIV 
and human herpesvirus 8 co-infection across the globe: Systematic review and meta-analysis͟. Int J 
Cancer, 138(1), 2016, pp. 45-54. 
- Rosti V, Bonetti E, Bergamaschi G, Campanelli R, Guglielmelli P, Maestri M, Magrini U, Massa M, 
Tinelli C, Viarengo G, Villani L, Primignani M, Vannucchi AM, Frassoni F, Barosi G; AGIMM 
Investigators. ͟High frequency of endothelial colony forming cells marks a non-active 
myeloproliferative neoplasm with high risk of splanchnic vein thrombosis͟. PLoS ONE, 5(12), 2010, 
e15277. 
- Rudland PS, Platt-Higgins A, El-Tanani M, De Silva Rudland S, Barraclough R, Winstanley JH, 
Howitt R, West CR. ͞Prognostic significance of the metastasis-associated protein osteopontin in 
human breast cancer͟. Cancer Res, 62(12), 2002, pp. 3417-27. 
- Russell JR, Orchard G, Zelger B, Wilson JE. ͞Immunostaining for CD31 and CD34 in Kaposi 
sarcoma͟. J ClinPathol, 48(11), 1995, pp. 1011-6. 
- Sabin FR. ͞On the origin of the lymphatic system from the veins, and the development of the 
lymph hearts and thoracic duct in the pig͟. Am J Anat, 1, 1902, pp. 367–89. 
- Salven P, Mustjoki S, Alitalo R, Alitalo K, Rafii S. ͞VEGFR-3 and CD133 identify a population of 
CD34
+
 lymphatic/vascular endothelial precursor cells͟. Blood, 101(1), 2003, pp. 168–72. 
- Samaniego F, Markham PD, Gendelman R, Watanabe Y, Kao V, Kowalski K, Sonnabend JA, Pintus 
A, Gallo RC, Ensoli B. ͞Vascular endothelial growth factor and basic fibroblast growth factor 
present in Kaposi's sarcoma (KS) are induced by inflammatory cytokines and synergize to promote 
vascular permeability and KS lesion development͟. Am J Pathol, 152(6), 1998, pp. 1433-43.  
- Sarid R, Sato T, Bohenzky RA, Russo JJ, Chang Y. ͞Kaposi's sarcomaassociated herpesvirus encodes 
a functional bcl-2 homologue͟. Nat Med, 3(3), 1997, pp. 293-8. 
- Schacht V, Ramirez MI, Hong YK, Hirakawa S, Feng D, Harvey N, Williams M, Dvorak AM, Dvorak 
HF, Oliver G, Detmar M. ͞T1alpha/podoplanin deficiency disrupts normal lymphatic vasculature 
formation and causes lymphedema͟. EMBO J, 22(14), 2003, pp. 3546-56. 
- Schmidt-Lucke C, Rossig L, Fichtlscherer S, Vasa M, Britten M, Kämper U, Dimmeler S, Zeiher AM. 
͞Reduced number of circulating endothelial progenitor cells predicts future cardiovascular events͟. 
Circulation, 111(22), 2005, pp. 2981-7. 
- Schmidt-Lucke C, Fichtlscherer S, Aicher A, Tschöpe C, Schultheiss HP, Zeiher AM, Dimmeler S. 
͞Quantification of Circulating Endothelial Progenitor Cells Using the Modified ISHAGE Protocol͟. 
PLoS One, 5(11), 2010, e13790. 
 
 
123 
 
- Schor SL, Ellis IR, Jones SJ, Baillie R, Seneviratne K, Clausen J, Motegi K, Vojtesek B, Kankova K, 
Furrie E, Sales MJ, Schor AM, Kay RA. ͞Migration-stimulating factor: a genetically truncated onco-
fetal fibronectin isoform expressed by carcinoma and tumor-associated stromal cells͟. Cancer Res, 
63(24), 2003, pp. 8827-36. 
- Schulz TF. ͞The pleiotropic effects of Kaposi's sarcoma herpesvirus͟. J Pathol, 208(2), 2006, pp. 
187-98. 
- Schwartz RA. ͞Kaposi's sarcoma: advances and perspectives͟. J Am Acad Dermatol, 34(5), 1996, 
pp. 804-14. 
- Schwartz RA, Micali G, Nasca MR, Scuderi L. ͞Kaposi sarcoma: a continuing conundrum͟. J Am 
Acad Dermatol, 59(2), 2008, pp. 179-206. 
- Schoppmann SF, Birner P, Stöckl J, Kalt R, Ullrich R, Caucig C, Kriehuber E, Nagy K, Alitalo K, 
Kerjaschki D. "Tumor-associated macrophages express lymphatic endothelial growth factors and 
are related to peritumoral lymphangiogenesis". Am J Pathol, 161(3), 2002, pp. 947-56. 
- Semeere AS, Busakhala N, Martin JN. ͞Impact of antiretroviral therapy on the incidence of 
Kaposi's sarcoma in resource-rich and resource-limited settings͟. Curr Opin Oncol, 24, 2012, pp. 
522-30. 
- Sgadari C, Monini P, Barillari G, Ensoli B. ͞Use of HIV protease inhibitoƌs to ďloĐk Kaposi͛s saƌĐoŵa 
and tumour growth͟. Lancet Oncol, 4(9), 2003, pp. 537–47. 
- Shintani S, Murohara T, Ikeda H, Ueno T, Sasaki K, Duan J, Imaizumi T. ͞Augmentation of 
postnatal neovascularization with autologous bone marrow transplantation͟. Circulation, 103(6), 
2001, pp. 897-903. 
- Shi Q, Rafii S, Wu MH, Wijelath ES, Yu C, Ishida A, Fujita Y, Kothari S, Mohle R, Sauvage LR, Moore 
MA, Storb RF, Hammond WP. ͞Evidence for circulating bone marrow-derived endothelial cells͟. 
Blood, 92(2), 1998, pp. 362-7. 
- Sirianni MC, Vincenzi L, Fiorelli V, Topino S, Scala E, Uccini S, Angeloni A, Faggioni A, Cerimele D, 
Cottoni F, Aiuti F, Ensoli B. ͞Gamma-Interferon production in peripheral blood mononuclear cells 
and tumor infiltrating lymphocytes from Kaposi's sarcoma patients: correlation with the presence 
of human herpesvirus-8 in peripheral blood mononuclear cells and lesional macrophages͟. Blood, 
91(3), 1998, pp. 968-76. 
- Skobe M, Hawighorst T, Jackson DG, Prevo R, Janes L, Velasco P, Riccardi L, Alitalo K, Claffey K, 
Detmar M. ͞Induction of tumor lymphangiogenesis by VEGF-C promotes breast cancer metastasis͟. 
Nat Med, 7(2), 2001, pp. 192-8. 
- “ŵadja DM, Mauge L, Gausseŵ P, d͛Audigieƌ C, Isƌael-Biet D, Celermajer DS, Bonnet D, Lévy M. 
͞Treprostinil increases the number and angiogenic potential of endothelial progenitor cells in 
children with pulmonary hypertension͟. Angiogenesis, 14(1), 2011, pp. 17-27. 
124 
 
- Sodhi A, Montaner S, Patel V, Zohar M, Bais C, Mesri EA, Gutkind JS. ͞The Kaposi's sarcoma-
associated herpes virus G protein-coupled receptor up-regulates vascular endothelial growth factor 
expression and secretion through mitogen activated protein kinase and p38 pathways acting on 
hypoxia-inducible factor 1alpha͟. Cancer Res, 60(17), 2000, pp. 4873-80. 
- Solinas G, Schiarea S, Liguori M, Fabbri M, Pesce S, Zammataro L, Pasqualini F, Nebuloni M, 
Chiabrando C, Mantovani A, Allavena P. ͞Tumor-conditioned macrophages secrete migration-
stimulating factor: a new marker for M2-polarization, influencing tumor cell motility͟. J Immunol, 
185(1), 2010, pp. 642-52. 
- Speciale L, Biffi R, Mancuso R, Borghi E, Mazziotti R, Ferrante P. ͞Big endothelin-1 and interleukin-
6 modulation in human microvascular endothelial cells after human herpesvirus 8 infection͟. Exp 
Biol Med, 231(6), 2006, pp. 1171-5. 
- Spiller OB, Blackbourn DJ, Mark L, Proctor DG and Blom AM. ͞Functional activity of the 
ĐoŵpleŵeŶt ƌegulatoƌ eŶĐoded ďǇ Kaposi͛s saƌĐoŵa-associated herpesvirus͟. J Biol Chem, 278, 
2003, pp. 9283-89. 
- Srinivasan RS, Dillard ME, Lagutin OV, Lin FJ, Tsai S, Tsai MJ, Samokhvalov IM, Oliver G. ͞Lineage 
tracing demonstrates the venous origin of the mammalian lymphatic vasculature͟. Genes, 21(19), 
2007, pp. 2422-32. 
- Stallone G, Schena A, Infante B, Di Paolo S, Loverre A, Maggio G, Ranieri E, Gesualdo L, Schena FP, 
Grandaliano G. ͞Sirolimus for Kaposi's sarcoma in renal-transplant recipients͟. N Engl J Med, 
352(13), 2005, pp. 1317-23. 
- Stine JT, Wood C, Hill M, Epp A, Raport CJ, Schweickart VL, Endo Y, Sasaki T, Simmons G, Boshoff 
C, Clapham P, Chang Y, Moore P, Gray PW and Chantry D. ͞KSHV-encoded CC chemokine vMIP-III is 
a CCR4 agonist, stimulates angiogenesis, and selectively chemoattracts TH2 cells͟. Blood, 95(4), 
2000, pp. 1151-7. 
- Strehlow K, Werner N, Berweiler J, Link A, Dirnagl U, Priller J, Laufs K, Ghaeni L, Milosevic M, 
Böhm M, Nickenig G. ͞Estrogen increases bone marrow-derived endothelial progenitor cell 
production and diminishes neointima formation͟. Circulation, 107(24), 2003, pp. 3059–65. 
- Stürzl M, Brandstetter H, Zietz C, Eisenburg B, Raivich G, Gearing DP, Brockmeyer NH, 
Hofschneider PH. ͞Identification of interleukin-1 and platelet derived growth factor-B as major 
mitogens for the spindle cells of Kaposi's sarcoma: a combined in vitro and in vivo analysis͟. 
Oncogene, 10(10), 1995, pp. 2007-16. 
- Stürzl M, Hohenadl C, Zietz C, Castanos-Velez E, Wunderlich A, Ascherl G, Biberfeld P, Monini P, 
Browning PJ, Ensoli B. ͞Expression of K13/v-FLIP gene of human herpesvirus 8 and apoptosis in 
Kaposi's sarcoma spindle cells͟. J Natl Cancer Inst, 91(20), 1999 a, pp. 1725-33. 
125 
 
- Stürzl M, Wunderlich A, Ascherl G, Hohenadl C, Monini P, Zietz C, Browning PJ, Neipel F, Biberfeld 
P, Ensoli B. ͞Human herpesvirus-8 (HHV-8) gene expression in Kaposi's sarcoma (KS) primary 
lesions: an in situ hybridization study͟. Leukemia, 13, 1999 b, pp. 110-2. 
- Sukmawati D, Tanaka R. ͞Introduction to next generation of endothelial progenitor cell therapy: a 
promise in vascular medicine͟. Am J Transl Res, 7(3), 2015, pp. 411-21. 
- Sun Q, Tsurimoto T, Juillard F, Li L, Li S, De León Vázquez E, Chen S, Kaye K. ͞Kaposi's sarcoma-
associated herpesvirus LANA recruits the DNA polymerase clamp loader to mediate efficient 
replication and virus persistence͟. Proc Natl Acad Sci USA, 111(32), 2014, pp. 11816-21. 
- Suthaus J, Adam N, Grötzinger J, Scheller J, Rose-John S. ͞Viral Interleukin-6: Structure, 
pathophysiology and strategies of neutralization͟. Eur J Cell Biol, 90(6-7), 2011, pp. 495-504. 
- Suzuki-Inoue K, Kato Y, Inoue O, Kaneko MK, Mishima K, Yatomi Y, Yamazaki Y, Narimatsu H, 
Ozaki Y. ͞Involvement of the snake toxin receptor CLEC-2, in podoplanin-mediated platelet 
activation, by cancer cells͟. J Biol Chem, 282(36), 2007, pp. 25993-6001. 
- Taddeo A, Presicce P, Brambilla L, Bellinvia M, Villa ML, Della Bella S. ͞Circulating endothelial 
progenitor cells are increased in patients with classic Kaposi's sarcoma͟. J Invest Dermatol, 128(8), 
2008, pp. 2125-8.  
- Takahashi T, Kalka C, Masuda H, Chen D, Silver M, Kearney M, Magner M, Isner JM, Asahara T. 
͞Ischemia-and cytokine-induced mobilization of bone marrow derived endothelial progenitor cells 
for neovascularization͟. Nat Med, 5(4), 1999, pp. 434–38. 
- Tammela T, Alitalo K. ͞Lymphangiogenesis: Molecular Mechanisms and Future Promise͟. Cell, 
140(4), 2010, pp. 460-76. 
- Tan YZ, Wang HJ, Zhang MH, Quan Z, Li T, He QZ. "CD34+VEGFR-3+ progenitor cells have a 
potential to differentiate towards lymphatic endothelial cells". J Cell Mol Med, 18(3), 2014, pp-422-
33. 
- Thompson EW, Nakamura S, Shima TB, Melchiori A, Martin GR, Salahuddin SZ, Gallo RC, Albini A. 
͞Supernatants of acquired immunodeficiency syndromerelated Kaposi's sarcoma cells induce 
endothelial cell chemotaxis and invasiveness͟. Cancer Res, 51(10), 1991, pp. 2670-6. 
- Timmermans F, Plum J, Yöder MC, Ingram DA, Vandekerckhove B, Case J. ͞Endothelial progenitor 
cells: identity defined?͟. J Cell Mol Med, 13(1), 2009, pp. 87-102. 
- To WS, Midwood KS. ͞Plasma and cellular fibronectin: distinct and independent functions during 
tissue repair͟. Fibrogenesis Tissue Repair. 2011;4:21. 
- Uhrin P, Zaujec J, Breuss JM, Olcaydu D, Chrenek P, Stockinger H, Fuertbauer E, Moser M, Haiko 
P, Fässler R, Alitalo K, Binder BR, Kerjaschki D. ͞Novel function for blood platelets and podoplanin 
in developmental separation of blood and lymphatic circulation͟. Blood, 115(19), 2010, pp. 3997-
4005. 
126 
 
- Urbich C, Dimmeler S. ͞Endothelial progenitor cells: characterization and role in vascular 
biology͟. Circ Res, 95(4), 2004, pp. 343-53. 
- Vano-Calvan S, Moreno C. ͞Classic Kaposi sarcoma͟. CMAJ, 183(13), 2011, E1040. 
- Vasa M, Fichtlscherer S, Adler K, Aicher A, Martin H, Zeiher M, Dimmeler S. ͞Increase in 
circulating endothelial progenitor cells by statin therapy in patients with stable coronary artery 
disease͟. Circulation, 103(24), 2001 a, pp. 2885–2890. 
- Vasa M, Fichtlscherer S, Aicher A, Adler K, Urbich C, Martin H, Zeiher AM, Dimmeler S. ͞Number 
and migratory activity of circulating endothelial progenitor cells inversely correlate with risk factors 
for coronary artery disease͟. Circ Res, 89(1), 2001 b, pp. E1-7. 
- Vaz P, Macassa E, Jani I, Thome B, Mahagaja E, Madede T, Muando V, Biberfeld G, Anderson S, 
Blanche S. ͞Treatment of Kaposi sarcoma in human immunodeficiency virus-1-infected 
Mozambican children with antiretroviral drugs and chemotherapy͟. Pediatr Infect Dis J, 30(10), 
2011, pp. 891-3. 
- Vogel J, Hinrichs SH, Reynolds RK, Luciw PA, Jay G. ͞The HIV tat gene induces dermal lesions 
resembling Kaposi's sarcoma in transgenic mice͟. Nature, 335(6191),1988, pp. 606-11. 
- Walter DH, Dimmeler S.Herz. ͞Endothelial progenitor cells: regulation and contribution to adult͟. 
Neovascularization, 27(7), 2002, pp. 579-88. 
- Wang HW, Trotter MW, Lagos D, Bourboulia D, Henderson S, Mäkinen T, Elliman S, Flanagan AM, 
Alitalo K, Boshoff C. ͞Kaposi sarcoma herpesvirus-induced cellular reprogramming contributes to 
the lymphatic endothelial gene expression in Kaposi sarcoma͟. Nat Genet, 36(7), 2004, pp. 687-93. 
- Webster-Cyriaque J. ͞Development of Kaposi's sarcoma in a surgical wound͟. N Engl J Med, 
346(16), 2002, pp. 1207-10. 
- Wen KW, Damania B. ͞Kaposi sarcoma-associated herpesvirus (KSHV): molecular biology and 
oncogenesis͟. Cancer Lett, 289(2), 2010, pp. 140-50. 
- Weninger W, Partanen TA, Breiteneder-Geleff S, Mayer C, Kowalski H, Mildner M, Pammer J, 
Stürzl M, Kerjaschki D, Alitalo K, Tschachler E. ͞Expression of vascular endothelial growth factor 
receptor-3 and podoplanin suggests a lymphatic endothelial cell origin of Kaposi's sarcoma tumor 
cells͟. Lab Invest, 79(2), 1999, pp. 243. 
- Werner N, Kosiol S, Schiegl T, Ahlers P, Walenta K, Link A, Bohm M,Nickenig G. ͞Circulating 
endothelial progenitor cells and cardiovascular outcomes͟. N Engl J Med, 353, 2005, pp. 999–1007. 
- Whitby D, Howard MR, Tenant-Flowers M, Brink NS, Copas A, Boshoff C, Hatzioannou T, Suggett 
FE, Aldam DM, Denton AS, Miller RF, Weller IVD, Weiss RA, Tedder RS, Schulz TF. ͞Detection of 
Kaposi sarcoma associatedherpesvirus in peripheral blood of HIV-infected individuals and 
pƌogƌessioŶto Kaposi͛s saƌĐoŵa͟. Lancet, 346, 1995, pp. 799–802. 
127 
 
- Wigle JT, Harvey N, Detmar M, Lagutina I, Grosveld G, Gunn MD, Jackson DG, Oliver G. ͞An 
essential role for Prox1 in the induction of the lymphatic endothelial cell phenotype͟. EMBO J, 
21(7), 2002, pp. 1505-13. 
- Wilting J, Papoutsi M, Christ B, Nicolaides KH, von Kaisenberg CS, Borges J, Stark GB, Alitalo K, 
Tomarev SI, Niemeyer C, Rössler J. ͞The transcription factor Prox1 is a marker for lymphatic 
endothelial cells in normal and diseased human tissues͟. FASEB J, 16(10), 2002, pp. 1271-3. 
- Wilting J, Tomarev SI, Christ B, Schweigerer L. ͞Lymphangioblasts in embryonic 
lymphangiogenesis͟. Lymphat Res Biol, 1, 2003, pp. 33–40. 
- Witte MH, Dellinger MT, McDonald DM, Nathanson SD, Boccardo FM, Campisi CC, Sleeman JP, 
Gershenwald JE. ͞Lymphangiogenesis and hemangiogenesis: potential targets for therapy͟. J Surg 
Oncol, 103, 2011, pp. 489–500. 
- Wu W, Vieira J, Fiore N, Banerjee P, Sieburg M, Rochford R, Harrington W Jr, Feuer G. 
͞KSHV/HHV-8 infection of human hematopoietic progenitor (CD34+) cells: persistence of infection 
during hematopoiesis in vitro and in vivo͟. Blood, 108(1), 2006, pp. 141-51. 
- Xiang L, Xie G, Ou J, Wei X, Pan F, Liang H. ͞The extra domain A of fibronectin increases VEGF-C 
expression in colorectal carcinoma involving the PI3K/AKT signaling pathway͟. PLoS One, 7(4), 
2012, e35378. 
- Xiao Q, Ye S, Oberhollenzer F, Mayr A, Jahangiri M, Willeit J, Kiechl S, Xu Q. ͞SDF1 gene variation 
is associated with circulating SDF1alpha level and endothelial progenitor cell number: the Bruneck 
Study͟. PLoS One, 3(12), 2008, e4061. 
- Xu Y, Yuan L, Mak J, Pardanaud L, Caunt M, Kasman I, Larrivée B, Del Toro R, Suchting S, 
Medvinsky A, Silva J, Yang J, Thomas JL, Koch AW, Alitalo K, Eichmann A, Bagri A. ͞Neuropilin-2 
mediates VEGF-C–induced lymphatic sprouting together with VEGFR3͟. J Cell Biol, 188(1), 2010, 
pp. 115–30. 
- Yamaguchi J, Kusano KF, Masuo O, Kawamoto A, Silver M, Murasawa S, Bosch-Marce M, Masuda 
H, Losordo DW, Isner JM, Asahara T. ͞Stromal cell-derived factor-1 effects on ex vivo expanded 
endothelial progenitor cell recruitment for ischemic neovascularization͟. Circulation, 107(9), 2003, 
pp. 1322-8. 
- Yang J, Hagan MK, Offermann MK. ͞Induction of IL-6 gene expression in Kaposi's sarcoma cells͟. J 
Immunol, 152(2), 1994, pp. 943-55. 
- Yang TY, Chen SC, Leach MW, Manfra D, Homey B, Wiekowski M, Sullivan L, Jenh CH, Narula SK, 
Chensue SW, Lira SA. ͞Transgenic expression of the chemokine receptor encoded by human 
herpesvirus 8 induces an angioproliferative disease resembling Kaposi's sarcoma͟. J Exp Med, 
191(3), 2000, pp. 445-54. 
 
128 
 
- Yaniv K, Isogai S, Castranova D, Dye L, Hitomi J, Weinstein BM. ͞Live imaging of lymphatic 
development in the zebrafish͟. Nature Med, 12(6), 2006, pp. 711–16. 
- Yoder MC, Mead LE, Prater D, Krier TR, Mroueh KN, Li F, Krasich R, Temm CJ, Prchal JT, Ingram 
DA. ͞Redefining endothelial progenitor cells via clonal analysis and hematopoietic stem/progenitor 
cell principals͟. Blood, 109(5), 2007, pp. 1801-9. 
- Yoo J, Kang J, Lee HN, Aguilar B, Kafka D, Lee S, Choi I, Lee J, Ramu S, Haas J, Koh CJ, Hong YK. 
͞Kaposin-B enhances the PROX1 mRNA stability during lymphatic reprogramming of vascular 
endothelial cells by Kaposi's sarcoma herpes virus͟. PLoS Pathog, 6(8), 2010, e1001046.  
- Zavos G, Moris D, Vernadakis S, Bokos J, Lionaki S, Mamarelis G, Panagiotellis K, Zavvos V, Boletis 
I. ͞Incidence and management of Kaposi sarcoma in renal transplant recipients: the Greek 
experience͟. Transplant Proc, 46(9), 2014, pp. 3199-202. 
- Zhang X, Wang JF, Chandran B, Persaud K, Pytowski B, Fingeroth J, Groopman JE. ͞Kaposi's 
sarcoma-associated herpesvirus activation of vascular endothelial growth factor receptor 3 alters 
endothelial function and enhances infection͟. J Biol Chem, 280(28), 2005, pp. 26216-24. 
- Zhi H, Zahoor MA, Shudofsky AM, Giam CZ. ͞KSHV vCyclin counters the senescence/G1 arrest 
response triggered by NF-κB hǇpeƌaĐtiǀatioŶ͟. Oncogene, 34(4), 2015, pp. 496-505.  
 
